var title_f20_5_20560="Follicular lesions";
var content_f20_5_20560=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F65775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F65775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Follicular lesions: Appearance on fine needle aspirate of a thyroid nodule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 290px; height: 436px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple fine needle aspiration specimens from thyroid nodules revealing microfollicles in syncytia with nuclear atypia and little or no colloid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephanie L. Lee.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_5_20560=[""].join("\n");
var outline_f20_5_20560=null;
var title_f20_5_20561="Post fossa ependymoma MRI";
var content_f20_5_20561=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Posterior fossa ependymoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 307px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A T1 weighted sagittal MR image of the brain without contrast identifies a large hypointense mass in the posterior fossa (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mark Kieran, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_5_20561=[""].join("\n");
var outline_f20_5_20561=null;
var title_f20_5_20562="PTH effect skeletal architecture";
var content_f20_5_20562=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F62933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F62933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Effect of teriparatide PTH (20 mcg) on skeletal architecture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 237px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADtAg0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6poorj9f+Jng3w7q0+ma14gsrO/g2+ZBITuXcoYZ47gg/jQB2FFeff8Ln+Hf/AENmnfm3+FH/AAuf4d/9DZp35t/hQB6DRXn3/C5/h3/0Nmnfm3+FH/C5/h3/ANDZp35t/hQB6DRXn3/C5/h3/wBDZp35t/hR/wALn+Hf/Q2ad+bf4UAeg0V59/wuf4d/9DZp35t/hR/wuf4d/wDQ2ad+bf4UAeg0V59/wuf4d/8AQ2ad+bf4Uf8AC5/h3/0Nmnfm3+FAHoNFeff8Ln+Hf/Q2ad+bf4Uf8Ln+Hf8A0Nmnfm3+FAHoNFeff8Ln+Hf/AENmnfm3+FH/AAuf4d/9DZp35t/hQB6DRXn3/C5/h3/0Nmnfm3+FH/C5/h3/ANDZp35t/hQB6DRXn3/C5/h3/wBDZp35t/hR/wALn+Hf/Q2ad+bf4UAeg0V59/wuf4d/9DZp35t/hR/wuf4d/wDQ2ad+bf4UAeg0V59/wuf4d/8AQ2ad+bf4Uf8AC5/h3/0Nmnfm3+FAHoNFeff8Ln+Hf/Q2ad+bf4Uf8Ln+Hf8A0Nmnfm3+FAHoNFeff8Ln+Hf/AENmnfm3+FH/AAuf4d/9DZp35t/hQB6DRXn3/C5/h3/0Nmnfm3+FH/C5/h3/ANDZp35t/hQB6DRXn3/C5/h3/wBDZp35t/hR/wALn+Hf/Q2ad+bf4UAeg0V58/xm+Hq288//AAlFk8cCB5PLV3IUsFztCknlh0FZ3/C//hl/0M6/+AVz/wDG6APUqK8t/wCF/wDwy/6Gdf8AwCuf/jdH/C//AIZf9DOv/gFc/wDxugD1KivLf+F//DL/AKGdf/AK5/8AjdH/AAv/AOGX/Qzr/wCAVz/8boA9Sory3/hf/wAMv+hnX/wCuf8A43R/wv8A+GX/AEM6/wDgFc//ABugD1KivLf+F/8Awy/6Gdf/AACuf/jdH/C//hl/0M6/+AVz/wDG6APUqK8t/wCF/wDwy/6Gdf8AwCuf/jdH/C//AIZf9DOv/gFc/wDxugD1KivLf+F//DL/AKGdf/AK5/8AjdH/AAv/AOGX/Qzr/wCAVz/8boA9Sory3/hf/wAMv+hnX/wCuf8A43R/wv8A+GX/AEM6/wDgFc//ABugD1KivLf+F/8Awy/6Gdf/AACuf/jdH/C//hl/0M6/+AVz/wDG6APUqK8t/wCF/wDwy/6Gdf8AwCuf/jdH/C//AIZf9DOv/gFc/wDxugD1KivLf+F//DL/AKGdf/AK5/8AjdH/AAv/AOGX/Qzr/wCAVz/8boA9Sory3/hf/wAMv+hnX/wCuf8A43R/wv8A+GX/AEM6/wDgFc//ABugD1KivLf+F/8Awy/6Gdf/AACuf/jdH/C//hl/0M6/+AVz/wDG6APUqK8t/wCF/wDwy/6Gdf8AwCuf/jdH/C//AIZf9DOv/gFc/wDxugD1KivLf+F//DL/AKGdf/AK5/8AjdH/AAv/AOGX/Qzr/wCAVz/8boA9Sory3/hf/wAMv+hnX/wCuf8A43R/wv8A+GX/AEM6/wDgFc//ABugD1Kisrwv4g0zxTodtrGg3Qu9Nud3lTBGTdtYoeGAIwykcjtWrQAV8B/tT/8AJdPEf+7bf+k0VfflfAf7U/8AyXTxH/u23/pNFQB5PRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGvof/Hjrn/XkP/R8VZFa+h/8eOuf9eI/9HxVkUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAff/7Ln/JCfDP/AG9f+lUteq15V+y5/wAkJ8M/9vX/AKVS16rQAV8B/tT/APJdPEf+7bf+k0VfflfAf7U//JdPEf8Au23/AKTRUAeT0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBr6H/AMeOuf8AXiP/AEfFWRWvof8Ax465/wBeI/8AR8VZFABRRRQAUUUUAFFFFABRRRQAUUU5FZ2CopZjwABkmgBtegaR8LtXv7XTZJZ7e1uL3LrbS582OHjbIy9gxzgexrZ+BHgSHWvHtsfEskVnYWYW4eKZwrysclEC9c8ZI64FeqeBHj1jxz4s1SFALdrtbWBDwyLGvAPp15oA5G1+C2jWq2y6jfXs07nayxlVDt6KMZH4mupg+BGg3cQhW1kgnc7hJ9qYhUBHGejNyTwO1dVZTW1z4sxLPCkggdoQASMZALE9BnAGfyrrlWL+z1urW4laWZgJbeTCqFwfmHvnjI/GgDw7xV+z/pcOoeVpGp31tnDeXcIsvy4OSCuM4x/PiuO8Q/ATxTpts9xYPa6jCAWURNtZxx0B4zz0zX0s1itxEzpBcRSDCqScovtkng/lTND1C3eyQT4KM3lPLG4ZCC+CR/ug8HrxQB8K3tpcWNy9tewS29xGcPHKpVl+oNQV9efFz4WaRrks99O8kepBEhS8t3BQncAplU/eAU9QQfWqfxO+BHhOx8HTTeGYr5NUt7fzhKJWkWUqpJDIc9cfw9M96APk+ilYFWIYEEcEHtSUAFFFFABRRRQAUUUUAFFFFABRRRQB9/8A7Ln/ACQnwz/29f8ApVLXqteVfsuf8kJ8M/8Ab1/6VS16rQAV8B/tT/8AJdPEf+7bf+k0VfflfAf7U/8AyXTxH/u23/pNFQB5PRRRQAUUUUAFFFFABRRRQAUUtfSHwW+HFk/g2+fxfo6Fr+ZWieYjcsQj+UrjkAmQk+6LQB83V7PB8MPD8fwYsvGOq6rPbXDwTyFEIKzylisMK8cEFct14J6YzXqV18IPBAtfKgsBN5Uf+uSaQOe/zZOM9eldh4Q0WHQ/D2n6atnb3mnWTO0KXsYmMYck7cEcfebkc8nk0AfC1FfWvjH4VeDLma4v7bQrmOeeXP2ayuvLAz/dVhtA49QAO1cb4t+EOm3WmSJ4eh+wXlku0edcCYT9WBZkBG4gj0C9D6kA+fKK9Hl+DPjBbJ7mC1trkIjO8UVwvmDHUbTgk+wzmuf8c+C9U8G3NnDq0Mim5t0mDGJlVWI+aPJGCyng4oA5iiiigAooooAKKKKACiiigAooooAKKKKACiiigDX0P/jx1z/rxH/o+KsitfQ/+PHXP+vEf+j4qyKACiiigAooooAKKKKACiinxo0kipGpZ2IVVUZJPoKAGVveGSdPuYtUF59nlhYmLy3XfnoT/s9fSut8P/C25vtKivby+t4ZZ2eOG1JwXdc5Ut0BGOfTpXOadpc+lXkM00ltHJFOjbnG7y8HhuRjrxg0Aep/ByKC11zWdZ1mORCGKpG03lMhIyXaTqM5A45O44rt/hNp1zod3rFjrMMcGoXU73hwuQ0bHjYOgHP5V5t408MTaVqOkS+Ip3N5q0iXV158wMrEN8zY52gjhS3XFeueJNWhtLqy1lJDEb3yLG1kddyw4Ygg+hx+uKAGSTf2J8WdN0q/hDWN/bsLUlcLjJYr/tHOOpPavRJZW0/yrS6gWMIgRGCYD4Hp2NZXxE8Mve6RY6nCGudW0qdLlZtwHlgDJC468dq9KkitNTtFXUbdZEdA/GSCPWgDjZWhltmWMfZONrAuSshPQ89D+lc9qFqIUEgIhTIYqRhSwIwR9Tx+NdVqGjR2isYbh5LHJ2uPmWEHoGHoPWszULWUafI/lm5jAaNlQgkAdcZ68jP+NAENtM0CL5rotuRujnH/ACzPYYxzz2NVk+zxS3T3TS/fZvPs3LMkmefqPUflSxM8cOXn3eby6Ecbsc9/x/zmmJcoCPKlR4+c4GQvtmgDB+I3w60rxho8Ud3HEl+V32usW6Lvzn7kqjG4fU5r5m8b/DTXvCUAu7mNLvTWOBdW+Sqn0cdUP1/OvrXTriCDXxYzgGO7QkgPjYV5z7e1SeJoLYpJE+PIndYSJASJN3AJHTvz2IoA+D6K9z8ffAnW11DU7zw3bRNDGzP/AGcpIkRR1KZ4YZ988454rw50aN2R1KupwVYYIPpQA2iiigAooooAKKKKACiiigD7/wD2XP8AkhPhn/t6/wDSqWvVa8q/Zc/5IT4Z/wC3r/0qlr1WgAr4D/an/wCS6eI/922/9Joq+/K+A/2p/wDkuniP/dtv/SaKgDyeiiigAooooAKKKKACiiloA6HwZZxzapHNcIskMbDKsM/j+FfWvgKaG7tZJLdXayQqisxJ6DofTnOPXBr5s8GwRyeH8omJVk69CfX+lez+AfFUnhfQdRltYI7iUwBVimPyI+eGbvsAPOOe9AHrRsNOmTfFJLHMflOT8v8A9b6ipPsuoWVr5UErBWGwGN92eemTn/PSuK+H3iTUfFmpX+mappS6XqdlbJdBWYGO4RjgtGRkFeQcjI5rsp1ms4dzPLvDYJiHA/3l7YoAz9SmkubKeE+X9pRBIGk4XKkHIz0bj60yze1l1i+msmVmdI9rKR93YpyR/wAD6dR6d62YJEu43TUI45Wcbg5B7dD0ptxoNlGqDT447YzSyTsVjyHYhck8gn7ooArxvds4gdIblQ3y42qw+hB/SquuWMWt6VJpd6qXmnhg0lleR5ZD2IB5455FWZLOXy4TcCFgeN0A2spHoO3r+NaBiuJFiJia6QHcjMqh1HYggDnnp7cUAeOap8E/Bmrah54XU9IVlIaKzKsitjqFfJx7A1594o/Zy8W6ZbTXuhzWeu2CIHRrdtkz9MgRnuOeMk/jxX0vJY3hR5TzGD8rx8t/wJTVWG61DT/MaMMsBznyzjP50AfEem+EPEWpald6fZaLfyXtopa5i8kqYQASd+cbeB3xWDX6EXOqAxXFo8cM6XsOLhJI2VpVIxgt16cV85eNfgYsWjC58KTPLexyzvLa3DYZ4iw8pE4xuC5zk89vSgDwSitNND1Ntfj0R7KeLVZJ1txbSoUcSMQACD06ium+MPguXwN4sGmTyWZd7eKXy7dy2w7QG3A9MsGI9sHjNAHDUUUUAFFFFABRRRQAUUUUAa+h/wDHjrn/AF4j/wBHxVkVr6H/AMeOuf8AXiP/AEfFWRQAUUUUAFFFFABRRSgEnA5NAAASQBkmut8GvFoGrx6hqNmJ3jGY1ZyojY9HIAJJHPHHJB7V0uj+FtI8PwXcGv3U3/CVLCZhbQFTFaLt4Ej8gyHIBUfdB654Gcmn3OoTQRWY33E8ixIp7sxAAoAXT/EOr6eLl4biS5nhj+y2Y8vKIjBmZgD6DJx+ecUxvFusT+Hk0eaSG9gMUfk/ulLQgEkKD2OTkg5617F4J8BJB4QN/cr5k81zKN7x4ARX2B0YZODgnNeX+P7PT7HVWa0n3XW4+fGDnYRgZzQBZ8U+Jn1LQrRLjT1hvICDeTySBZp5GHyYBJLAdeBjpmvQNHW68T/DnV7cIqpbW6z+ajYzICpQ4PQEE5PqK8jj1C2ms/s+oILiDH3SPmT6GvWfBOriD4ZXmoW5cywSkMTjMsOCASPYHH4UAeq+BfGf/CRwaXa2VvAthDZmDUpXnImjnGAAE6EH72fQ16PA6pbiMb5IwSDxkYB45/GvlTR7afQfEmleINBZ42nSNyiAmOcsMoXHZflwT7GvoO78f6bcWaSJbzx3G/Dx4GSMdQenXHvQB2OImtywC7WBB5zn2xXOvpJRv9HcQHGFZWPz/UHgGsNPG9k7qrwXEUZ6ngkfiDXVxPZXFrHOJGNvKuY3Rsg84x9fagDkb7TfLvJUVNsi7WGSCZSCST7c7emOlRyOLqCVLhXEsa4EgwpzjODjj0/Oug1KxnEsT/LcIQdhY4YYHIz9O/4Vi6xcPb280oP790VYy+DuY/KAfXow/CgDntClhuLy8W+t4sRhV3Md2+NdwY5PbkECty506VTHYai8ZjZd0Vwo4HPy7vbpXIaTbzQavD9qhjuxJcSqLcjqyp8uPpjca9jsoPt2mwyXiRvdBRHMmcB9uRke9AHB3Uk8CpbzFzLav5qyyZchsg5B64IA7nOMY715r8S/hTbeM7VdT0CG307WdrzzRFMC5UjOeOM579eec17J4rRrIWCvbSfYmlS3FwcBreM4Bz/eHIwPY1kPILO0WNS0sNuxETlCuR2IHUrycf8A1qAPhfVdMvdIvXs9TtZrW5T70cqlT9fce9U6+yvG3gXR/iAJYLlEstRECi0vJTjMmOUyD0z0UjnnHNfImuaVd6Jq11puoxNFdW7mN1Pt3HsetAFCiiigAooooAKKKKAPv/8AZc/5IT4Z/wC3r/0qlr1WvKv2XP8AkhPhn/t6/wDSqWvVaACvgP8Aan/5Lp4j/wB22/8ASaKvvyvgP9qf/kuniP8A3bb/ANJoqAPJ6KKKACiiigAoopyqWYBQSTwAO9ADaWr+k6gdMuPM+x2dy4ZTtuovMUYOcbTxz3zXaatpeneJvBmnaxoVhb2Go2a/ZNQhhbCzyZJWQKT8uVxk9Cc+lAFzQBFZNaaZLNE8k9nDdxvGpC4ZdxTnqQeCfXNd1p4lgtmdVLiRAuScbd2QMjvyRXz/AAS3Gm6gki7o7m3fOD1BB6GvevCGqf2vptpc7Njy5fGehBx+WRxQBraTq0vg3x9oM11e3EGiW0DSPbTOTDh8pJ5Z7DHzY45+le9JcpfxpdaXe217bPjy7qFgwIxnBIOO44NeT6NdwlBbX0aSW7o6PuQOVJXqAwxn296oeHbTxV8OvECJ4dt21rw/dH57W2+aQDcCWVegcDj0bPsMAHszswk/fySQODkn+En1HanuY5ka2mhjiR1GZ1lMavz1GOP5fWrouUexikurZ4nmAZdybNqnqHUEjI7gGpoLSa2mceVB5BXO1Gzz6rkY59DQBz5hYSLJCEEa4DmP94CP72PX8qqPFN5jut21vyQpVyoIz2zke/41sTx29/xGUWcd84x7EZ4PSoPs0NpEFYoY92HBHJ9v/r/rQBGby8iiVo5Uldj8yt8m7A/I/XioPtkkDf6WrQ7gTvIBXIGewq1bWs9xMUt4YJAQWCGRkyO+M9T/AJBqrHE32yOMmSJwDkMCMe2eh/rQBXikjlncp5GGzlGfaHJGcjHQ0yUrb7XJKk/Llsv+GR1H1rWjtLKRlYsqOoYNG6gxSeueOvGQeorLgtddsNZkmtLuxutGZGOx0MdxbPuBCkDh125w3B9aAMG/8OaPqeu2etXEf2bWbE/6JfQSgt0wAVYYcDPGemfSvPPG/wAHLe/1fVPEceo32p3IzdHR5APOujn/AFayg8ADjoWwOMk8e1C6tJ7nGp20LCQAeZCpRgfUkVV1LTLzzpBPdQzRSNvTd8yqOOMD+n1oA+F/EFzdX+r3d5eWqWsksrAwxxeWkRXjYq9towMdfWs2vsbxt8P9M8S20FhrVk1h5Usk8NxaEJh5cFywI+bdtXk88YzXz/8AEr4U6x4NmknhJ1HSc/LcxIQyDsJF6r9elAHnNFei/Efw5oVp4d8O6p4WmguF+xxRat5ExkWK6YEjOehIByBx8vQZ586oAKKKKACiiigDX0P/AI8dc/68R/6PirIrX0P/AI8dc/68R/6PirIoAKKKKACiiigAra0NLax1KxudWRxb+YsmAM7lByT+mK6nwx8OLzVNBs9Ua1v7wXwlFvBZR5ZdmQGfIPBIPA5ODS3dlAiKJNPtUaBvMYspLEYC7Tz93jp60AepamfAepJHrGo2d75l6inzIrli0mwfeA/i9/euA0rWxFrUcGl28scl1Mba3EiEmMynywScdQrN+NZmgagn2dLKEmN4fkKvISG5J4z93qOPXNdx4CtXuvFliWtDdrZP9seLJyAnO4YPY469s0AfQfxB1620l4tHgkKbIliSOJcBAAOw7Adq+S/HFjbS+Kr9rC9JHmncZEbDNjnn65GMV694p8Z+HtZ8e6fdST3ErzxeREqLtSKVm3N5hJ7AKBgHr2ryzxqlvF4kEsE8TW+oXMhQxE5jAbGWz0JP9aAKfhnw1f3OlajrKW7XLaXc2wksRbtKJlkJySRwANv613k99Hol1P4e1C1RLXVImSyKfKg5JCY6j7wGK9M+A+nGLR7ieNZZ4XkUXBxlpG6Djtir/wAYvA+n+Jmgv200kQh0Vo2KvHJ25XscdD6UAcP4ftZNP0GysLkh5LYMqueWVSSQm7uADx+NX6NE8N6//wAI6Li30576G2BVnjnV5GAJ52n5icVWtrmO4D+WWDodsiOpVkPowPIoAtA1NDdTQkGGaWPByNrEc+tVc02107W7synToYL7YeIVcLMRjsuefwz9KAO+0Lx1LEI4NXQzRqQFmThlHuO/4YNa72fngXURFzB5RmXyzwuGLKw/3eRXkOmXpvYpC8ElvLG5R436gj/PfFbVhql5Yo0dvcOkLgqyHlcHg8GgDofDkscGoxaheN58pLmZFTOwHHK46fKwB9f0r1mRIBaRzWsiGJgGQ9R9Qf8AGvKPBUcia3NFdtvttQgEcJCgeWyjhgfXjGOM5FXdY1HWdJ1RraXL2jL5u93PygA5Cgdjj8z70AdxJvnWVpHeO3VS0qq6gED2x/KuYFvp12Vg+0COWQsUcNwkY5JYdAOQBjqTxVuB4r2ws0uGVoL6VY5kDg7VfcMZBxg8euazL++06HXdL8NXyB4PsszW97KRGqvGQBCWB5wCMg+goAp6pbQ2sKhHMkiqZIxF0lKnsw6Hvzjpx6V5f8b/AA5/wmui3F/a2efEmk7fmhTJvLcjJUgfxoOR64bv19f05PsCPaykym4zIxcAo4AAO0r0444xWfZacwuZbi3EoAkkRvJ5aMKSQTjrjpkcjPNAHwgQQcGkr2/4yfDmEGXXPDoHmHfJe2wIUHHJkjXr0ySv5V4hQAUUUUAFFFFAH3/+y5/yQnwz/wBvX/pVLXqteVfsuf8AJCfDP/b1/wClUteq0AFfAf7U/wDyXTxH/u23/pNFX35XwH+1P/yXTxH/ALtt/wCk0VAHk9FFFABRRVnT7Oa/u47a2CmV843MFAABJJJ9gaAEsbSa+uo7e2jaSZzhVUZJ/CvZvAHhmLwTqXjbW9Skt76LQbTyLSREBSeWZco6hvRMn2LCvJtLe5sreS/tioEUioSRycg8A/hz+Fdp4Jur+S5fw3bQS6jPeHyksuAJSoDIGzxj5e9AHnU0jzzPLIcu7FifUmur8ARXkWtSwmGcI8BMiFCAFxncc+g5/GrXiPWZtK1Dyo/D7aJepFJBPDLDs3bsDO0gYOB1rTTxVeSwW+pmwlhtEthZzkHcki8AHae3bNAC2Xw/TW7+/vb3WrfTrJG/5aRtLK5zghVHoeOSK6PS/Dt14UkkltnkvLJ3/dQE/OoUkHnpnIPA9qrw/EHS72KRdQgSNluPNt8KVViRtZ2x/EB6+tdNoPibSrnTBaQ3UMqpI0gWRhnOSSf1oA2tHuE1BAUBDBA3zcEqcc/l/Ktn7ZcLbGKOZljJyWQbSx9+/wCVZVpLDBaJJEyRRug+ZmGCB2z6VjX/AIz0K0uBCLtJrl8bYrf5yT9RwPxNAHdaXr+qaaoS1vJUhznyWAZPyNdZY+MrOaaEX9tLDuwHeGTMefXbjcB7A14tovjvQtVXFtcTLKBuaJoGLL+IHNXpPF2jW+GmvGiU8hnhcD8cjigD6DaLTb+QC0uIZ5VIZDE4Yj64+YfXH1rOe0WWcLdzOkoPBmUAHjgYwM/XmvL7W4RljubW4UIeRKjYH1DCui07X9aiQx2h/tFQCVt5pFYOeuAXOB+YoA6yWWO2Yxt5bYOFUE8N/eU+1E9zPc2xZ1EiIFG9E54+mMdeorI0XxLZyAHU9Ok05m+8qfOobuGXJ6eqmunuNOF/Ypc6JNEJXXn5yEf/AGgc9aAMeVJZJCPth3sCQDnGSP54NTSFDCsMUa+Y7AhoZSCg6HJOeD6djVxW+Zra/DRSsvBPILDHB7fjTSYZbec2ht3dVHnRyMQQRwGXB60ASJBDBI1rdxkMflUj78bdmHqOOaqWl9ZWvml44VnUbXDpuSQeoHUfQVTKoZPNnkkddmEZFJMRz3/w96hl00XczzylimN2IxgqPXB4NAGpqUTPHGqzRPbMoETM+QncDnp+NUD9oCMlxCZI2UBSOx9ADxUI025HmvayJc2rHLLnytxHfHT9KfLaW08MljJBcWc0qFVngb5jkY3KOm4eooA4fx78N7bxH4cm0jw81po11cXAmdI4xGs0gBASUDt6HsfXNfJ/inw9qfhfW7jStbtXtr2E8q3RgejKe6kdDX3VDazxaNGL65t7l40VWfkEFQB5iE889wTwciuN8eeBNO8dpbDxIl1bXSLtttSiGSV67Twdy/qPXrQB8YUV6d4p+Fl74S8Q6c96G1Xw5LcRiS7tUYYjLDcGGMqcZ56ehrC+LnhMeCviBq2jQiQ2ccgktXk6vCw3Kc98Zxn1BoA46iiigDX0P/jx1z/rxH/o+KsitfQ/+PHXP+vEf+j4qyKACiinAEkAAknoBQAg68V1vg/w7p+piS41a+mtLKJHEs0cYcxPg7Bt/iydo7dfau08PfBTVZ/Bz6zqm22u7lhHZ2kh2OGzk+YDypIyAMZrmLXRrmfUND0mzWP7XcSFJfKJ+/GxBDfQdT+VAH1D8ERB4V8IGGWRNQuNioCkRRSgyVC8HJO4nNJ4q8L2HjHSpbWy0O30E3MqzyXlwFLnnL4A+bJz04qppWt22h6GLGGIkwsF3j+L5efy7D3rn7XxNrQ8RzxXVqt9pywKIoYp2RsHkvuB6nj8vegDm/ih8O/D/hfQ7G+/tO7n1maNIoYCUj3RpwZSoBIHIHJ/E1yHwv8AG174Q8SXZW0tr0yQFWW4Jx5ePmGRzzXp3iC80nU4tRNtaRWtwsW2eN33bQCDzuyehH6V4zZyRan4sivLKNI/NmWzaONflYHgnb7j+VAEPiCwiK3V1br5MUsvmCEnBjZj0X26c+1cy9vI1xHveQhnAYyHIGT1Ne7/ABv8Oz6JZaLC1q6NdMWZtm0YUcZ688/pXCaD4Xm1FZZponjt0QlDjl27AdPzoA9P0S8h0KAWWn6l5Lwp5cmy42seOd3ORmtGHUJzuliu5j5uCzpKTv8AcnPNeDeE9I1fVfGFsNPtp2mZ288yZQYGd29m4/OvRdPtNYs78iK1dYY5VWZgcxKGPPTgnHOBQB21td3NrKZLW4mhkPVonKk/XFLeXlze3BnvJ5Z5iADJI25sDoM1zfiHW20YwObK4uIXOGaFd20+9Pu/Een2Onw3eozG0WUZWKVSJP8AvnrQBtZqRRNEUlB2jqkiSAkH3wcqfr+FYeg+I9M15JG0y5EjRn542BV198Ht71rZoA1NSn0zUIVu5LOaHXs/vbuGQBLkesiHqfUjBJ5zVA5U4JBGAcg/55qvNK0UZk8qZ415do0LBB6tjoPeiC4jnQPC6yKe6mgDX0/VprRBC2JLXdkxHj8j1B969F8Karb+I4Zbe9O+6jBKE8Owzwc92AxzXk+auaTfyabqNteRAMYZA+w9GwehoA9XW2Q2FxZeUouzH5UVyQWPGSMr1yMkjFc/pvhqLw/q6ahOy6iWiW23XKEvGgcswxnC8nIwB0I9BXXLeWOpRtf6ROszOvzR5IIY9zj7pGOtRtdiUGDVreOSUf8ALSOT5gPcd/qKAMXVYfI02d4JVvMMZYYYkJLuQeFH8IwOf8TVDRI7hbSIiaG2imEiqA5EkG1D5bMOzM3XHHGDnNa1nHaTW9xZea8ZhIMEjA4dT0Bx0YHjP0NQTW0kN1K7EpcR5Y4Yc+4xwRQBDJpMd5cCaEA6uyHfBKBGs5P3jGegyD0r5K+MngK68La3PfW8B/se6lJjZR/qXOSY2H8PfHt9DX1yvm3ECI7sYJcyRttIKEf3SP8AD1qO+Nvr1sdI1ezFwtyhjdzHubZ0O7+9xyD94dqAPgOkrvvi98PbjwFryxxzR3Wj3mZLK5Rwdy/3WHUMMgHIrgaACiiigD7/AP2XP+SE+Gf+3r/0qlr1WvKv2XP+SE+Gf+3r/wBKpa9VoAK+A/2p/wDkuniP/dtv/SaKvvyvgP8Aan/5Lp4j/wB22/8ASaKgDyeiirmk6fdatqVtYadA893cyCKKNBksxOAKAG2Fhd6hcxW1hbTXNxKSEjiQszYGTgD0HP0rR07S76C5DhEWTYxCtz1GOg+tfT9zoN74R+C1zBbvDbtFCqbWjxKiyMvmncPuux+8D/CAvavKfhe0GmeKLbVb0mSGKRAxYbv3efmOPXHP4UAeeXFubPRpbQSmRnkWU4UgLgEH+YrV8M3s1z4piuY98MwiQ70JUqy4AYEd8jOa9i+Lnhrw1Nqmq6noJjfT20v7Zi1+VElaQJE3PUMSxIH92uU+CWkQXPjyxtLtd9pqNvLavgfcJxgg+oOCPwoAj8T+JNX1yR/NePUmtWEBa+kL7eMnGenP5muV16/eK1mimgjeJl2ARlgqenB9PatG5s/sd9qVqJnEi3DbiRglg+N2D2OKh12KGaF5JZkt4iFXDIzZJOMDaD9eaAOpl8Awax8EbLxfbLHG0RME6qmCP3gXePXBP5V5roenNOZTbyrHcxbgOmGIOOCeK+0/CXhrTX/Z1ttIhug1lPpbStchCuGbMhbHXhiffivlbwN4bnn1iW1luord7zTjd2qyoQ0z7Mqig45bqPXIoAwGvLwLJDcXEaPHlRuUMo59aqwM7XQuZ7GIpyrtGNrD/aB9eK7XSfDl1rGuxeGrt00q5C7nM+Vyo54BGd5PQHn8K2fiXoei6Dqy+G9GtixsYlN7cSysXlkYAkAcAKoIHHUk0AecaFa2+m3731tfCWKMEGEoRIQe34e3pWnrdnHrOlHVFuRbr9oaGItINrlVTfx1Jwy/gRUtnqMb2emRD5YVbNwUABOBwpHpnrUF8ltfeH7O1nc+fHqF3dNGqYysiwhct3/1ZGKALfhnWrjwMsF3FM1zaNKqzW0gzFIp6kKeAcf0r3uCaGa2hmKx+VKoeIAjkY4xXkFpqWmP8H76zvBFNq0OoRGxDAsUjUHcSfQBsc+1eU3l9OxRPtMhSM/IA5+X6elAH11uVmy7mMDgnsv4etXbLVrzS0VYLkwRO33RJs8w+uDx+XNfL+h+I9Y01LfGtzzW0uAI1nLeW3bKnr27YrY8Y+L7y9gWDVbpTsbeiQx7WDdMkjpz05oA+m08T3oOL5YblcZImhC8eoZcEVonWbC7hxNcPZsW37JoDcAH/ZkGGH86+b/BnxhhisoLTxAk/nx/KLtAHDD1ZeufcV6PpHivQ9YdYtPvLZpuPkLFJP8Avk4NAHrUEbyQi6t7lb8MSG2LuUfUgcH64NNUTNGCkt1CkRzsba+Of0HNcAtzc21xFNp2p3NlIpIlgEY2yjtl8gqR1HBrWtvGGoRsPtSQX+w8u6gMfoy4P55oA6/E/lsPNRSedixhQx9wckH3FVJWV2VpRgK+Tlhx6jBPINZ0fi3Tbxo47uO5stuSpB81VJ7joy/r9K2rS10+9ObaSC/deQ8ZDHH+0n3gfcUAVprezuCzEyQXGQwjPCt9McZ4/GmTR7FEcpea1Lbj5Q5Q9Mg9eKS6VYZibizuGXBCMuVIPtkcj2IqzH9muoVZikW0YxkoJDjg+x9u9AEVrdx2rYab7RBv3lWUZQ56EHHpXgH7Qnw58R6nqt74ptjd39miKqQNFzDCASdhBOVBOf8AgR64r30hIWaO5t5o5FxiQEYQ+pP8P1FVba+lh8yFZ91pKSGUEAL9Dgjn8OaAPgOive/2jPh/DbXh8Q+HIES0SKOK8tYodgh2gKJABxggDPTB5714JQBr6H/x465/14j/ANHxVkVr6H/x465/14j/ANHxVkUAFdX8OYbP/hK7GTU/L+xxt5krMcbQOQQcjBzjntzXN20e8yMVYqiljtHTsM+2SK6HSLFpNPSeGN/9IY26+W2W3KNzEjrjFAHuvxf8XzavYWn2NZItJtbT7RaOxy078gykjr8wOOnc96qfAjwml/4dstdu/NS6t7ljbFRncrKQxP8ALFaOs+GoNa+FnhrVtPQhZYW0yNGyTc8kJgDplt/Nd/8AD7T30DwnpGh3nlTy2qopKAq6tklgD360AYXiPS5o/tkgZUgMwRmddjRkjOfpXOwWetSgvpX2W4lWwSSGSAr5gePIKsOMnbjHXPSuu+Pel6ra+A7+70gOUuZ44pFBwyqeDx78D8a8R+DupPo3iu2sruT7I8260nSTjBIJT8cgYPvQB6B4c1y71ibUY9TtrSW+NlCjBQoM7mIERnJOW4RR346ZrgfDFhJZ/ESC51KxkiilfzjC0ewq6hg0ag4zjjJ7fjS+NL3UvAvie6XTpbO6SaJJpHYK7pklvvDowYsMjtjiuD1DVX1zWmvbvz1uZ5Cwl85mYt35PNAH1F8QfEtt4utoLN9MjigtmzFMzEy9s9OADgZHP1rlLWGO1t0ghBEaDCgnPvXnuk+JLjT7Hy3LyOgB2yktuH1PNegwTJNBHNEwaJ1Dqw6EEZzQBZilaJi0TFGPUqcE1Zl1K8mh8mS6maI/8s95C/l0rnY/EGmSXptRdosuNy7/AJVcf7JPBrUUhlDKQVPII5BFAEoJB4JFcz4u0GDUiLmRY2kUbdhXJc+3vXRZrzvxlqOsWOszPNaO+m4HlMjEqODz6BvagCnY+BdTjv5biwzYMrZid5CrYwOML2znrXplnJcQ2KNq0luJl4Z0+VT789zXmWiPqVxCJHv7mMNg+VvYk55zknOPap9TtriYbrm+YsAwXe57jBNAHpWj69avcRz6RqcRnQko0Mo3DHX3qxM4lu5rp1QTzHMjIgTcfoABXklkj27eYuydl+X5Oo9+PWtSDxBd2kh8ouR3SUlh+FAHoxdVUszAKBkknAFLuG3dkbTzmuHg+IdjFFI95bXEM0JOBGN+WHp0x+NdRDeRahDHd26bIrkeaoAIyTycKelAG7oPiKbRdQEtuC8TECZRgFlBzgZBwferR8RXcOp3NxpV7qKWtzIZnt7po5BknPBCg49jnFcpDqFq10bcs0c442SRsmfZdwGfwrSjZVPIwcjNAHo+l+IbTUwsdwVsLpjnz1fCHseTyox9RU0sFyl9BJZrB9qAmMRc74pDgFQGHYgEDHQ4/Hz2GXIAXG4gkbjgZ61t6Hrl5YhoZlKwhvntmk3xsD0YFeOfUdKAPQNLt59U0qWeEi3MT7jZOd3lMoyMHsfQ9DnFV7yE3d0pYILknazEeWC3GG46MD09c1nWd7b3s4NpPsd+sM7bXGBwA38Yz9D061ducGaC5mJKqdm9xkMfRsfTGaAOI+L/AIMh8Z+HJbGPzYdUtFe7tdigi5lCt+7x1BPpn0NfGs0UkE0kMyNHLGxV0cYKkcEEdjX6DyWcl/p0k8GVEZw21tzRuOQwz7EcfhxXzL+0P4Fgs71vE2gwMbW5kb7asYdlSUk5kO5QUDEjg9zwTmgDw6iiigD7/wD2XP8AkhPhn/t6/wDSqWvVa8q/Zc/5IT4Z/wC3r/0qlr1WgAr4D/an/wCS6eI/922/9Joq+/K+A/2p/wDkuniP/dtv/SaKgDyqNGkcIgLMegr6M/ZT0GCDVbrW3jSW7gxBFkZKk9SPwxXh+kWTx2Et2qkuAMYPQE4z79DX0d+zhbrZLrd4+FspkgeM9drtxjHUGgD1n4jWlvqWjXi6rB5kc0WGWLIZx/8AW4rxjxr4StdCs7ax0fTWhvv7O/tF1effvh5VlIP8SYBOOvzccCvbdSh1bU4bZTKDbRzCViqjdIq5+Un+6e+PSvOfjNd3MEOn3Vt5ianpjl4JDx5kbfeX3HHTPTPrQBzmk2jR+DNQubyKSXT7vRI7SZ4RueMqfMDqv8W3lto5wpxXI/D+/Twt8TLS01J0AgO6OVPuy/MrhgfQrgjPrzXa6rqX2f4Z+GrBLg2j3VzPILlflVXRQoz22/O6+wOecGuK8U6Ob+PwfcmFIb825s7pwd0Zkhyitx3aNQevPWgC78TvDI0nxBd6nA8Uul3ty5typy6AneUYHnvjOecCuRhW11F0stRkmht5cIHjQO24kBQASO/vXUaXZ2viBJLSTWwXs3XfNMzO0a/dKqgwDyCc+wFZ/i/QYdGttHumnJs71cSShMmJlfDgepAKt/wLHbNAHUJ4j1T4X+Ko4LC1u7jQmtBE9lfXG4XsTZHnHqEOQVCgcAY5rzrw/oF7e2txf3Ev2G0s45rrT5UcM8ksckY8lTnIYB1wcenbOO5utKeTxXDd6/rFhcadDOpaTUbrDTQLyqiMZb/gIGM8dK2vFGofD5JdPuH8rUorKOZoBZwMyws8m8gq23POcZ4AJoA8h1a7hvLyS6ea4muWYmWSckyhvUknOR9elb2tW91JFo1/qfktcajYrcRYlLuYgNm5s85Own/OKx7zTrPxBqN3eaNFdWcMshaNJ5BIy+oJAAx6DsOMmsi4gl0m9tnjllk8s8CTqm3kp9CM4oAhSGSe5uHtUaOTz9hiPXnv9e9WLj9xbLLDcu6yr1CrtLZGBj+f0qTVnitZoL+AsIJ8biB09GJ9e2ParNpod3qWpyWFuEa5aJpjD91m/dl1KjHJPHHckYoAi1CJdW0nT4bd1t5JkLHbGFEjLwVOO/fFYreFbkopinjbPXcCMV6F/ZWlw+ELe5W9TdNcQ7lnPl+XuQAn1XbIpyR2IPHNVLm0gsbhotX1eGNADuNmfM8w9sEAAZHOaAMDSYZ7aLT1OmQ6jcWdzv8AIYnbLt+YA45IwTn6Cur1j+y7rSBM9qqRxwpvNyytufAywwBgE9B71l6zqk2n6dp82g2UsaXMmI2fDh1QhiBnklsrn6Yo8f2Gn3Xg3TdY0XUHKXBw+mzRsJISM7trDIZVPy9iBjigDjJ45ZkmfT4IikYyfKUbgM1mWV15F8k04Z8H5sHDD3B7GorS6ms51ltpGjkXoRXUeItVglsLVJrCF5bmFZTMMBgckdce1AFqTXNa0CwSaw1y4uIZJyE3uXUrtB5VsjPNbGkfF/UIFVNTsYbkD+OJvKb+ork7G0+06f8AZInjdJGEoimkCOhx1U9D34qprFvb2jJbKsYeMfM4O7J9z3oA9u8OfETSdbfyzHcWzZAJlX5QScDMg4HPc11rXosiJ47yOEjkFiECe4fOSa+W5NTuBa/ZonZIC29gON5xjn6YrpPD9jFrOmRPeBiIJ8IM/f8AlyVz6HigD6R0nxrfPDtsdaNzGhzsLrMo+oOT+ddVo/jGzm82PW7LbFKPmktCVB+q5/kfwr4lt9Xvk1wX1vcG3ui+FZDtCDoBx2HpXqem+KfFyrcNq8NiYbeNm8xouZSPoQMcdcUAfU1rqOmSSxDTLu0vIxyYpH2Tc9fvYDf/AFqTUf8ASJpkNgVjfawYQupwfcDHb1NfN2jfELSLnTYptRuEtJzjdCWZwM98gdP5V2enaxHJapdWepMsGMpNHMQoH1HT9KAPSzp9rEsgeN7Xd8reehIYY5GO4PrjFfNvxf8AhXf20uoeJtCt4ZNMkkEj2lnC4+zLjlvugbc+nTPpXs0fxDu7mzEHm2Oo+WQvmMNzqfdlIwf1rz345fEKS88ESaIYUt3vZ0dvs8rYZU5wwYnjOOncD6UAeE6J/wAeOuf9eI/9HxVkVr6H/wAeOuf9eI/9HxVkUAWbRiFnXcQrIQcH8f8ACu4+H94unXYieIzC4s7lSOu1tmQQOxwD9a4iw3lpkRVbdE2Q3oBnj34ruvDV41r4Xup5Y5JLqN1e2kVclMpIGyevPT60AfZXhDQYZfBnhhYHWW1trOEw7flXpyw9G5qp4n0a4s9QluRcebboHkYv8u3AycnpgDnPtXQ+CdVsb/wrp91p8sJ07yI/KMTYC5UZDA8gg547VW+IukTeJfAmt6Rp0qC+mtm8os+0F/vAMccA4wfagDOW5TUrW/0nV1+0aTf2olWTcdyAgcj6Hn2r561v4VazqesRQadcWcoWVrSW9875ThSysQBuB4PH617t4XkRbfQodZik/tCa3aELKdpMm0bYyccjH8WMZ7mvCPCd7rWh+PbK+1SPUreC61VWFtI7PG+ZWRyx/vKCMAgcHOKAOZa00LULNrYai1texW0rrJdoI45WQZ8sY/vjhechhyMHhg0+2tvCNt9mt44dWjjW4ZerMAQynPoSpHWuh+Inw11lb3WLez0q8njguJFhkSE7HTO5Tn6YruYZNO134VGJ4xapZw7YA207JIxhoiw/vAtjnuKAOf0PTYPiLpk0aFRqFvbGaIgcuOSU49QMexrn/A+oef4fu7ZU5sneJQBkkdRwe/OKxPg/r8uj6+ps5i8uWWIOMYCMCv14znNaHi5rjw34utGt9PfT7LVFN3ENxEUm5uQvfbx35H0xQBq6RBY3OsRpI0Vz5CeZ5qAYZHxjK9jxgg9CPTFW/Dcc0vxQTQ9ItRqNkd6/ZVlaFDwDu3fw45PTtS+H4reO1cwcyO26TPUeg+ldX4I8NaTLc6rqh1K/0/XAwmtp4ioRNq4xjHPcnnoaAOQuoNblvLwxQ3f2ZJXRPJ+fYAxAzjn05I5rnRc6hcaVd6de3SyrIpWKZ1y68Y59a9KsvhR4x1fXY7+bUVbR5VKyxw3DIX4OCvH3cnPPPUc9a7S0+B1ha6UPOurp9REm8SxPsKj+6o5B+p5oA8B0kCXSvt8Ns0EYk+zumS4TaoCnceTuwTzjniqesafLfjKStGMdM8fWvTr3wdrPgzxjdS6VqdzeQXjZnsrqHYLhdoyCOjDjqBW7rfwzi8cXdne6BqEPhwNH+9sPIJR24yyuCPfjAoA+f7fw+YrlZTczEgfKNxzn14q9Na3LxuxdmcDgnmvozSvgToljZSnVtU1KeblvOVwFTA5IUg8fXNeJ+I9S8PR36QeGpNRmtWfyke6RcyNnAI29j2yAeaAOCe1lRZNyuxJLMSByal8N+Jb3w9c+UN8tg7fPCRyvuh7H9DW5rtrLawMZ42SU8LEylTz65rnIrRZH/wBNy59AxUf40Ae1WHiGPxBpKAy/2jp7KFNtOxZUA7HurDJwRyO1NhsYrJy1lqVxPYucx2t2haaL2Eo++vuQDXkP9mqkqzaNcXNrOvOPMyvHY9677wtrkt6fseqII9QVSfNGNsyj+7jv6j8aAOpVgM/N0+9nt+NSrI4AHXjHBrF1PUodNjVpoLh1AyBFGXCD1Pv7dauxyLJGr43o4ztcEGT6jqBQBqreSjJJO7IIyOhFdpo3jCxk06aw1aFotw/d3MJ5B/2hzx+B+lecK7IMAgBfxC+w9aes/OGUZ64749z2oA9VvtPt9S0fybDxA1pA0sUxlt5AwLoeMtg7B0BDDFV/HHhebxP4a1XRtOlNtfzW7KqyPgyEgYz2CHkZ5HcV53Z3kEZZZ7eK6tph5csMq7klX0x7HnNbCeJdD8JeHvItLm7t9OtctHcSODc24blo03BlcZzgcY4xQB8k6vp8+k6readeAC5tJngkCnI3KSDg9xkVTroviDrFhr/jHU9V0m3nt7S6k8wJOQX3EDcxx3JyeveudoA+/wD9lz/khPhn/t6/9Kpa9Vryr9lz/khPhn/t6/8ASqWvVaACvgX9qJQ3x38QBjgH7KD/AOA8VffVfAf7U3/JdPEX+7bf+k0VAGPqUKWiXSRsyQSxIkb9QpCZx+ZPNemfDDUH0zVYpX3+TJ5cLpuKgrgKTx0OBnNeRWEjXXhtXlUfuJ9oLc7iVI5Pbkj867zQp/s8NrIozGpIc5+ZSD3HcYz+dAH1ZfyImjLptnKsagKF2SA4HUYzjAqlrng7QtRs7eae6b92hSEjL7GPUAehPWvGD4mvdKneeG9UFJCGhlOVkHBwB34zivWfCnirTPFeneZbFIbgHYbaSZFkVgODt7j3AoA4HS9BvL/Q77w9rtsksFnfLLbSQ5TKN8uR1xwSPwGa5qO/t9F17QdCW28u80K9Ae1mUhmBOFY9iCrHnvmvf7SD7BbKkkTNcSvsCqhAVAc7v58k15H+0fpaL4m8LeL4GWNUmW0unZShVQwZXPHb5hQB518RPD+o6f8AFB9K0O2mlkW8k8qFRtMkbENz0GBk89Biux8P2d1c6DrfgrU4bedp0e4tb25jdWgRyNuAVOM7Qc5GQeMiu30PRNA+JGsyX6arLOIrNbeSBWMMqyZx5oOc4KBQcgg45qxrnwyk0+/h1HwbqF3Z38MyJLHdXLukqAjbuPUL27jrxQByXgj4YaZO2r2/ia2N1qcDoIpYLg4MTAkMpyCckEc9MdBWN8R/hrZaLa2baU9ytq8yx3QlYMY1ZgAy8DPJ5zXsHiy0sNU8Q6THa3v2a7smZrr7KMrgjDRFuwyPQnHpTLm2sr4z6fc6ct6j4YtgsMgjggn27c8UAeReNPhhdeCfCMGqWN6LgSOI5lZRmJjnacjsTx04rzBvD+t6hnUp7edtMjZY5bphwgZ9oYDqRn0r678caxokvgy+t9Vt5FRojEIGTDyv/CEPZtwHJ6deleffE3R7nTPDHhieKKW1aC3giltyQ3zBec46kEk5oA8c1fQrTT7CfTr+3m8+4eO6s5tw8h7Zgd3APXeDj2ya0PCU8sGuWWouY5JrXyLSMDLM6/P85JJ+6IkTHbC+9dVewWureNdHEtp9t0/7JFZz2m7y3hCR/O3ByNoO8Hoa4rxtf6B8P/iJH/wi0s15YSWa3LNJKsi+a5Y/KVHTAHUZzQBmr4Xk1+/vLO4nmkmiuJw24bAMEsWAx2Gc1na7BaXWnKpgjjMcYEXlDBbA43Hv+leuaBpdzrWlXl5ovlrqGpLL5d9cXHlI3m53hTg7nIJGeApPXPTgNM8IXl1qt9pGq3tvpc1uQplvW2KGzjaWHGe49cGgDL8JT2az2Wl3cYW1uUMse7c72sxUgEEc7TkZU5/DFegeFfCs8XgzxVpGo6Zd216HOp6fI8JAZURS6hj7MCB0wWrgbbTYtA1+MateQ3Fnpt6sc7WbhiiE7cqe45B969I8A6rqOnfFPxQl5rFvNbXFtJPHLzPGwXJiYYHy/JlWDYwp56UAeRXNjaSOHaCF36klRz9azNW0eWe3t7iJvMtLZQkka8FBnJK+o6+9d14xigsvFmo2n2OOCAOJrbYSVeGRQ6HknnDYPPUVkxXGPMVUGNv3ccEelAHCz2ZNwqR5YLkrtPVT90/rU9tot9rf2NdLhM7SSi2wCAQ5xjOT05xn2rRhtLi2uJ7hY1l8sBIlyOWPIGO+KraFqzeF9TAimEyuMTKpwEbsQR3GaANfU9B0bT9ROlyzm9Nmu2a5t5du9gx3bQQQFzkAnkjnHOK7jxLomi6L4D0XxF4Xv5rrR5Lj7N5UiBbiC5xnD44PQ8+h75riNeuLVdNkvYVjeJ38nMa8M3JwT09efaui+B+r6dcWuu6Jr0MdxBNt1GyimYLG95CrbIyTx8ys3XH3aAOD1Q2k120ltLEsmdwgW2AO7uM96u3WqS6o9m+oTx21k8TbXLMUBUcgovJYnGB05HI5rD1fRtR0P7DNexiI3SedCyyK5wGI5wTg8ZwecEeteh/8I1Z3/wAG5/FEN3C8UdwY7y3CESW1ySApGMgqwIPbrigDzW9vhKqxQIY4U6AnJPuaq+fL5Xlea/lddm44/KoqKALmmane6XOZtPuZIJCNpKHqPQjvUN1cz3UzS3MryyMclnbJqGigDX0P/jx1z/rxH/o+KsitfQ/+PHXP+vEf+j4qyKAHIxRww6ivT/hgF1Sc6RJlZ3jEkW0437GU4z64ya8urpfAGpJpfiS1vWuWt5rcl4JM4AfsCfTGaAPbrrxPqfhrUWsrhgkttJBcxnJVJogrHoO/3Q2PSvRvGnjRbvT7S3WSa6sWt1vLhI8w/bCUysayLztzznHOMGvHdVvptevrOzvb6DUbb/XsjJ5c1uWByoIxkNgfdJyOo9Na2YCKJfJe3yvyIy4wB6Y4OPY0Ae9aB4ds9O1RNRsYYvLmlEpmluZLieSUjDMd33QBjHJPHal8XJbaZoN/fapMyWNvDLcMzLltwdTuA6gnpXB2XxN1q0t44kttNJQ53+QVLHuTggE4qYfEnWry6RWsdOndwUETRMwb2xuoAydf+IepxeOr5oorp9NsbYS28Rh3rcSYwGY9lO/OegC+9Q2HhrUfHug3TX1v9i1I3zTi2x5cBEiqC+0qGO1VIAPqADWkfijrNuNQvprrT2ERET2ckPJ5IKqOuBjJycfyrn7X4u3ustvivYYjCPL2fZVUIPQcH+dAHEaf4HufB/i26s7ly725cpLtx5kTggZ9DwD+Br6A8T2PgnxZ8PdNuPEWoxWNtYACIo6q0Um0KV2kck46fjXjmpeKo7+/zeXU93c7QuQhY4HQdKyPE2n6jPpmn3mo2bWdjelxbmRwX+XGSVHKkgjr2oAi1SDS7O+T/hH9fjvY4CzEgNEwUf7LH5uOw/Kui0HVZZ9KiukmUCeP955Z+UgHkH8q8b8T20um3SmDe8EyFW3nPzfWvX/C2lxeJdFNrod2sUcFi88sUUYdggTOCc/KxPHPJyaAKmtap488StNBZ6lc6fpkbbbeK1fYrjsWZTnn07VQ8P8AxB8d+AvENrZXWq312kRKy2d6TKjIBkYzyM9iDW18F7wNrX9hzNHPHLHvt3ydwHQr+GRge9dl438FjV/H12Lmeaws7PT4pprpVPmAkMqovONzY6E9AaAPRPG/jTw7Y3Re6AuLy3tVumTcq+WrAFQGYgEnPQc1yXgf40+F9W1kaHJaXdrDcttWScKU3twBkHjJ4z61zHir4V654htrnWdG1HTNSi2JN9kjkJk4QARkDIyAMdecV5FZaIunQTPfP+8iDZDAgIASSD34oA+34ftVnBItwgFtFtjRpHBJTbyzenpg180+JPAPhrxD4kv7bw1rUClJBJcWjfMYQ3O5COq9/b2qX9ofXR4ovtKh0K9d7a0tl87y5z5EpcZKnnBIGOorxyC71HwxefbrC5a1mjRgkttKFkGQRtyO2cflQB9D/Hu3tbrwVoL26faZLB4rc3Q5YJtIO49cEhfxrwi+hG6KGJtryuqAnoCe9dB4B+L2tNcLb+K7i01Gwkysr3ForS+2WUqSPrnA7HpW38RIPATvEY9XbSbzG+O4tM3dnJnOOVG5SOv3cDNAHjmr6oLHVmhtJJZY4jtcyYBJ74wK6G1uvt9rDPGWDZyjjqrDp+IqJvhzr0aprFlJaazpXLyXlhMJ9oAOd6H516ckrgZ60zS4SbC4htlVJBdAR7GwNxAwAfTuaAPXPDviDUBosT215PDHcIGmETFQ7dDx+dOK3FwWjhkiS5lBCvOSEQ9ix9M9a8/tvFUfh2yazvx9suIeVeAggZP8QPKnJ685zWXceJ31KeN3uAId3+pRiB+P978aAPVta8B+M9Nt7fU47qHVLcLyNNG+IHPderfgfyrK0jVVv2kt54/Ku4/mkjJzuGcZHftyCOK4u0+I2reDbiRNIurq2lGGSMOWhlU99p6fhVfxr8W7nxMLecaLpttqkYOb9I8TZxjjGB+YNAHceIdf03QoS+oXAWYrlYk5kYegHYe9eL+K/E134huQZsRWsZPlQL0X3PqfesW4nluJWlnkeSRjks5yT+NRUAFFFFAH3/8Asuf8kJ8M/wDb1/6VS16rXlX7Ln/JCfDP/b1/6VS16rQAV8B/tTf8l08R/wC7bf8ApNFX35XwH+1P/wAl08R/7tt/6TRUAcn4f1I3GmXWnkKjCMOmMAFl4HHc85rtba7ZY5YXRxh0mic8hlKg4NeQxuY3VgSMHsa7+11/TGgQCfysL9xwcjA6UAdBc3ElzMZZ2LuQBn2FRdwe4rL/ALc03Kj7ZHlue/8AhV+KVJVDROjqehUg0AakWqXSqI7ia5uIVUqsT3EiquehGDxjrUmlatHaO/8Aa9nFrSyDBivZpNhbruwpBJ69fWsrIBwC5H+1/KloA6CG50281S3mSFdA8lH2S6QhebJ6bt75K/Q9q09N+IuseHdSmaHXNS1u0iXdNBfw5YL3YbSSoxj8fWuLdQ3ltgllJyM4BB/XtW2fEkiadFY2lvb25WN4pHt4UEssZ6h3xlx7N+dAHuWhfEzwveaerfahp1w4y0c8J2kn3Uc/kK1IvGmmW6q8V9ot3Gr4cxXSI4HcAPivmHFsxia3a4RymHWZsRk8nK56cehpfIleWTy7aOSaMY3Qqdzr23e46UAfRfhdtT8Z6vYa9rlxayaPpqGO1iT5jPP82ZGHbaCB7kcccnc11NM1rUpdDS5uIJtvlx/abVwnHaOQ/Ln/AAOK8L8FeNvEelWps9IsZ76KImVoGtPN8sdyBgYHfrXRaP8AFoalIianZ2CRGULeSqjrIEB67VJ+ZecZ9aALeoada6X8T4p5FZfMi8hjG3LHynQ7T2OD19hXNTfBCPVLO1v5JJXuYRG97HGylZ0JYmOPGCHCgDce/bFT618QtMvbaK1trf7RqFrIxivpZMIy7jtYpjIJHBGetaHw2+I8ek6xqtv4pl1KC4BEeAg2Qj72NmeM5zuB6UAW/iXBqWnaNpp0j7Ki2Sm3to4cqUjJATIAwXA5PPqa5r/hG9Q1HQ7Y2GvXk8V/IUvRdgEMwHXgZPzDqcYHH19K8QeLfCV1asYNYsCzfMSbWTzPcAYI/WsLZo+v+HYNG8Ja7FbSx3JuLhrhBC0pPIRQzZK5JJGMHigDw7xH4V/siZw8kX2eVxBJcRBtm4HlTx8p479j3r13RvhK9xZQ6nN4osbOynAcSQNmbDJtaLOQCuONvU8+tVvEvw08YjSvsdrYW9zbTz+ZKbGQ4kfkBmQnAwCRlfXmr3w30a18MFtP16CGK/mlMe7AYW+ASpBORuJxgKPSgDS1D4beGLzRrPTWvLu3k0/fHC5YtKq8f3skxEjcq8YycAZxXJy/BrULYNN/bVpJaMTiVIm3Ef7uf617mYJLzU0mubmCSYQiMGBBtlPdjk8E+mcVSv47mwvVilWC3d1B2Fd27njvx060AeDaX4CdvAt1rdpbXF1cm6O1Rw0NquQZNvcs2D7AfWvOvEnh9dQhNxaBBOg5YcB/Y+/pX2voVtbx2+2wjUII/LdHH3AOCoHr7mvJvFqXHgfxzLrOl2cV1a3MDpLAg2gkY+Y9QDnn3wfWgDwLw3byap4AvtLtHAuhexCW3uCAmCHAkXHzb1yRjpgk1N4z8Cx+FPBtle6hevFeXcoa1tGGGmQcNIR2Hofw65p3hKee+l8T39re2VjeJE04W5XCzBclo0IGFP1xnpXBa1q9/rd+95qt1NdXDALukcthR0UZ6AdhQAmralNqVz5kpIRRtRAeEFQx3lzFaTWsVxMlrOVaWFXISQrnaWHQ4ycZ6ZqvRQAUUUUAFFFFAGvof/Hjrn/XiP8A0fFWRWvof/Hjrn/XiP8A0fFWRQAUUUUAd58Lri2GqbJ7srOwwkT9HPQBT+fFero06KwaOSJHyFJYESDPXgnHI6HB9q+blYqwZSQwOQR1Br0Dwh48lhaO01t/MhPyrcnll/3vUe9AHpkjSRq8u3fCuC237yL3bHcZ6+nWkms7W/2JdPIkfUSRYOM98HgipLa6aJ457eXaw+ZJEP6g0HAJ2xpGp5Cou1R9B2HtQBYk+HOovB52kXFrqETpkwk+U7r32g/KfzrC0z4Y6/Z3LnT9B1DbM210wGC8ZHfgV1uha9faYypB++tw28wt+u09V/CvV/CXiq31XYsNy0d4DtNvIwWYe4GMOPpz7UAcB4Y8HNoegyz3Uaf25LcfZ5mU5MK5A2hvyORwd2Kz/j/ptzp8/h2SRXayFqy4AwBJu+bPvgL+Rr2ODSvs0mqTTSb4LuXz/m55wM/qKPiVZWWqeE4XuovtFrG6iYDg+W3BYHqMHacj0oA8p+G/wu0Txv4Gnm1YynUJS4tnEhCIo+UNgdeQc/hXB6Wmo/Bjx3fWstwLa3uIgyNNHvSQFsEZAwcgd8fhXqWiXN38NdUj0a581tFu5fM0y7PKxsxG6Jj056qff3qx8ZvClnrngxdcgZprizY+f5khbcjHBYA9DnafpmgD57ttVGj+MbXWNLDeVbXomjXkZQtyv0wf0FfQnxBv7m5+GfjPxLYgJLPfQBPlz5aQmNCSf94NXkfw38Hw6/4ts9IuHzBKsjFZFLKdqE4OOeor2P4aTxan4Y1j4Za5F9k1C3gntxLnK3K72RpFPUsG5I9xQB87+Gde1TRL0X2i6jNZ3pBBliIwc9mU/KR7EVJoesaroupHUYpBczglnFygnRyc5yGBxnJ5GMZrf+F/hS31LxNqOm60oAszLb7SSA0wyADjp0J/Kum8IWGnaD43v9A1aBJLDU44xEtwvUK2Su7rnK8YPOBQBwfxZuJPFPjS8vbmXyoJoIXslVdiRxmNWClR7sea4LU7eSxtFRlUuDglZC28fTtX16PBvh6XUr/T5dKs3kt12WyupZhEUDKOTnAJcA/7NeeeOPDml2AuInW2s2wrKFwNpx1H0P8AWgDxfS/Bus3MaSWunzbXUNyVUH8Sf0pdR8GahFDuktGjdT18xcH8M17p8M9Pi1TwBcantIVZHQOrFQxB57e3WvNvFvie+0u+uba2W0uolXzJIrpQflHbPUk0Ab3gP4P6xrWhSXttr50VYz5ctvFIT5gxywKkAZB6HP8ASpPih8O/+Ec8MafP4Ut7hxZOTesWEidP9Z1yPft9KPhz8QLKx8KXtoqJBNNKz+W8rFIFb+Fc9R3AzV8ajNLcrdOwmJHCN8wkX0b/AGSO1AHhFzexRzv/AGlYWrySZLMmQTnrkZrIvJrfzs2EbxR45DtuzXZfEzwhDo8p1bTbqx/s66lwLNJyZrZiM7SrcsvBwwJ98VwNAEkkryBQ7lgowuT0HWo6KKACiiigAooooA+//wBlz/khPhn/ALev/SqWvVa8q/Zc/wCSE+Gf+3r/ANKpa9VoAK+A/wBqf/kuniP/AHbb/wBJoq+/K+A/2p/+S6eI/wDdtv8A0mioA8nooooAWnI7xsGjZlYdwcGmUUAadnreoWn+ruGZf7snzD9a0LfxZeo/7+OGVe4xtP51zlFAHbQ+LrUj97BOv0Ib/Crdn4qsZJBukkgxgKSuCPxGRXn1LQB6XBqGn3cMi/aLaeLqqP8AuiP125/Cty+utDvGsLrR9Km0u8gQKZluJH809z1I5+uK8Yqe2vLm2BFvcSxg9lYigD2Gy1G8tb+K6hvbiGdDxMjHcv68/SnPeKl+1xtiu5fM8wTTRYZjnuMkH8c15Ta6/qNvkLcs4JziQbv51s2Pi/kLe24x/eiP9D/jQB6VrWtQa5dwXF/plpDPHEYS9jGsG4ZyMgDB/Ks++kkuiGkeYtCixK7ES5UcBd3GBjp1x0rmo/FGlMygySg5/ijO38wc5rcs9Xt7h2KzwyqV5EcmP0DDH1oAsXElvcC3E1jZwSwJs81bYh5QccsCQGPHX61LctbIrCxupkBAwq2scQPrnDH86r3RyzOJ98Y243yZYZ6DBOajt1g8w+YxhXBIMUYb5u2QSOM9aAOjttV8YeGTZ6hZalELKV8B4btSyHsJI9xyPwpL7xjqQ8Rwavc3x/tAMdklsgZFJ4PBAHTPHNYri6a13H7NJA/VfMx5ZBByF6CprdEnt44L1yNPLb5Wt4VeaM8glR3H6UAdPJ488QR6lbXs907W28OyLAsCyjuCUxnj3rt9c+Jvhu7itpUGozXIjHmL5IB3em4tjH0rxm1hhWOaFdWlkQ/6tnhCg4PG4npx6Uzy1KZRhJk7dyj5B/wLpQB7l4b+LWi3F6IrtLjSXYKpkZhMj443MQAy/kRV/wAZ674N+wyxnxHp0t3NyERizuD6ADP614HdhhFbQy2torxbilxHEvmOD1DOOWHoD0ou/EH2LRI7e5isltYGLq5tlMhY+rYy3sKAO01Lwj4e8MabbXvidbWM6jL5sQnO0urKSN6g47EnPQ4HvXl3xik8FzLpknhGWBr8b0uxaRMkO0Bdh5Ay2SwJHpzVDxx8R77xVodro9xbWptbWTzIpnhXzxwRjeP4cHp7D0rg6ACiiigAooooAKKKKANfQ/8Ajx1z/rxH/o+KsitfQ/8Ajx1z/rxH/o+KsigAooooAKKKKAN/w54r1TQcx2sxe1bAe3k5RhnOPavTPD/jHTNYMcQP2a8fI8iTkE+zdD+PNeKU5WKsGUkEcgjqKAPorzCSAQxAHBqWUXUdvFePb3ItQ/lrdJGSqN/dZh09s15H4b8dXViot9U8y6tugkB/eIPY9/xr0rTb7T9S0Y3Wla1L5zYEtldqPKdfZlOQ3swx70AdgfGfieOwewe6MtrkASNhmTHTJPP86o2HjTULWZ7WfUXuoJV2S29zIWV1PZQeh+lYSsHAwd47bRhB+Per6Xd9d2X2KOaGWKLMiRzOscYI5+Ukfe9OevegD6C8OX1l4t8KQwvGDsHlqGHJC/dz78D8RmsV7d9GW7064hN3pV0jRNC3UKc5APbuQexryDwv4hvdAv47yyc4yDIsvAb2x6+/869qtPG/h3xKlsGdrW/3rmGdQnm+oDdO5xQB4XY3dz4K8Z2tyhV2s5RIpPSWI5BP4qT9DXo3jO5t9D+NWiavcRMumTKL5bhVyArR+XIc4z2jJX1IPenfGLwNNc6UupaIonaEl1C8lh3T6+3rnuayvCU2j/EXwvpui6pcPYeItHbyredeZBD8pKsjcEHAUjttBGOlAFHXr+3i8eG5sJ0ntr+7M8LqMB0cgMOeQVOSQaxfiTA1xdar5xOyKVJYJ24MeRwMehweRVX4z+EdU8BR6RfvqI1DTpbkhJvs3lm2fggthiOcH0zjmuwjs08U+DGvbR1S6CeXMCcrKoGNo9j60Ac14A8f6pq3iNNIuLgW2vXthJDZ374YSSKMw5HTd80gDerDI4rynxLZah/aQN3DdXWotKY5I3VnklJJOGzznP8AM10MnhW+0y4g1N7bKWDNtiMwVlIHrnJwfSrWoeKdbuU806m001qC/kiJfnXGNpbG88DAyTj9KAPcdF0k+H/hh4c8N288a7YnnvpQwIQgFmX/AHsnGK+d/iRoEaatp8itKY7uHznlcYBbkke2ARxXV2viSK28O6hc291GbeS3f52bpJtOMDsc8Yrnb/U4ta+FT3l1Kn2u0XcH8z52kbCnI79T+ftQB5ddavO9nJYwsEs2cOygcuw6Emo7DWdS09StnezwoRjarnH5Vn0UAS3E8txKZLiV5ZD1Z2JNRUUUAFFFFABRRRQAUUUUAff/AOy5/wAkJ8M/9vX/AKVS16rXlX7Ln/JCfDP/AG9f+lUteq0AFfAf7U//ACXTxH/u23/pNFX35XwH+1P/AMl08R/7tt/6TRUAeT0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUopKKANDT9Y1DT/MFndyxCRDGwzkFT1GDV3/hKtW8oI06MAc5Ma5P6VhUUAdRb+L7gMv2m2gdR/Eg2tj61sxeMNNluvMjt5LBsAZVmYEjvkkkfyrz6igD05Nf0ua48170NKh3fNlAT9eDV1L6ykBezuFAc7nhVw6H365/A15JTlYqcqSD6igDvfEHij7Java2Lp5xbnai7V9e3WuIuru4u33XM0kp/2jnFQUlABRRRQAUUUUAFFFFABRRRQBr6H/x465/14j/0fFWRWvof/Hjrn/XiP/R8VZFABRRRQAUUUUAFFFFAC1c0vU7vS7jzrKZonPBweGHoRVKigD0jRPHkUu2LVo/Lb/noMsn5Z4/Wu4hnhuIo5YX8xSOSzL5fsQAM/qa+f6v6Xq19pcoexuGjPXb1U/geKAPd0V5GHl4ZzwrPkLnsAKqWN1JMsguYvst1E5SWN23Ovpx2zXHaJ4+hneKPVIvIl6G4HzLn129v1r0K/wBTk1T7PcXYt5Z1Tal4Yk8509CyjLD65oA6PTvG3ivR47QK6z6LKGULKFk/eLglXH3hkHIYnnFbdk/hnxR4i0/VZXl0TX7c4BWXEcy/3GbGCPTOD7mvOSoIZTO1uzD5WEfmMT2BGRx/Kg4+4wz/ALC8k/U0AfQHxktf7S+FGs2c9oblTbh4fKUtudSMdO/XmvFvCGsXfhrw9bWVrteYRIHdl3YbA4C9yDxn+dZ1xqV1b28cE8t/HaEhUDCRbfJ6Ddjbn8ajZcOk8V2W42yQywgKhHRkcHnPQqR+PagDb8ZfD/xJLpSeJdTlW9gdPPaFGwbYHnLLgZPPPXGenGa47RtJvNY1GSLTDGJltZZXaT7qqils8fTH419RfDnWYdb8OxQSurBohEdxzyOOc98fnivKP2if+Eb8OeBr829raWfii/YWi+QxVnjJHmHYrYClBycdT60AfJU9xLPJI80jM0jb2yep9akN/dGw+w/aJPse/wAzyd3y7vXFVaKACiiigAooooAKKKKACiiigAooooA+/wD9lz/khPhn/t6/9Kpa9Vryr9lz/khPhn/t6/8ASqWvVaACvkT49/Bzxz4r+K2tazoOirdadcCARSm7hTdtgRW+VnBHKkcivruigD4D/wCGevib/wBC4v8A4H23/wAco/4Z6+Jv/QuL/wCB9t/8cr78ooA+A/8Ahnr4m/8AQuL/AOB9t/8AHKP+Gevib/0Li/8Agfbf/HK+/KKAPgP/AIZ6+Jv/AELi/wDgfbf/AByj/hnr4m/9C4v/AIH23/xyvvyigD4D/wCGevib/wBC4v8A4H23/wAco/4Z6+Jv/QuL/wCB9t/8cr78ooA+A/8Ahnr4m/8AQuL/AOB9t/8AHKP+Gevib/0Li/8Agfbf/HK+/KKAPgP/AIZ6+Jv/AELi/wDgfbf/AByj/hnr4m/9C4v/AIH23/xyvuvxJq0Wg+HdU1i5jeSDT7WW7kSPG5ljQsQM8ZwK4nwX8W9G8S2+ozy2d7pkNjaw3skk+yVDFKMpzEzYY/3DhvbOQAD5K/4Z6+Jv/QuL/wCB9t/8co/4Z6+Jv/QuL/4H23/xyvs9PiP4SfSX1Ia1ALVLgWhBRxJ5xGRH5ZG/djnGOmTSXvxJ8IWNtZz3eu20UV3GZYiwbOwNsLsMZRdwK5bAyCKAPjH/AIZ6+Jv/AELi/wDgfbf/AByj/hnr4m/9C4v/AIH23/xyvr+2+I0Fxqd1aLaRR+Rr0ehh5boKJS0XmB0+Xk9gnfrmtHTviN4Q1HWk0my1+yl1B/M2xBiMmPO8ZIxkAEkZzjnpQB8X/wDDPXxN/wChcX/wPtv/AI5R/wAM9fE3/oXF/wDA+2/+OV9t+GvGnh3xNdz22harBeTwoJHRMglCcB1yBuXIxuXI966GgD4D/wCGevib/wBC4v8A4H23/wAco/4Z6+Jv/QuL/wCB9t/8cr78ooA+A/8Ahnr4m/8AQuL/AOB9t/8AHKP+Gevib/0Li/8Agfbf/HK+/KKAPgP/AIZ6+Jv/AELi/wDgfbf/AByj/hnr4m/9C4v/AIH23/xyvvyigD4D/wCGevib/wBC4v8A4H23/wAco/4Z6+Jv/QuL/wCB9t/8cr78ooA+A/8Ahnr4m/8AQuL/AOB9t/8AHKP+Gevib/0Li/8Agfbf/HK+/KKAPgP/AIZ6+Jv/AELi/wDgfbf/AByj/hnr4m/9C4v/AIH23/xyvvyigD4T0v4B/Ei3tNVSXw8oae1EcYF9b/M3mxtj/Weinr6Vmf8ADPnxP/6Fn/yftf8A45X3/RQB8Af8M+fE/wD6Fn/yftf/AI5R/wAM+fE//oWf/J+1/wDjlff9FAHwB/wz58T/APoWf/J+1/8AjlH/AAz58T/+hZ/8n7X/AOOV9/0UAfAH/DPnxP8A+hZ/8n7X/wCOUf8ADPnxP/6Fn/yftf8A45X3/RQB8Af8M+fE/wD6Fn/yftf/AI5R/wAM+fE//oWf/J+1/wDjlff9FAHwB/wz58T/APoWf/J+1/8AjlH/AAz58T/+hZ/8n7X/AOOV9/0UAfAH/DPnxP8A+hZ/8n7X/wCOVs6D8Hvi9osn+i+Hd0Lfeia/tSp/8i8fhX3NWd4k1aLQfDuqaxcxvJBp9rLdyJHjcyxoWIGeM4FAHzVYfDXxxNbB7nw9JaS5w0X2y3cn33CQ8VbT4YeL15bRsr/zzW6iGfqQ+a9X8MfFbStX0SbWNRtJ9G0xUheOa6mhkMxlzsVUidm3HH3SAfbg1Y1H4maVHe6FHpSrqdrq1vfzpcRS7RGbVAzIVIzkk4wcEEcigDyaL4eeO4LOS1i0+ZbWX78CX0QjP+8N/NQN8MfGI2/8SXe2cZFzDhffBevY7D4oeGzoGhajrN/BpcurWiXiW0rlzGjYG5yBhVycbmwM1tv4w8PpcCB9WtVm+3LpgQtg/aWXcsX1I5HY0AeDW/gj4haHK15oukTm7XgeXeW6l/Y7n24+ufpXnvjn4Z/GrxpqH2nW9FeVVYmOIX9oqJxjgCQDOB1r7L0bVrDWrM3elXMd1beY8Xmx8qWVirAHvggj8KzV8ZeHmt7WddWtjDdSzQwtk4d4gxkUcdVCtn6UAfEH/DPnxP8A+hZ/8n7X/wCOUf8ADPnxP/6Fn/yftf8A45X274d8beHPEl89noerW95crALnZHkFoicb1yPmGSASM4PBwa6KgD4A/wCGfPif/wBCz/5P2v8A8co/4Z8+J/8A0LP/AJP2v/xyvv8AooA+AP8Ahnz4n/8AQs/+T9r/APHKP+GfPif/ANCz/wCT9r/8cr7/AKKAPgD/AIZ8+J//AELP/k/a/wDxyj/hnz4n/wDQs/8Ak/a//HK+/wCigD4A/wCGfPif/wBCz/5P2v8A8co/4Z8+J/8A0LP/AJP2v/xyvv8AooA+AP8Ahnz4n/8AQs/+T9r/APHKP+GfPif/ANCz/wCT9r/8cr7/AKKAPP8A4C+HtU8K/CfQtG161+yalbef5sPmK+3dPI6/MpIPysDwe9egUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZXizSP8AhIPC2s6N5/2f+0bKaz87Zv8AL8xCm7bkZxnOMjPrXlOkfA6fT9N1GGPxQbW8uNJh0iKfTLAWiqkbq/mSKJCZZG27WbcCVZhxnj2uigDxZPgey6VqNo2s6c73l/Fff8gpljiKReXhAs4dT33BweoOc068+B/mx6cy+IpLu6g08addSapam6W5QOzg7RIhUjeVALMNoAIJGT7PRQB5bbfCYQXEMq6yMReIoNeCi0wP3UHleT9/jPXd26Y702H4QQ/2Zoljdau0sGn3t/dSbbfYZlulkBQHedpUSfe5zjoK9UooA82+GfwxPgnU1uW1K2vlhsjYQsLHypxHuVgHk8xg2NgGAqjua9JoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKyvFmkf8ACQeFtZ0bz/s/9o2U1n52zf5fmIU3bcjOM5xkZ9a1aKAPNP8AhUml2vhDQ9M0ZrLTdX0qWzuhqcFgi/abi3QqJJkBBcHfIcFsgsec1Ws/hELe7068fW2lu4n1We6c2oAuJr5VVmVQ/wC7VdowvzZ9RXqlFAHj9x8GJDpNrY2fiNrdW0SLQdQY2Qf7TAjEhowX/dPywz8w56ZGak8RfBW01XxDqGpW2sz2cc9nElvAId/2a8iCLHdBtw3ELGo24GeTmvXKKAOJ8M/DTw7o+j+Hra606z1G/wBFiRIL+eAeYJA28uvUqTIWbGTgnqetcdJ8HtQtTGbfxIbqwsLm+vbLT2sUVt1xHICjS7+eX6kAe3p7PRQB5V8I/h7qmiLoWreJ75X1Gw0ZNMgsY4FRbVSVZwzq7ea2VAyMDGeOc16rRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the Neer et al trial (NEJM 2001), one biopsy in one subject shows significant changes in bone architecture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Jiang, Y, Zhao, JJ, Mitlak, BH, Wang, O, et al. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003; 18:1932. Copyright &copy;American Society for Bone and Mineral Research.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_5_20562=[""].join("\n");
var outline_f20_5_20562=null;
var title_f20_5_20563="Breech extraction4";
var content_f20_5_20563=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Delivery of the head",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 314px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mauriceau maneuver to deliver the after coming head.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: LifeART, Obstetrics &amp; Gynecology. Copyright &copy;2009 Lippincott Williams &amp; Wilkins. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_5_20563=[""].join("\n");
var outline_f20_5_20563=null;
var title_f20_5_20564="Mepivacaine: Pediatric drug information";
var content_f20_5_20564=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mepivacaine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?39/55/40821?source=see_link\">",
"    see \"Mepivacaine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/7/42099?source=see_link\">",
"    see \"Mepivacaine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F192931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Carbocaine&reg;;",
"     </li>",
"     <li>",
"      Polocaine&reg;;",
"     </li>",
"     <li>",
"      Polocaine&reg; MPF",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F192932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Carbocaine&reg;;",
"     </li>",
"     <li>",
"      Polocaine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1023950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Local Anesthetic, Injectable",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1023975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/55/40821?source=see_link\">",
"      see \"Mepivacaine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Injectable local anesthetic: Dose varies with procedure, degree of anesthesia needed, vascularity of tissue, duration of anesthesia required, and physical condition of patient. The smaller dose/concentration (0.5%) will produce more superficial blockade, a higher dose (1%) will block sensory and sympathetic conduction without loss of motor function, a higher dose (1.5%) will provide extensive and often complete motor blockade, and 2% will produce complete sensory and motor blockade. The smallest dose and concentration required to produce the desired effect should be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Children: Maximum dose: 5-6 mg/kg; only concentrations &lt;2% should be used in children &lt;3 years or &lt;14 kg (30 lbs)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults: Maximum dose: 400 mg; do not exceed 1000 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cervical, brachial, intercostal, pudendal nerve block: 5-40 mL of a 1% solution (maximum: 400 mg)",
"     <b>",
"      or",
"     </b>",
"     5-20 mL of a 2% solution (maximum: 400 mg). For pudendal block: Inject",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     the total dose each side.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Transvaginal block (paracervical plus pudendal): Up to 30 mL (both sides) of a 1% solution (maximum: 300 mg). Inject",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     the total dose into each side.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Paracervical block: Up to 20 mL (both sides) of a 1% solution (maximum: 200 mg). Inject",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     the total dose into each side. This is the maximum recommended dose per 90-minute procedure; inject slowly with 5 minutes between sides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Caudal and epidural block (",
"     <b>",
"      preservative free solutions only",
"     </b>",
"     ): 15-30 mL of a 1% solution (maximum: 300 mg)",
"     <b>",
"      or",
"     </b>",
"     10-25 mL of a 1.5% solution (maximum: 375 mg)",
"     <b>",
"      or",
"     </b>",
"     10-20 mL of a 2% solution (maximum: 400 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infiltration: Up to 40 mL of a 1% solution (maximum: 400 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Therapeutic block (pain management): 1-5 mL of a 1% solution (maximum: 50 mg)",
"     <b>",
"      or",
"     </b>",
"     1-5 mL of a 2% solution (maximum: 100 mg)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F192914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carbocaine&reg;: 1% [10 mg/mL] (50 mL); 2% [20 mg/mL] (50 mL) [contains methylparaben]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Polocaine&reg;: 1% [10 mg/mL] (50 mL); 2% [20 mg/mL] (50 mL) [contains methylparaben]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carbocaine&reg;: 1% [10 mg/mL] (30 mL); 1.5% [15 mg/mL] (30 mL); 2% [20 mg/mL] (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Polocaine&reg; MPF: 1% [10 mg/mL] (30 mL); 1.5% [15 mg/mL] (30 mL); 2% [20 mg/mL] (20 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F192902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1023979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Administer in small incremental doses; when using continuous intermittent catheter techniques, use frequent aspirations before and during the injection to avoid intravascular injection",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F3462004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature of 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Brief exposure up to 40&deg;C (104&deg;F) does not adversely affect the product. Solutions may be sterilized.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1023951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local or regional analgesia; anesthesia by local infiltration, peripheral and central neural techniques including epidural and caudal blocks;",
"     <b>",
"      not",
"     </b>",
"     for use in spinal anesthesia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F192969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Mepivacaine may be confused with bupivacaine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Polocaine&reg; may be confused with prilocaine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (epidural administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F192967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, cardiac arrest, cardiac output decreased, heart block, hyper-/hypotension, myocardial depression, syncope, tachycardia, ventricular arrhythmias",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, chills, convulsions, depression, dizziness, excitation, restlessness, tremors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioneurotic edema, diaphoresis, erythema, pruritus, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Fecal incontinence, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Incontinence, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Chondrolysis (continuous intra-articular administration), paralysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, pupil constriction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea, hypoventilation, sneezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, anaphylactoid reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1023955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to mepivacaine, other amide-type local anesthetics, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F4412256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with extreme caution as lumbar or caudal anesthesia in patients with existing neurologic disease, spinal deformities, or severe hypertension. Use with caution in patients with cardiac disease, hepatic or renal disease. Use caution in debilitated, elderly, or acutely-ill patients; dose reduction may be required.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1023956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local anesthetics have been associated with rare occurrences of sudden respiratory arrest; convulsions due to systemic toxicity leading to cardiac arrest have been reported presumably due to intravascular injection. Degree of adverse effects in the CNS and cardiovascular system is directly related to the blood levels of mepivacaine, route of administration (less observed with infiltration than systemic administration), and physical status of the patient. A test dose is recommended prior to epidural administration and all reinforcing doses with continuous catheter technique. Do not use solutions containing preservatives for caudal or epidural block. Chondrolysis has been reported following continuous intra-articular infusion; intra-articular administration of local anesthetics is not an FDA-approved route of administration.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the adverse/toxic effect of Local Anesthetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F192911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2234302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Mepivacaine has been used in obstetrical analgesia.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F4412258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate, respiration, signs of CNS toxicity (lightheadedness, dizziness, tinnitus, restlessness, tremors, twitching, drowsiness, circumoral paresthesia)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1023966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F4412257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Route and dose dependent:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Range: 3-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: 2-2.5 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1023968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &sim;75%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily hepatic via N-demethylation, hydroxylation, and glucuronidation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: 8.7-9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 1.9-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (95% as metabolites)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1023982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/7/42099?source=see_link\">",
"      see \"Mepivacaine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     You will experience decreased sensation to pain, heat, or cold in the area and/or decreased muscle strength (depending on area of application) until effects wear off; use necessary caution to reduce incidence of possible injury until full sensation returns. Report irritation, pain, burning at injection site; chest pain or palpitations; or respiratory difficulty.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Oral injection: This will cause numbness of your mouth. Do not eat or drink for 1 hour after use. Take small sips of water at first to ensure that you can swallow without difficulty. Your tongue and/or mouth may be numb, use caution to avoid biting yourself. Report irritation, pain, burning at injection site; chest pain or palpitations; or respiratory difficulty.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Dodson WE, Hillman RE, and Hillman LS, &ldquo;Brain Tissue Levels in a Fatal Case of Neonatal Mepivacaine (Carbocaine&reg;) Poisoning,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1975, 86(4):624-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20564/abstract-text/1127509/pubmed\" id=\"1127509\" target=\"_blank\">",
"        1127509",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Torres MJ, Garcia JJ, del Cano Moratinos AM, et al, &ldquo;Fixed Drug Eruption Induced by Mepivacaine,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 1995, 96(1):130-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20564/abstract-text/7622755/pubmed\" id=\"7622755\" target=\"_blank\">",
"        7622755",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13030 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-210.101.131.232-947418B5B9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_5_20564=[""].join("\n");
var outline_f20_5_20564=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192931\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192932\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023950\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023975\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192914\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192902\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023979\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3462004\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023951\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192969\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192967\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023955\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4412256\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023956\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299669\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221552\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192911\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2234302\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4412258\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023966\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4412257\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023968\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023982\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13030\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13030|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/55/40821?source=related_link\">",
"      Mepivacaine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/7/42099?source=related_link\">",
"      Mepivacaine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_5_20565="Metacarpal shaft fractures";
var content_f20_5_20565=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Metacarpal shaft fractures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/5/20565/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/5/20565/contributors\">",
"     Josh Bloom, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/5/20565/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/5/20565/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/5/20565/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/5/20565/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/5/20565/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metacarpal fractures are common. They account for up to 50 percent of all hand fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20565/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Fractures of the metacarpal shaft are usually the result of direct or indirect trauma, but fatigue fractures can occur in athletes or as occupational injuries due to repetitive stress. The biomechanics, diagnosis, and treatment of stress fractures are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23866?source=see_link\">",
"     \"Overview of stress fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review issues related to metacarpal shaft fractures. A general overview of metacarpal fractures is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2149?source=see_link\">",
"     \"Overview of metacarpal fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RELEVANT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The heads of the metacarpals are bulbous and \"cam\" shaped, thereby permitting adduction, abduction, flexion, extension and passive rotation of the fingers. The collateral ligaments join the metacarpal to the proximal phalanx and are taut in flexion, while having some laxity in extension (",
"    <a class=\"graphic graphic_figure graphicRef65855 \" href=\"UTD.htm?0/25/415\">",
"     figure 1",
"    </a>",
"    ). The functional importance of this is that the metacarpal phalangeal (MCP) joints should be immobilized in flexion to prevent shortening of the collateral ligaments and subsequent loss of motion.",
"   </p>",
"   <p>",
"    Metacarpal shaft fractures are more common on the ulnar side of the hand and occur most frequently in the metacarpal of the little finger [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20565/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Metacarpal shaft fractures occur in three patterns: transverse, oblique, and comminuted.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transverse fractures are pulled into apex dorsal angulation by volar-directed forces of the interosseous muscles and extrinsic flexor tendons on the metacarpal shaft.",
"     </li>",
"     <li>",
"      Oblique fractures, on the other hand, usually do not angulate but instead tend to shorten and rotate. These fractures are relatively unstable. As in any metacarpal fracture, rotational malalignment is not tolerated. However, simple shortening with no associated angulation or rotation is acceptable.",
"      <br/>",
"      <br/>",
"      Less angulation is acceptable in metacarpal shaft fractures relative to metacarpal neck fractures because angulated shaft fractures tend to have greater associated deformity, more functional problems, and higher risk of pseudo clawing. Fractures of the border metacarpals (second and fifth) are inherently less stable than fractures of the third and fourth metacarpals because they only have one adjacent metacarpal and transverse metacarpal ligament to provide stability.",
"     </li>",
"     <li>",
"      Comminuted fractures of the metacarpal shaft are typically associated with soft tissue injury and require orthopedic consultation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct blows cause transverse fractures of the metacarpal shaft; torsional forces cause oblique fractures. It usually requires significant impact and trauma, such as a crush injury, to cause comminuted fractures of the metacarpal shafts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SYMPTOMS AND EXAM FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with metacarpal shaft fractures complain of pain and exhibit significant dorsal swelling and bony tenderness along the affected metacarpal. Flexion at the metacarpal phalangeal (MCP) joint is usually difficult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Extensor apparatus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The function of the extensor apparatus should be evaluated. In an angulated metacarpal shaft fracture, efforts to extend the finger may result in hyperextension at the MCP joint with flexion at the proximal interphalangeal (PIP) joint (so-called \"pseudo-clawing\").",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Angulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deformity secondary to apex dorsal angulation is frequently apparent with metacarpal shaft fractures. Angulation greater than 10 degrees in second and third metacarpal shaft fractures and greater than 20 degrees in fourth and fifth metacarpal shaft fractures requires reduction. Up to seven degrees of extensor lag and eight percent of grip strength are lost with each two mm of metacarpal shortening [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20565/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Rotational alignment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rotational alignment should be assessed with the MCP joint in flexion. The rotational alignment of the metacarpals can be assessed in two ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a semi-clenched fist (flexion to 90 degrees at the MCP and PIP joints), fingers in normal alignment point toward the scaphoid pole and lines drawn through the middle of the shaft converge just past the wrist, although not necessarily to a single point (",
"      <a class=\"graphic graphic_picture graphicRef73269 graphicRef71612 \" href=\"UTD.htm?4/2/4134\">",
"       picture 1A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      With the MCP joint flexed 90 degrees and the PIP and distal interphalangeal (DIP) joints in full extension, the plane of the fingernails should be aligned, and can be compared with the contralateral side (",
"      <a class=\"graphic graphic_picture graphicRef52326 \" href=\"UTD.htm?14/14/14575\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Skin integrity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggressive decontamination to avoid potentially disastrous intraarticular infections is necessary if skin integrity is compromised. Prophylactic antibiotics appear to be beneficial with hand bites. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31013?source=see_link\">",
"     \"Soft tissue infections due to human bites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard three views of the hand (anteroposterior [AP], lateral, and oblique) are generally adequate for evaluating metacarpal shaft fractures. Angulation is measured using the lateral view (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67394 \" href=\"UTD.htm?41/49/42782\">",
"     image 2C",
"    </a>",
"    ). Shortening is also determined radiographically.",
"   </p>",
"   <p>",
"    Oblique fractures are more prone to shorten and rotate (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72535 \" href=\"UTD.htm?34/39/35441\">",
"     image 1",
"    </a>",
"    ). This is particularly true for long oblique fractures (when the fracture length is greater than two times the bone diameter). Transverse fractures (particularly isolated third and fourth metacarpal shaft fractures) are generally stable (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56431 graphicRef63589 graphicRef67394 graphicRef74745 graphicRef50842 \" href=\"UTD.htm?33/63/34808\">",
"     image 2A-E",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76416 \" href=\"UTD.htm?6/43/6847\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81085 \" href=\"UTD.htm?6/43/6832\">",
"     image 4",
"    </a>",
"    ). Bone callus from fracture healing may not appear until four to six weeks from the start of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR SURGICAL REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metacarpal shaft fractures with malrotation, comminution, or shortening greater than 5 mm all warrant hand surgery referral. If more than one metacarpal is fractured or if adequate reduction is not attained or maintained, orthopedic or hand surgery referral is indicated. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Closed reduction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients whose fractures involve between 2 to 5 mm of shortening may be managed on a case-by-case basis by physicians familiar with fracture management or they may be referred.",
"   </p>",
"   <p>",
"    Acceptable angulation is &le;10 degrees in second and third metacarpals and &le;20 degrees in fourth and fifth metacarpal shaft fractures. Long oblique fractures often cannot be reduced by closed means and may require surgical fixation. Early orthopedic referral in these cases is reasonable.",
"   </p>",
"   <p>",
"    Athletes with metacarpal shaft fractures who desire a quick return to competition, particularly those involved in contact sports, should be referred for possible treatment with operative fixation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splinting is used in the initial immobilization of, and sometimes is the definitive treatment for, metacarpal fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20565/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. A detailed description of the techniques for applying splints is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=see_link\">",
"     \"Splinting of musculoskeletal injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Non-displaced metacarpal shaft fractures should initially be splinted using a gutter splint (",
"    <a class=\"graphic graphic_picture graphicRef65376 \" href=\"UTD.htm?28/12/28879\">",
"     picture 3",
"    </a>",
"    ) or Burkhalter-type splint (",
"    <a class=\"graphic graphic_picture graphicRef77846 \" href=\"UTD.htm?7/0/7183\">",
"     picture 4",
"    </a>",
"    ) with the wrist in approximately 20 to 30 degrees of extension, the MCPs at 70 to 90 degrees of flexion, and the",
"    <span class=\"nowrap\">",
"     PIP/DIP",
"    </span>",
"    in slight flexion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20565/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ulnar gutter splints work well in fourth and fifth metacarpal fractures, while radial gutters are effective for second and third metacarpal fractures. Patients with metacarpal shaft fractures should be seen within five days and advised to aggressively ice and elevate the injured hand.",
"   </p>",
"   <p>",
"    Less angulation is acceptable in metacarpal shaft fractures than metacarpal neck fractures. Angulation &gt;10 degrees at second and third metacarpal shafts is unacceptable due to the lack of mobility these metacarpals have at the carpometacarpal (CMC) joints. The fourth and fifth CMC joints have greater mobility and, accordingly, shaft fractures in these metacarpals can tolerate slightly more angulation. However, &gt;20 degrees of angulation in either of these bones warrants reduction. In addition, more proximal metacarpal shaft fractures tolerate less angulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Closed reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute reduction is indicated if there is pseudo-clawing as evidenced by hyperextension at the MCP joint and flexion at the PIP joint with attempted extension of the finger. Reduction is also indicated for significantly angulated metacarpal fractures. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Angulation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There are several methods for reducing a metacarpal neck fracture, the following is our preferred method:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anesthesia is typically adequately and expediently achieved with a hematoma block. Preparation for a hematoma block includes cleaning the skin with an appropriate antiseptic (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    ), followed by alternating injection and aspiration of 5 to 7 cc of 1 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    without epinephrine or 0.5 percent marcaine without epinephrine.",
"   </p>",
"   <p>",
"    This technique involves initial injection of approximately half of the anesthetic directly into the hematoma at the fracture site. The same volume of",
"    <span class=\"nowrap\">",
"     blood/anesthetic",
"    </span>",
"    mixture that was initially injected is then withdrawn from the hematoma. Some clinicians perform repeated injections and aspirations before removing the needle to enable distribution of anesthetic throughout the fracture site. A volume of blood and anesthetic equal to the initial anesthetic volume is ultimately aspirated, thereby ensuring that the fluid volume of the hematoma is unchanged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;When adequate anesthesia is confirmed, fracture reduction is undertaken using the 90-90 method. Initially, flex the MCP, PIP, and DIP all to 90 degrees. Pressure is then directed axially through the flexed PIP joint creating a dorsal force on the distal fracture fragment. Simultaneously a volar force is applied over the fracture site until it is felt that anatomic reduction is achieved. The fracture is then immobilized with a Burkhalter-type splint or an ulnar gutter splint.",
"   </p>",
"   <p>",
"    Closed reduction generally corrects angulation but typically does not restore length [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20565/abstract/5\">",
"     5",
"    </a>",
"    ]. Post-reduction radiographs are imperative to ensure adequate reduction and alignment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-displaced metacarpal shaft fractures can be immobilized in a gutter splint or Burkhalter-type splint for a few days to allow swelling to decrease. The splint may be exchanged for a short arm cast or a custom orthosis, which is then used for the remaining period of immobilization.",
"   </p>",
"   <p>",
"    Traditionally, metacarpal fractures are immobilized with the metacarpal phalangeal (MCP) joint in significant flexion (approximately 70 degrees) to prevent the loss of MCP extension following removal of the cast or splint. However, a retrospective case series suggests that this approach to immobilization may be unnecessary [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20565/abstract/6\">",
"     6",
"    </a>",
"    ]. In this study, no difference in joint motion, grip strength, or fracture alignment was noted among 263 patients with extra-articular metacarpal fractures immobilized with the MCP joint either flexed or extended and the interphalangeal joints either immobilized or not.",
"   </p>",
"   <p>",
"    Repeat radiographs are indicated within one week to ensure adequate fracture position. Patients should be informed that oblique fractures and border metacarpal shaft fractures (2nd and 5th) are at highest risk for displacement.",
"   </p>",
"   <p>",
"    Typically, metacarpal shaft fractures require four weeks of immobilization. After the initial week, radiographs should be obtained at one- to two-week intervals to ensure maintenance of alignment and to assess bony healing. Initial bony resorption peaks at two weeks, but callus should be present at four weeks. If adequate callus formation is absent at four weeks, an additional immobilization period is necessary with radiographic monitoring at two-week intervals. Usual healing time is on the order of six to eight weeks.",
"   </p>",
"   <p>",
"    After immobilization is discontinued, a two to three week period of gentle passive and active ROM work at the MCP, PIP, and DIP joints should be initiated at home. If stiffness persists after two to three weeks, formal hand therapy (occupational therapy) is helpful to restore motion.",
"   </p>",
"   <p>",
"    As for metacarpal neck fractures, custom orthoses are now widely available and can provide adequate immobilization of the fracture while allowing improved mobility of the fingers and rest of the hand. These are typically constructed by an occupational or hand therapist and should be considered in patients at high risk of chronic stiffness, such as the elderly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     RETURN TO SPORT OR WORK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Athletes seeking to return to contact sports should be protected for an additional four to six weeks after immobilization with a firm and well-padded orthosis. If adequate stability is achieved with operative fixation, athletes engaged in contact sports may be allowed to return to play in some cases within two weeks, provided they use a fracture brace.",
"   </p>",
"   <p>",
"    Patients requiring regular use of the affected hand may return to full duty when they are pain-free, non-tender, have radiographic evidence of healing, and functional range of motion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Metacarpal shaft fractures occur in three patterns: transverse, oblique, and comminuted. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Relevant anatomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Less angulation is tolerated in metacarpal shaft fractures than metacarpal neck fractures. Acceptable fracture angulation is &le;10 degrees in second and third (index and middle) metacarpals and &le;20 degrees in fourth and fifth (ring and little) metacarpal shaft fractures. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Angulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Metacarpal shaft fractures with malrotation, comminution, or shortening &gt;5 mm should be referred to a hand surgeon. If more than one metacarpal is fractured or if adequate reduction is not attained or maintained, surgical referral is indicated. Referral is also necessary for athletes with metacarpal shaft fractures who desire a quick return to competition. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Indications for surgical referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Second and fifth metacarpal shaft fractures and oblique fractures are inherently less stable than other metacarpal fractures. Oblique fractures tend to shorten and rotate while second and fifth metacarpal shaft fractures often angulate and displace.",
"     </li>",
"     <li>",
"      Assessment for rotational malalignment and pseudo-clawing is imperative. Evidence of either problem necessitates referral to an orthopedist or hand surgeon. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Rotational alignment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute reduction is indicated if there is evidence of pseudo-clawing (hyperextension at the MCP joint and flexion at the PIP joint with attempted extension of the finger). Reduction is also indicated for significantly angulated metacarpal fractures. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Initial treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gutter splinting or casting or Burkhalter-type splinting provides adequate immobilization of metacarpal shaft fractures. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Initial treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Follow-up care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Less bulky custom orthoses are widely used. They provide necessary fracture immobilization while allowing improved mobility and function in adjacent hand structures, which reduces the risk of chronic joint stiffness (eg, in the elderly). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Follow-up care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13141757\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and editors would like to acknowledge Kevin E Burroughs, MD, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20565/abstract/1\">",
"      Ashkenaze DM, Ruby LK. Metacarpal fractures and dislocations. Orthop Clin North Am 1992; 23:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20565/abstract/2\">",
"      Chung KC, Spilson SV. The frequency and epidemiology of hand and forearm fractures in the United States. J Hand Surg Am 2001; 26:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20565/abstract/3\">",
"      Geissler WB. Operative fixation of metacarpal and phalangeal fractures in athletes. Hand Clin 2009; 25:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20565/abstract/4\">",
"      Burkhalter WE. Closed treatment of hand fractures. J Hand Surg Am 1989; 14:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20565/abstract/5\">",
"      Henry MH. Fractures of the proximal phalanx and metacarpals in the hand: preferred methods of stabilization. J Am Acad Orthop Surg 2008; 16:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20565/abstract/6\">",
"      Tavassoli J, Ruland RT, Hogan CJ, Cannon DL. Three cast techniques for the treatment of extra-articular metacarpal fractures. Comparison of short-term outcomes and final fracture alignments. J Bone Joint Surg Am 2005; 87:2196.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 188 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-DB525E7F52-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_5_20565=[""].join("\n");
var outline_f20_5_20565=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RELEVANT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SYMPTOMS AND EXAM FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Extensor apparatus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Angulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Rotational alignment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Skin integrity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RADIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INDICATIONS FOR SURGICAL REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Closed reduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      RETURN TO SPORT OR WORK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13141757\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/188\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/188|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/39/35441\" title=\"diagnostic image 1\">",
"      Oblique fracture 4th metacarpal shaft",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/61/2015\" title=\"diagnostic image 2A\">",
"      Fifth metacarpal shaft fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/55/16255\" title=\"diagnostic image 2B\">",
"      Oblique metacarpal shaft fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/49/42782\" title=\"diagnostic image 2C\">",
"      Measuring angulation of a metacarpal shaft fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/37/28255\" title=\"diagnostic image 2D\">",
"      Oblique shaft fracture of second metacarpal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/34/40494\" title=\"diagnostic image 2E\">",
"      Fourth metacarpal oblique shaft fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/43/6847\" title=\"diagnostic image 3\">",
"      Transverse metacarpal shaft fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/43/6832\" title=\"diagnostic image 4\">",
"      Transverse fracture of the 5th metacarpal shaft",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/188|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/25/415\" title=\"figure 1\">",
"      MCP collateral ligaments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/188|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/37/40528\" title=\"picture 1A\">",
"      Examination metacarpal malrotation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/20/39232\" title=\"picture 1B\">",
"      Metacarpal fracture with malrotation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/14/14575\" title=\"picture 2\">",
"      Examination metacarpal malrotation 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/12/28879\" title=\"picture 3\">",
"      Ulnar gutter splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/0/7183\" title=\"picture 4\">",
"      Burkhalter splint for metacarpal fractures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2149?source=related_link\">",
"      Overview of metacarpal fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23866?source=related_link\">",
"      Overview of stress fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31013?source=related_link\">",
"      Soft tissue infections due to human bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=related_link\">",
"      Splinting of musculoskeletal injuries",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_5_20566="Pazopanib: Patient drug information";
var content_f20_5_20566=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pazopanib: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"     see \"Pazopanib: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9511644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Votrient&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13108831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Votrient&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700734",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause liver problems. Call your doctor if you see dark urine, feel tired, are not hungry, have an upset stomach, are throwing up, or have yellowing of the skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691921",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat kidney cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat thyroid cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2898959",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat soft tissue sarcoma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705229",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pazopanib or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are having surgery, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697230",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a stroke within the last 6 months, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an ulcer or bleeding from your stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698509",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have a heart function test. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698469",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your urine checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid grapefruit and grapefruit juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698137",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of high blood sugar like confusion, feeling sleepy, more thirst, more hungry, passing urine more often, flushing, fast breathing, or breath that smells like fruit.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of hair.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698154",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Holes in the GI (gastrointestinal) tract may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3576463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699078",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin wound that will not heal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696587",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it has been 12 hours or more since the missed dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12280 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-200.215.4.194-6EBEB1F6CE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_5_20566=[""].join("\n");
var outline_f20_5_20566=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9511644\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13108831\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028134\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028136\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028135\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028140\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028141\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028143\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028138\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028139\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028144\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028145\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=related_link\">",
"      Pazopanib: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_5_20567="Echocardiographic evaluation of the pulmonic valve and pulmonary artery";
var content_f20_5_20567=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Echocardiographic evaluation of the pulmonic valve and pulmonary artery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/5/20567/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/5/20567/contributors\">",
"     Nelson B Schiller, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/5/20567/contributors\">",
"     Bryan Ristow, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/5/20567/contributors\">",
"     Ameya Kulkarni, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/5/20567/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/5/20567/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/5/20567/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/5/20567/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/5/20567/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/5/20567/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H17588884\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiographic imaging of the pulmonic valve and Doppler measurement of transpulmonary flow are potent tools in the clinical evaluation of disorders of the pulmonic valve and pulmonary arteries. &nbsp;",
"   </p>",
"   <p>",
"    The majority of clinically important lesions at the level of the valve, both stenotic and regurgitant, are associated with congenital heart disease. Rarely, acquired lesions, including endocarditis, rheumatic heart disease, and carcinoid heart disease, involve the pulmonic valve. Identification and characterization of these pathologies requires thorough echocardiographic interrogation and consideration of clinical context. Finally, evaluation of flow through the pulmonic valve and right ventricular outflow tract (RVOT) are essential elements for evaluating hemodynamics. Careful measurements can yield significant information regarding flow, pressure and resistance in the pulmonary circulatory bed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17588891\">",
"    <span class=\"h1\">",
"     VIEWS FOR EVALUATION OF THE PULMONIC VALVE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17588898\">",
"    <span class=\"h2\">",
"     Basic transthoracic views",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interrogation of the pulmonic valve by transthoracic echocardiography (TTE) begins with the parasternal short axis at the level of the aortic valve, where pulmonic valve anatomy can be examined for thickening, vegetation or prolapse. Color flow Doppler is placed over the RVOT to detect flow acceleration or regurgitation. Then, using both continuous wave and pulse wave Doppler at the level of the pulmonary valve, velocities across the pulmonary valve in systole and diastole and peak velocities around the RVOT can be measured (",
"    <a class=\"graphic graphic_figure graphicRef81698 \" href=\"UTD.htm?10/38/10863\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77775 \" href=\"UTD.htm?20/61/21461\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70165 \" href=\"UTD.htm?34/39/35444\">",
"     image 2",
"    </a>",
"    ). Several cycles of these views should be recorded to account for small variations in velocities during the respiratory cycle. M-mode through the pulmonary valve can also be obtained in this view. Tilting the probe in a slight cranial direction gives a clearer view of both the pulmonic valve and the proximal pulmonary artery (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64091 \" href=\"UTD.htm?42/33/43551\">",
"     image 3",
"    </a>",
"    ). Color Doppler demonstrates flows proximal and distal to the valve and pulsed and continuous wave Doppler records the waveforms from that flow. The valve and artery may also be viewed from an orthogonal plane to assure complete interrogation of the structures and the most axial flow signals. Although the apical and subcostal views can be useful in imaging the right ventricle as it relates to the pulmonic valve and arteries (and occasionally allows for visualization of the pulmonic valve), it is often difficult to adequately image the pulmonary arterial system in these views. For further imaging of the branch pulmonary arteries, the suprasternal notch view with visualization of the aortic arch may be used (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76850 \" href=\"UTD.htm?27/21/27985\">",
"     image 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17588999\">",
"    <span class=\"h2\">",
"     Three-dimensional transthoracic views",
"    </span>",
"    &nbsp;&mdash;&nbsp;If there is excellent visualization of the pulmonic valve in two dimensions, a three-dimensional reconstruction may be helpful in further defining valvular and proximal arterial anatomy. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17589022\">",
"    <span class=\"h2\">",
"     Transesophageal echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pulmonic valve is most successfully viewed on transesophageal echocardiography (TEE) in the high esophageal view at 50 to 90&ordm; near the short axis view of the aorta. Slight withdrawal of the probe from the level of the aorta in the horizontal (0&ordm;) plane may facilitate visualization of the pulmonic valve, main pulmonary artery and its bifurcation. Once anatomy is defined, flow and velocities can be acquired as described in the section on TTE views. TEE transgastric views with adequate torque can allow visualization of the RVOT as well [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20567/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17589041\">",
"    <span class=\"h1\">",
"     PULMONIC VALVE STENOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonic valve stenosis is primarily diagnosed using Doppler echocardiography, although traditional two-dimensional and M-mode echocardiography can be helpful in confirming the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17589048\">",
"    <span class=\"h2\">",
"     Two-dimensional echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Basic two-dimensional TTE views can show the anatomic features associated with isolated valvular pulmonic stenosis, including [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20567/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Right ventricular hypertrophy",
"     </li>",
"     <li>",
"      Systolic doming of the valve",
"     </li>",
"     <li>",
"      Valve thickening &mdash; Thickening can range from mild in the young patient to severe calcification in the elderly.",
"     </li>",
"     <li>",
"      Post stenotic dilation of the main pulmonary artery",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17589067\">",
"    <span class=\"h2\">",
"     Color Doppler echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Color flow Doppler signals around the point of stenosis will show aliased flow and are used to identify accelerating blood flow across the stenotic lesion. These images can also help target specific areas for interrogation by spectral Doppler.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17589082\">",
"    <span class=\"h2\">",
"     Continuous wave Doppler",
"    </span>",
"    &nbsp;&mdash;&nbsp;A continuous wave Doppler signal across the area of stenosis is a key component of any examination in pulmonic stenosis. The peak flow velocity across the valve is measured and converted to a peak pressure gradient via the modified Bernoulli equation (",
"    <a class=\"graphic graphic_figure graphicRef81698 \" href=\"UTD.htm?10/38/10863\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef57785 \" href=\"UTD.htm?31/29/32209\">",
"     waveform 1",
"    </a>",
"    ). Of note, although pulsed wave Doppler can be used to quantify velocities, due to the Nyquist limit, it can quantify only the mildest degrees of obstruction.",
"   </p>",
"   <p>",
"    Unlike aortic stenosis, where velocities are used to generate peak pressure, mean pressure and valve area that determine severity and drive management, the hemodynamic severity of pulmonic stenosis is usually defined solely by the peak pressure gradient across the valve. To calculate this pressure drop, peak velocities (V) obtained from continuous wave Doppler signals are converted into a pressure gradient by the simplified Bernoulli equation:",
"   </p>",
"   <p>",
"    Peak gradient (mmHg)&nbsp;=&nbsp;4&nbsp;x&nbsp;v",
"    <sup>",
"     2",
"    </sup>",
"   </p>",
"   <p>",
"    Note that pre-stenotic RVOT velocity is ignored as it is usually less than 1",
"    <span class=\"nowrap\">",
"     m/s.",
"    </span>",
"    However, in so-called &ldquo;double chamber right ventricle&rdquo; when a dynamic prevalvular gradient is present in the distal RVOT, this accelerated velocity must be factored into the equation.",
"   </p>",
"   <p>",
"    The 2009 European Association of",
"    <span class=\"nowrap\">",
"     Echocardiography/American",
"    </span>",
"    Society of Echocardiography",
"    <span class=\"nowrap\">",
"     (EAE/ASE)",
"    </span>",
"    recommendations for echocardiographic evaluation of valve stenosis identified the following criteria to stratify the severity of pulmonary valve stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20567/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild: peak velocity &lt;3",
"      <span class=\"nowrap\">",
"       m/s;",
"      </span>",
"      peak gradient &lt;36 mmHg",
"     </li>",
"     <li>",
"      Moderate: peak velocity 3 to 4",
"      <span class=\"nowrap\">",
"       m/s;",
"      </span>",
"      peak gradient 36 to 64 mmHg",
"     </li>",
"     <li>",
"      Severe: peak velocity &gt;4",
"      <span class=\"nowrap\">",
"       m/s;",
"      </span>",
"      peak gradient &gt;64 mmHg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although only mentioned in passing in the",
"    <span class=\"nowrap\">",
"     EAE/ASE",
"    </span>",
"    guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20567/abstract/1\">",
"     1",
"    </a>",
"    ], RV enlargement is considered by some clinicians as an important means of interpreting the systolic transpulmonic gradient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17589167\">",
"    <span class=\"h2\">",
"     M-mode echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;M-mode findings in pulmonic stenosis are usually limited to the occurrence of an exaggerated \"A wave\" during diastole. The A wave is due to a powerful right atrial contraction that because of low diastolic pulmonary artery pressure, is able to open (or at least dome) the stenotic pulmonary valve in late diastole. The A wave is most pronounced during inspiration and accounts for the disappearance of the pulmonic ejection sound at that point in the respiratory cycle. This behavior makes the pulmonic ejection sound the only right-sided event that diminishes with inspiration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17589174\">",
"    <span class=\"h2\">",
"     Transesophageal echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;When rare anatomic variants involving the right ventricular outflow tract are suspected, TEE can provide significant information about the right ventricular anatomy. Case reports of thrombosis after a gunshot wound, sinus of Valsalva aneurysm, subarterial ventricular septal defects, and membranous ventricular septal aneurysm in the setting of L-transposition have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20567/abstract/2\">",
"     2",
"    </a>",
"    ] and visualized primarily by TEE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17589193\">",
"    <span class=\"h2\">",
"     Other considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a pressure gradient across the pulmonic valve is strongly suggestive of pulmonic stenosis. However, it is important to eliminate other causes of increased flow velocity. When high RVOT velocities are encountered, examine the RVOT carefully to seek dynamic muscular subvalvular stenosis proximal to the valve that provides evidence of a double chamber right ventricle. A ventricular septal defect (with or without evidence of a double chamber right ventricle) can introduce flow acceleration into the right ventricular outflow tract. Interrogating the septum in the apical two and four chamber can help to exclude this diagnosis. Right ventricular outflow tract obstruction may also result from extrinsic compression due to postoperative hematoma, thoracic tumors or a pericardial cyst [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20567/abstract/2\">",
"     2",
"    </a>",
"    ], and these possibilities should be entertained in the appropriate clinical situation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/27/12727?source=see_link\">",
"     \"Natural history and treatment of pulmonic stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39910?source=see_link\">",
"     \"Clinical manifestations and diagnosis of pulmonic stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17589234\">",
"    <span class=\"h1\">",
"     PULMONIC VALVE REGURGITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonic regurgitation is most frequently diagnosed with two-dimensional color Doppler in combination with pulse or continuous wave Doppler signals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17589241\">",
"    <span class=\"h2\">",
"     Two-dimensional echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the parasternal short axis view, examine the valve for thickening, vegetation or prolapse prior to interrogation with color as valvular anatomy can be a first clue to the etiology of the regurgitant lesion. Pulmonic valve carcinoid, for example, manifests as a short, thickened valve with both stenosis and regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20567/abstract/3\">",
"     3",
"    </a>",
"    ]. Endocarditis is suggested by a vegetation-like mobile mass, and congenital dysplasia of the pulmonic valve is associated with thickening of the leaflets [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20567/abstract/1,4-6\">",
"     1,4-6",
"    </a>",
"    ]. Additionally, dilation of the right ventricle is an important adjunctive clue to hemodynamically significant PR [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20567/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17589314\">",
"    <span class=\"h2\">",
"     Color Doppler",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of antegrade and retrograde flow in the short axis view across the pulmonic valve with visualization of both the RVOT and the proximal pulmonary artery gives the most information about PR (",
"    <a class=\"graphic graphic_movie graphicRef79177 \" href=\"UTD.htm?34/18/35107\">",
"     movie 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Trivial or trace pulmonary regurgitation is normally present in a high percentage of healthy people and is almost never clinically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20567/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. A small amount of diastolic flow into the RVOT is consistent with this diagnosis. Distinguishing between mild and more significant (moderate to severe) regurgitation can be more challenging and requires closer attention to the morphology of the pulmonic regurgitation jet. Jet characteristics important in delineating regurgitation severity include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The vena contracta (the diameter of the narrowest portion of the pulmonic regurgitation jet as it crosses the pulmonary valve varies with severity proportionally.)",
"     </li>",
"     <li>",
"      Volume of RVOT occupied with regurgitation and the degree of retrograde jet penetration.",
"      <span class=\"nowrap\">",
"       (AHA/ACC",
"      </span>",
"      criteria for severe pulmonary regurgitation include a jet that fills the RVOT) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/5/20567/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Percentage of time in diastole occupied with regurgitation (severe pulmonic regurgitation will have a dense jet that rapidly decelerates so that regurgitant flow ends around mid diastole while mild to moderate pulmonic regurgitation flow persists throughout diastole. Occasionally a jet of mild pulmonic regurgitation will decelerate quickly, but its signal density is low.)",
"     </li>",
"     <li>",
"      Velocity of flow is not proportional to or indicative of severity (higher velocities suggested by aliasing of the Color Doppler signal or by continuous wave Doppler peak velocity reflect higher pressure gradients between RVOT and pulmonary circulation. Higher velocities are associated with pulmonary hypertension.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17589382\">",
"    <span class=\"h2\">",
"     Continuous or pulsed wave Doppler",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most regurgitant lesions can be imaged with continuous or pulse wave Doppler signals across the pulmonic valve. Density of the pulmonic regurgitation signal increases with increasing regurgitation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67037 \" href=\"UTD.htm?9/23/9584\">",
"     image 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55374 \" href=\"UTD.htm?27/6/27747\">",
"     image 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70165 \" href=\"UTD.htm?34/39/35444\">",
"     image 2",
"    </a>",
"    ). Additionally, in severe pulmonic regurgitation, rapid equalization of pressures between the pulmonary artery and the RVOT early in diastole results in rapid termination of regurgitant flow around mid diastole. On Doppler this signature of severity is seen as an abrupt return to baseline of the signal well before the onset of the next systole (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70165 \" href=\"UTD.htm?34/39/35444\">",
"     image 2",
"    </a>",
"    ). The rapid decrease in slope of the PR signal that is typical of severe pulmonic regurgitation may be masked by fast heart rates that shorten diastole and, in doing so, diminish regurgitant fraction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17589457\">",
"    <span class=\"h2\">",
"     Three-dimensional echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three-dimensional assessment of pulmonic valve anatomy can be helpful, although the technical factors limiting visualization in two dimensions affect three dimensions to a greater extent. Quantification of the pulmonary regurgitant jet and specifically the cross sectional area of its vena contracta may be better achieved with three-dimensional Doppler [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20567/abstract/9\">",
"     9",
"    </a>",
"    ]. Three-dimensional echocardiography may also have a role in measuring the diameter of the pulmonary artery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17589476\">",
"    <span class=\"h2\">",
"     Transesophageal echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the relatively distal position of the pulmonary valve with respect to the esophagus, it can be difficult to accurately determine the severity of pulmonary regurgitation with this modality. Additionally, visualization of the pulmonary artery is almost always more complete with transthoracic studies. As such, TEE has limited utility in the evaluation of pulmonic regurgitation. However, for supplemental anatomic information about the pulmonic valve, TEE can be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17589483\">",
"    <span class=\"h2\">",
"     Clinical considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically significant pulmonary regurgitation is rare and the differential diagnosis is fairly limited. As such, understanding the clinical context prior to performing the echo is extremely important, and the exam should be guided by the specific clinical question being asked.",
"   </p>",
"   <p>",
"    In adults, the most common cause of moderate PR is pulmonary hypertension.(See",
"    <a class=\"local\" href=\"#H17589936\">",
"     'Pulmonary hemodynamics'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Severe pulmonic regurgitation is most commonly caused by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tetralogy of Fallot (or other conotruncal abnormality) repair, remote. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/7/28794?source=see_link\">",
"       \"Overview of the management of tetralogy of Fallot\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Endocarditis. Vegetations are difficult to detect on TTE and TEE, and both modalities are frequently required to confirm the diagnosis. Most of the TEE literature on this condition is limited to single-case reports, but the availability of multiplane imaging capability has led to an increased frequency of this diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/5/20567/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20617?source=see_link&amp;anchor=H25#H25\">",
"       \"Role of echocardiography in infective endocarditis\", section on 'Right-sided endocarditis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Carcinoid. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12472?source=see_link\">",
"       \"Carcinoid heart disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17589557\">",
"    <span class=\"h1\">",
"     PULMONARY ARTERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main pulmonary artery and the proximal branches are routinely examined as part of a standard TTE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17589564\">",
"    <span class=\"h2\">",
"     Two-dimensional echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main pulmonary artery is seen in the parasternal short axis view through the base of the heart. A slight cranial tilt to the probe (RVOT view) reveals the main pulmonary artery and proximal branches longitudinally from the pulmonic valve (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64091 \" href=\"UTD.htm?42/33/43551\">",
"     image 3",
"    </a>",
"    ). In some patients, an anteriorly angulated four chamber apical view, a precordial long axis view (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63066 \" href=\"UTD.htm?20/44/21199\">",
"     image 7",
"    </a>",
"    ), or a subcostal short axis view will better demonstrate the pulmonary artery. If there is significant difficulty with visualization, a suprasternal notch view examining the transverse aortic arch will often show the right pulmonary artery (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76850 \" href=\"UTD.htm?27/21/27985\">",
"     image 4",
"    </a>",
"    )",
"    <strong>",
"    </strong>",
"    or main pulmonary artery. Of note, in the parasternal view in adults, the lateral wall of the main pulmonary artery is usually not well visualized because of overlying lung. In children, the success rate of imaging the lateral wall and measuring the transverse diameter of the main pulmonary artery is much higher. Since the right pulmonary artery is readily imaged, doubling its area has been used as a rough substitute measurement for the main pulmonary artery. However, this method awaits further confirmation.",
"   </p>",
"   <p>",
"    Anatomic evaluation of the pulmonary artery is important in several disease processes. In the presence of an atrial septal defect, the size of the main artery gives some indication of the duration or magnitude of the shunt. Severity of pulmonary artery dilation can also give clues as to the severity or duration of pulmonary hypertension (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76850 \" href=\"UTD.htm?27/21/27985\">",
"     image 4",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17589639\">",
"    <span class=\"h2\">",
"     Color Doppler",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal systolic color flow by Doppler in the pulmonary artery is best seen in a short axis view through the base of the heart; a diastolic color flow Doppler signal is not usually detectable (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50884 \" href=\"UTD.htm?15/59/16319\">",
"     image 8",
"    </a>",
"    ).",
"    <strong>",
"    </strong>",
"    In patients with a patent ductus arteriosus (PDA), a high velocity jet coming from the left main branch of the pulmonary artery and travelling retrograde to the pulmonic valve can be detected during both phases of the cardiac cycle (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65214 \" href=\"UTD.htm?2/49/2834\">",
"     image 9",
"    </a>",
"    ). The high-velocity PDA signal may pollute the pulmonary regurgitation signal and confound its use in hemodynamic evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17589936\">",
"    <span class=\"h1\">",
"     PULMONARY HEMODYNAMICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A noninvasive survey of hemodynamics is crucial to the management of patients with heart failure and pulmonary hypertension as it may obviate the need for repeated catheterizations. Calculations can be obtained using measurements in the right ventricle, tricuspid valve and pulmonic valve. Measurements obtained at the level of the pulmonic valve will be discussed here. Measurements utilizing the tricuspid valve and right ventricle are discussed in the following topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/7/27766?source=see_link\">",
"     \"Echocardiographic evaluation of the right ventricle\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17589943\">",
"    <span class=\"h2\">",
"     Pulmonary pressures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler interrogation of the pulmonic valve provides a wealth of information about pulmonary hemodynamics. First, pulsed wave Doppler velocities across the pulmonic valve when integrated over time provide a velocity-time integral, or VTI (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77775 \" href=\"UTD.htm?20/61/21461\">",
"     image 1",
"    </a>",
"    ). This well-validated technique gives an estimation of the stroke distance during one beat through the pulmonic valve [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20567/abstract/7,11\">",
"     7,11",
"    </a>",
"    ]. If multiplied by the area of the RVOT, a stroke volume can be calculated. Multiplying this value by heart rate provides a cardiac output in",
"    <span class=\"nowrap\">",
"     L/min.",
"    </span>",
"    In practice, as the area of the RVOT is similar in most people, the stroke distance (as calculated by the VTI) is a reasonable estimate of right ventricular cardiac output (over a range of normal heart rates). Reduced VTI across the pulmonic valve (&lt;17 cm) has been shown to predict heart failure hospitalization and mortality independent of clinical and other echocardiographic parameters among individuals with coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20567/abstract/12\">",
"     12",
"    </a>",
"    ]. Technically, proper positioning of the Doppler sample volume can be assured by choosing a spot across the pulmonary valve where the opening valve signal is more intense than the closing. If only a closing signal is seen, the sample volume is not across the valve but in the RVOT. This malpositioning may result in an artificially low VTI because the RVOT is wider than the diameter of the passage between the PV leaflets.",
"   </p>",
"   <p>",
"    Noninvasive measurement of pulmonary arterial pressures requires a continuous wave Doppler of the pulmonary regurgitant jet. The PA EDP (pulmonary arterial end diastolic pressure) is defined by the velocity immediately after the atrial notch on the R wave at the end of diastole in the PR signal (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55374 \" href=\"UTD.htm?27/6/27747\">",
"     image 6",
"    </a>",
"    ). Evaluation of this end diastolic pulmonary regurgitation gradient provides prognostic value and indicates an increased risk of heart failure and mortality when the gradient exceeds 5 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20567/abstract/8\">",
"     8",
"    </a>",
"    ]. If more precise calculation of the pulmonary artery end diastolic pressure is desired, the Bernoulli equation (Pressure gradient = 4v",
"    <sup>",
"     2",
"    </sup>",
"    ) is used to estimate the PA diastolic pressure: pressure gradient + baseline diastolic pressure in the right ventricle (which is approximately right atrial pressure) = PA diastolic pressure.",
"   </p>",
"   <p>",
"    To calculate mean pulmonary pressures, the peak pulmonary regurgitant velocity and right atrial pressure may be used",
"    <sup>",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20567/abstract/11\">",
"     11",
"    </a>",
"    ]. By again using Bernoulli&rsquo;s principle (4 x peak PR velocity) and adding the right atrial pressure, a close approximation of pulmonary artery mean pressure is obtained. Pulmonary arterial pressure measurements are more commonly obtained using the tricuspid regurgitant jet.",
"   </p>",
"   <p>",
"    To calculate the mean pulmonary artery systolic pressure in the physiologic range of heart rates, the following equation can be used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mean PA pressure = [(2 x PA diastolic pressure) + PA systolic",
"      <span class=\"nowrap\">",
"       pressure]/3",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Solving for PA systolic pressure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PA systolic pressure = (3 x Mean PA pressure) &ndash; (2 x PA diastolic pressure)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17590020\">",
"    <span class=\"h2\">",
"     Pulmonary vascular resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calculations of pulmonary vascular resistance (PVR) using Doppler-derived pulmonary systolic flow are especially useful in monitoring patients with heart failure due to left ventricular systolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20567/abstract/10\">",
"     10",
"    </a>",
"    ]. Measurements that have been used include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pre-ejection period: The time from the onset of the QRS interval on the ECG to the onset of pulmonary artery systolic flow. &nbsp;",
"     </li>",
"     <li>",
"      Acceleration time: The time between onset of flow and peak systolic flow.",
"     </li>",
"     <li>",
"      Ejection time: The interval from the onset to the cessation of flow.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A composite calculation putting these measurements together estimated PVR with a strong correlation coefficient in one study (0.96):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PVR (Woods Units) = -0.156 + 1.154 * (Pre-ejection period",
"      <span class=\"nowrap\">",
"       /",
"      </span>",
"      acceleration",
"      <span class=\"nowrap\">",
"       time)/total",
"      </span>",
"      systolic time [",
"      <a class=\"abstract\" href=\"UTD.htm?20/5/20567/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another technique utilizes a ratio of peak tricuspid valve velocity (in",
"    <span class=\"nowrap\">",
"     m/s)",
"    </span>",
"    to pulmonary artery VTI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20567/abstract/11,13\">",
"     11,13",
"    </a>",
"    ] to estimate PVR. The upper normal of this ratio is 0.15 units. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/7/27766?source=see_link\">",
"     \"Echocardiographic evaluation of the right ventricle\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12160155\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most pulmonic valve stenosis and regurgitation is associated with congenital heart disease. Other causes include endocarditis, rheumatic heart disease, and carcinoid heart disease. (See",
"      <a class=\"local\" href=\"#H17588884\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pulmonic valve stenosis is primarily diagnosed using Doppler echocardiography, although traditional two-dimensional and M-mode echocardiography can be helpful in confirming the diagnosis. (See",
"      <a class=\"local\" href=\"#H17589041\">",
"       'Pulmonic valve stenosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pulmonary regurgitation is most frequently diagnosed with two-dimensional color Doppler in combination with pulse or continuous wave Doppler signals.",
"     </li>",
"     <li>",
"      In adults, the most common cause of moderate pulmonic regurgitation is pulmonary hypertension; severe pulmonic regurgitation is most commonly seen in Tetralogy of Fallot following remote repair, and less commonly endocarditis or carcinoid heart disease.",
"     </li>",
"     <li>",
"      Doppler interrogation of the pulmonic valve provides prognostically important measurements of cardiac output and pulmonary artery pressure.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20567/abstract/1\">",
"      Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr 2009; 22:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20567/abstract/2\">",
"      Shively BK. Transesophageal echocardiographic (TEE) evaluation of the aortic valve, left ventricular outflow tract, and pulmonic valve. Cardiol Clin 2000; 18:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20567/abstract/3\">",
"      Bhattacharyya S, Toumpanakis C, Burke M, et al. Features of carcinoid heart disease identified by 2- and 3-dimensional echocardiography and cardiac MRI. Circ Cardiovasc Imaging 2010; 3:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20567/abstract/4\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20567/abstract/5\">",
"      Winslow T, Foster E, Adams JR, Schiller NB. Pulmonary valve endocarditis: improved diagnosis with biplane transesophageal echocardiography. J Am Soc Echocardiogr 1992; 5:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20567/abstract/6\">",
"      Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003; 16:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20567/abstract/7\">",
"      Borgeson DD, Seward JB, Miller FA Jr, et al. Frequency of Doppler measurable pulmonary artery pressures. J Am Soc Echocardiogr 1996; 9:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20567/abstract/8\">",
"      Ristow B, Ahmed S, Wang L, et al. Pulmonary regurgitation end-diastolic gradient is a Doppler marker of cardiac status: data from the Heart and Soul Study. J Am Soc Echocardiogr 2005; 18:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20567/abstract/9\">",
"      Lancellotti P, Tribouilloy C, Hagendorff A, et al. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 1: aortic and pulmonary regurgitation (native valve disease). Eur J Echocardiogr 2010; 11:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20567/abstract/10\">",
"      Scapellato F, Temporelli PL, Eleuteri E, et al. Accurate noninvasive estimation of pulmonary vascular resistance by Doppler echocardiography in patients with chronic failure heart failure. J Am Coll Cardiol 2001; 37:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20567/abstract/11\">",
"      Ristow B, Schiller NB. Obtaining accurate hemodynamics from echocardiography: achieving independence from right heart catheterization. Curr Opin Cardiol 2010; 25:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20567/abstract/12\">",
"      Ristow B, Na B, Ali S, et al. Left ventricular outflow tract and pulmonary artery stroke distances independently predict heart failure hospitalization and mortality: the Heart and Soul Study. J Am Soc Echocardiogr 2011; 24:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20567/abstract/13\">",
"      Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010; 23:685.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5290 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-61DB87C3C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_5_20567=[""].join("\n");
var outline_f20_5_20567=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12160155\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17588884\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17588891\">",
"      VIEWS FOR EVALUATION OF THE PULMONIC VALVE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17588898\">",
"      Basic transthoracic views",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17588999\">",
"      Three-dimensional transthoracic views",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17589022\">",
"      Transesophageal echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17589041\">",
"      PULMONIC VALVE STENOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17589048\">",
"      Two-dimensional echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17589067\">",
"      Color Doppler echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17589082\">",
"      Continuous wave Doppler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17589167\">",
"      M-mode echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17589174\">",
"      Transesophageal echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17589193\">",
"      Other considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17589234\">",
"      PULMONIC VALVE REGURGITATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17589241\">",
"      Two-dimensional echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17589314\">",
"      Color Doppler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17589382\">",
"      Continuous or pulsed wave Doppler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17589457\">",
"      Three-dimensional echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17589476\">",
"      Transesophageal echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17589483\">",
"      Clinical considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17589557\">",
"      PULMONARY ARTERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17589564\">",
"      Two-dimensional echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17589639\">",
"      Color Doppler",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17589936\">",
"      PULMONARY HEMODYNAMICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17589943\">",
"      Pulmonary pressures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17590020\">",
"      Pulmonary vascular resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12160155\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5290\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5290|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/61/21461\" title=\"diagnostic image 1\">",
"      Right ventricular cardiac output",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/39/35444\" title=\"diagnostic image 2\">",
"      Severe pulmonary regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/33/43551\" title=\"diagnostic image 3\">",
"      2D TTE RV outflow tract view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/21/27985\" title=\"diagnostic image 4\">",
"      2D TTE Suprasternal view right pulmonary artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/23/9584\" title=\"diagnostic image 5\">",
"      Doppler pulmonary regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/6/27747\" title=\"diagnostic image 6\">",
"      Pulmonary regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/44/21199\" title=\"diagnostic image 7\">",
"      Long axis pulmonary artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/59/16319\" title=\"diagnostic image 8\">",
"      Color flow Doppler main PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/49/2834\" title=\"diagnostic image 9\">",
"      Color flow Doppler PDA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5290|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/38/10863\" title=\"figure 1\">",
"      Pulmon stenosis CW Doppler II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5290|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?34/18/35107\" title=\"movie 1\">",
"      Pulmonary regurgitation short axis color Doppler echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5290|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?31/29/32209\" title=\"waveform 1\">",
"      Doppler pulmonic stenosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12472?source=related_link\">",
"      Carcinoid heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39910?source=related_link\">",
"      Clinical manifestations and diagnosis of pulmonic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/7/27766?source=related_link\">",
"      Echocardiographic evaluation of the right ventricle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/27/12727?source=related_link\">",
"      Natural history and treatment of pulmonic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/7/28794?source=related_link\">",
"      Overview of the management of tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20617?source=related_link\">",
"      Role of echocardiography in infective endocarditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_5_20568="Iodine-induced thyroid dysfunction";
var content_f20_5_20568=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Iodine-induced thyroid dysfunction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/5/20568/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/5/20568/contributors\">",
"     Martin I Surks, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/5/20568/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/5/20568/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/5/20568/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/5/20568/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/5/20568/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The central role of iodide in thyroid physiology has been known for many years. The four iodine atoms of l-thyroxine (T4) constitute 65 percent of its weight; the three iodine atoms of triiodothyronine (T3) constitute 59 percent of its weight. Iodine is a trace element in the crust of the earth and its distribution is quite variable. Many areas, particularly inland and mountainous regions, have minimal iodine while others, often coastal regions, have sufficient or even excessive iodine.",
"   </p>",
"   <p>",
"    Both iodine deficiency and excess can cause thyroid dysfunction. This topic will review the mechanisms by which normal subjects adapt to excess iodine and the mechanisms of iodine-induced thyroid disease. Iodine deficiency disorders and the therapeutic use of iodine in patients with hyperthyroidism are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39864?source=see_link\">",
"     \"Iodine deficiency disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10852?source=see_link\">",
"     \"Iodine in the treatment of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7754869\">",
"    <span class=\"h1\">",
"     SOURCES OF IODINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iodide is essential for thyroid hormone synthesis. In order for the thyroid gland to synthesize adequate amounts of thyroxine, approximately 52 mcg of iodide must be taken up daily by the thyroid gland [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33320?source=see_link\">",
"     \"Thyroid hormone synthesis and physiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Iodine can be obtained by consumption of foods that contain it or to which it is added. Dietary iodine is absorbed as iodide and rapidly distributed in the extracellular fluid, which also contains iodide released from the thyroid and by extrathyroidal deiodination of the iodothyronines. Iodide leaves this pool by transport into the thyroid and excretion into the urine. The recommended minimum daily intake of iodine is 150 mcg for nonpregnant adults, 220 mcg for pregnant women, 290 mcg for lactating women, and 90 to 120",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    for children aged 1 to 13 years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/2\">",
"     2",
"    </a>",
"    ]. The average intake in the United States is about 150 to 200",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/3\">",
"     3",
"    </a>",
"    ]. In the US, iodized salt contains 76 mcg of",
"    <span class=\"nowrap\">",
"     iodine/g.",
"    </span>",
"    In many countries, however, it contains less, and in some countries iodized salt is not available. As a result, iodine deficiency is the most common cause of goiter, hypothyroidism, and mental deficiency worldwide. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39864?source=see_link\">",
"     \"Iodine deficiency disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sources of excess iodine include over-the-counter and prescription medications that may be ingested or applied to the skin or vaginal mucosa, radiographic contrast agents, and dietary supplements (kelp, seaweed) (",
"    <a class=\"graphic graphic_table graphicRef60901 \" href=\"UTD.htm?18/26/18861\">",
"     table 1",
"    </a>",
"    ). In the context of a person's usual dietary iodine intake, the amount of iodine in many of these substances is very large. As an example, a patient undergoing vascular imaging may receive several thousand mg of organic iodide. Those substances that contain organic iodide are partially deiodinated to form inorganic iodide, the form that has thyroidal actions. Some of these substances that are deiodinated to form inorganic iodine, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , are stored in fat and may provide excess iodide for months after the last dose is administered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ADAPTATION TO IODIDE INTAKE IN NORMAL SUBJECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;If thyroid hormone production and secretion were solely dependent upon iodide supply, people who lived in areas of iodine deficiency would be hypothyroid while those in areas of iodine sufficiency would be euthyroid or hyperthyroid. Instead, regulatory mechanisms maintain the euthyroid state unless the deficiency is severe or the patient has some thyroid disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Follicular cell autoregulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key factor that protects organisms against wide variations in dietary intake of iodine is autoregulation by thyroid follicular cells. Sudden exposure to excess serum iodide inhibits organification of iodide, thereby diminishing hormone biosynthesis; this phenomenon is called the Wolff-Chaikoff effect [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, within two to four weeks of continued exposure to excess iodide, iodide organification and thyroid hormone biosynthesis resume in a normal fashion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/5\">",
"     5",
"    </a>",
"    ]. Studies in experimental animals suggest that this escape from the Wolff-Chaikoff effect results from decreased trapping of iodide and, therefore, restoration of the intrathyroidal iodide pool to its normal value, even though serum iodide concentrations remain elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. The mechanism for this escape is unknown but may relate, in part, to decreases in iodide trapping brought about by a fall in",
"    <span class=\"nowrap\">",
"     sodium/iodide",
"    </span>",
"    symporter (NIS) activity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Iodide effects on thyroid hormone secretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most rapid (hours to days) effect of pharmacologic doses of iodine is to decrease thyroglobulin proteolysis, thereby decreasing thyroid hormone secretion. The resulting slight reductions in serum T4 and T3 concentrations cause transient increases in serum concentrations of thyrotropin (TSH) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. This may occur after exposure to iodine-containing radiocontrast; in one study, 18 percent had transient increases in serum TSH above the normal range [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/14\">",
"     14",
"    </a>",
"    ]. Older subjects may not have this increase in serum TSH in the presence of increased iodine intake [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     IODINE-INDUCED THYROID DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of iodine administration in patients with abnormal thyroid glands differ from those in normal subjects and depend upon the underlying disease process. As an example, iodine administration may result in hyperthyroidism in patients with endemic goiter or in patients with nodular goiters containing autonomously functioning tissue. In contrast, iodine administration may induce or exacerbate hypothyroidism in patients with underlying autoimmune thyroiditis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Iodine-induced hyperthyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;In regions of iodine deficiency, a prevalence of hyperthyroidism that varies from 1 to 20 percent has been reported after the introduction of iodine [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The higher frequency of hyperthyroidism (10 to 20 percent) occurs in individuals with nodular goiter living in areas of iodine deficiency. Thyrotoxicosis occurs because of underlying areas of autonomy within the thyroid gland. When the iodine supply increases, the autonomous areas produce thyroid hormone independent of normal regulatory mechanisms (the Jod-Basedow phenomenon) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/18\">",
"     18",
"    </a>",
"    ]. Such patients may have had subclinical hyperthyroidism before iodine repletion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lower frequency of hyperthyroidism (approximately 1 to 2 percent) noted in regions of iodine deficiency probably reflects the prevalence of undiagnosed Graves' disease in these populations. These patients are clinically euthyroid before iodine repletion because their hormone production and secretion have been limited by the limited supply of iodide. When more iodide becomes available, however, hormonogenesis and hormone secretion become excessive and clinical hyperthyroidism ensues.",
"   </p>",
"   <p>",
"    Iodine-induced hyperthyroidism can rarely occur in patients without underlying thyroid disease (eg, iodine-induced thyroiditis) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/19\">",
"     19",
"    </a>",
"    ]. In one study, as an example, only 2 of 788 unselected patients from an iodine deficient area developed hyperthyroidism within 12 weeks after coronary angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/20\">",
"     20",
"    </a>",
"    ]. Both patients had normal TSH levels at baseline and thyroid ultrasound did not show evidence of nodules. Surprisingly, 27 of the patients had subclinical hyperthyroidism before angiography, none of whom became hyperthyroid.",
"   </p>",
"   <p>",
"    In North America and other iodine replete populations, iodine-induced hyperthyroidism may occasionally occur in patients with autonomous thyroid nodules after treatment with high doses of iodine, usually in the form of drug therapy (",
"    <a class=\"graphic graphic_table graphicRef60901 \" href=\"UTD.htm?18/26/18861\">",
"     table 1",
"    </a>",
"    ) or exposure to iodinated contrast agents during diagnostic radiography (eg, computed tomography or angiography) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/1,17,21,22\">",
"     1,17,21,22",
"    </a>",
"    ]. As an example, in a prospective study of 73 patients (mean age 65.7 years), only two developed hyperthyroidism after exposure to radiographic contrast [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/23\">",
"     23",
"    </a>",
"    ]. In another study, the risk was higher in patients who had subnormal serum TSH concentrations and increased technetium thyroid uptake prior to radiographic contrast exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26089362\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of iodine-induced hyperthyroidism is similar to the diagnosis of hyperthyroidism due to other causes and is based upon clinical manifestations and thyroid function test abnormalities (low serum TSH, high free T4",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    T3). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=see_link\">",
"     \"Overview of the clinical manifestations of hyperthyroidism in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=see_link\">",
"     \"Diagnosis of hyperthyroidism\"",
"    </a>",
"    .) On physical examination, many patients with iodine-induced hyperthyroidism will have a thyroid nodule or nodular goiter. A history of iodine ingestion or administration should be sought in any hyperthyroid patient who has these findings. Iodine-induced hyperthyroidism typically begins weeks",
"    <strong>",
"    </strong>",
"    or even months after iodine administration; a single large dose of iodine can be sufficient. In most patients, the history of iodine exposure is apparent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2880101\">",
"    <span class=\"h3\">",
"     Evaluation for underlying thyroid disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general recommendation to obtain a 24-hour radioiodine uptake in a hyperthyroid patient to distinguish underlying Graves&rsquo; disease or thyroid autonomy (high or normal uptake) from thyroiditis (very low uptake) is problematic if iodine-induced hyperthyroidism is suspected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=see_link&amp;anchor=H25975118#H25975118\">",
"     \"Diagnosis of hyperthyroidism\", section on 'Radioiodine uptake'",
"    </a>",
"    .) An exogenous iodine load will dilute the administered radioiodine tracer, and the uptake will be lowered depending upon the amount of the exogenous iodine load, whether the exposure is continuous (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ), and the interval since the iodine exposure. Usually a single iodine load (eg, radiocontrast for a CT scan) may transiently reduce the radioiodine uptake in patients with Graves&rsquo; disease or toxic nodular goiter to less than 10 percent for up to two to four weeks, but rarely reduces the uptake to less than 1 percent as occurs in patients with painless thyroiditis. A continuous iodine load, however, may reduce the uptake to less than 1 percent. Thus, the distinction between Graves&rsquo; disease and painless thyroiditis may be very difficult in the setting of continuous iodine exposure.",
"   </p>",
"   <p>",
"    Depending upon the nature of the iodine exposure and the severity of the hyperthyroidism, taking into account the patient&rsquo;s comorbidities, some experts obtain a radioiodine scan upon diagnosis and interpret the scan results with regard to the recent iodine load, realizing that it may not be definitive and may need to be repeated later; others defer the scan until sufficient time has passed for most of the iodine load to be excreted (approximately two to four weeks for most radiographic contrast agents). In other clinical settings where the underlying thyroid disease is apparent (eg, a patient with a multinodular goiter on physical examination or ultrasound), an uptake and scan need not be performed at all during the acute setting. However, it might be helpful as part of long-term management to differentiate functioning from nonfunctioning nodules in making a decision about fine needle aspiration biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\", section on 'Thyroid scintigraphy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a 24-hour radioiodine uptake is obtained and is unexpectedly low in a patient with presumed Graves&rsquo; disease or autonomous thyroid nodular disease, and the history of iodine exposure is uncertain, a 24-hour urinary iodine level (or a spot urine iodine and creatinine to estimate the 24-hour urinary iodine concentration) can be obtained to assess the degree of iodine exposure. When urinary iodine levels are above 1000",
"    <span class=\"nowrap\">",
"     mcg/day,",
"    </span>",
"    iodine-induced thyroid dysfunction is likely, and the results of the radioiodine uptake should be interpreted accordingly [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26089418\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iodine-induced hyperthyroidism is usually self-limited (lasting 1 to 18 months) if the source of iodine is discontinued. The appropriate therapy for patients with iodine-induced hyperthyroidism is discontinuation of iodine, avoidance of further exposure, and the administration of a beta-adrenergic antagonist drug (assuming there are no contraindications to its use) to minimize the manifestations of hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/26\">",
"     26",
"    </a>",
"    ]. We typically use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    in an initial dose of 25 to 50",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    However, all beta-adrenergic blocking drugs effectively diminish hyperthyroid symptoms. Thyroid tests (TSH, free T4, total T3) should be measured initially at four to six week intervals and then less frequently (TSH and free T4 every three months) depending upon the results of prior testing. Beta blockers can be tapered and discontinued after thyroid tests return to normal.",
"   </p>",
"   <p>",
"    Administration of a thionamide may speed recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/25\">",
"     25",
"    </a>",
"    ]. When hyperthyroid symptoms are severe or prolonged (&gt;1 month), or the patient is elderly and has underlying heart disease, we add",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    (starting dose 10 to 20 mg once daily) because of its long duration of action, allowing for once daily dosing, more rapid efficacy, and lower incidence of side effects.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/9/5271?source=see_link\">",
"     Propylthiouracil",
"    </a>",
"    should be used instead of methimazole in pregnant women during their first trimester. Thyroid function should be assessed after four weeks by measurement of serum TSH, free T4, and T3. The dose of methimazole is then tapered with the goal of maintaining a euthyroid state. Thereafter, thyroid function tests (TSH, free T4) should be measured every three months. Many patients with underlying autonomous nodular thyroid disease are able to taper and discontinue methimazole within 6 to 12 months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/17/275?source=see_link\">",
"     \"Beta blockers in the treatment of hyperthyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12696?source=see_link\">",
"     \"Thionamides in the treatment of Graves' disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41303?source=see_link\">",
"     \"Pharmacology and toxicity of thionamides\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After resolution of the acute episode of iodine-induced hyperthyroidism, treatment of the underlying thyroid disease should be addressed. For patients with underlying Graves&rsquo; disease, treatment options include continuing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    , radioiodine ablation, or surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21143?source=see_link\">",
"     \"Treatment of Graves' hyperthyroidism\"",
"    </a>",
"    .) Patients with underlying autonomous adenoma or multinodular goiter who return to euthyroidism after discontinuation of iodine do not necessarily require definitive treatment. However, these patients are at risk for recurrent hyperthyroidism if given iodine again. For this reason, many clinicians prefer to treat with surgery or radioiodine, particularly if they develop persistent subclinical hyperthyroidism (low serum TSH but normal free T4 and T3). The management of patients with subclinical hyperthyroidism is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=see_link&amp;anchor=H20#H20\">",
"     \"Subclinical hyperthyroidism\", section on 'Endogenous subclinical hyperthyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radioiodine treatment for an underlying adenoma or multinodular goiter with autonomy may not be possible for several weeks to months after iodine exposure, since the exogenous iodine will limit entry of radioiodine into the thyroid gland. Urinary iodine can be measured to assess the clearance of the iodine load. Once the iodine load has cleared, treatment with radioiodine can proceed. In a previously iodine-exposed patient, a radioiodine uptake should be obtained to calculate the radioiodine treatment dose rather than using fixed-dose radioiodine treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/30/41448?source=see_link\">",
"     \"Treatment of toxic adenoma and toxic multinodular goiter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12410?source=see_link&amp;anchor=H30632293#H30632293\">",
"     \"Radioiodine in the treatment of hyperthyroidism\", section on 'Dosing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Prevention in the elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iodine-induced hyperthyroidism is particularly important in geriatric patients for several reasons: the prevalence of thyroid nodular disease is higher than in younger patients, the hyperthyroidism may be more difficult to detect clinically, and the elderly more often have underlying heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/18\">",
"     18",
"    </a>",
"    ]. These points are well illustrated by a retrospective study of 60 hospitalized elderly patients (average age 80 years) with hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/27\">",
"     27",
"    </a>",
"    ]. The diagnosis of hyperthyroidism was not initially suspected in 62 percent, and many were diagnosed only upon routine screening of thyroid function. Apathetic hyperthyroidism (lack of typical symptoms and signs of hypermetabolism) was present in 15 percent of patients. Contrast radiography with iodide-containing material had been performed in the six months before diagnosis in 23 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of the clinical manifestations of hyperthyroidism in adults\", section on 'Geriatric hyperthyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In high-risk patients (elderly, history of multinodular goiter with autonomy), treatment with a thionamide or perchlorate prior to the administration of an iodine load (eg, coronary arteriography) may blunt or prevent the induction of hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. However, there is insufficient randomized trial data to support the use of thionamides or perchlorate (not available in US) for the prevention of iodine-induced hyperthyroidism. In addition, even in high-risk patients, the occurrence of iodine-induced hyperthyroidism is not common, the hyperthyroidism is usually transient, and beta-adrenergic drugs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    can be administered if hyperthyroidism develops. Thus, we do not suggest preventive therapy. However, elderly patients with known multinodular goiter",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    subclinical hyperthyroidism should be told of the risk for iodine-induced hyperthyroidism, and alternatives to CT scanning with contrast should be considered when appropriate (eg, non-contrast CT, MRI).",
"   </p>",
"   <p>",
"    Routine measurement of thyroid function tests (TSH, and if low, free T4 and T3) in elderly patients after exposure to iodinated radiographic contrast agents is favored by some experts, particularly since the symptoms of hyperthyroidism in the elderly may be atypical [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/27\">",
"     27",
"    </a>",
"    ]. We do not suggest routine measurement of thyroid function tests in all elderly patients. However, in elderly patients with known nodular goiter and borderline low or subnormal TSH concentrations, we suggest measurement of thyroid function tests three to four weeks after exposure to radiographic contrast agents to assess for iodine-induced hyperthyroidism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Iodide-induced hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients at risk for iodine-induced hypothyroidism include those with chronic autoimmune thyroiditis, with Graves' hyperthyroidism previously treated either with radioactive iodine or subtotal thyroidectomy, and those with painless, postpartum, or subacute granulomatous thyroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/1,13,30-32\">",
"     1,13,30-32",
"    </a>",
"    ]. Such patients appear to be unusually sensitive to the inhibitory effects of iodide upon its own organification, in part due to a sustained activity of the",
"    <span class=\"nowrap\">",
"     sodium/iodide",
"    </span>",
"    symporter [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/1\">",
"     1",
"    </a>",
"    ]. This sustained activity of the symporter results in a prolonged inhibition of thyroid hormone synthesis and an increase in TSH. Thus, hypothyroidism occurs in these patients because of failure to escape from the acute Wolff-Chaikoff effect (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Follicular cell autoregulation'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Iodide-associated hypothyroidism has also been reported after hemithyroidectomy for thyroid nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/32\">",
"     32",
"    </a>",
"    ]. The cause of the iodide-induced hypothyroidism in patients after hemithyroidectomy for nodular disease is not known. In addition, several nonthyroidal diseases also appear to place patients at increased risk for developing iodide-induced hypothyroidism. These include cystic fibrosis and thalassemia major in conjunction with repeated blood transfusions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Iodine-induced hypothyroidism may rarely occur in individuals with normal underlying thyroid glands [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Iodide readily crosses the placenta and the fetal thyroid appears particularly sensitive to its inhibitory effects [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/36\">",
"     36",
"    </a>",
"    ]. Thus, maternal exposure to iodide during pregnancy may result in fetal goiter and hypothyroidism. Exposures as minor as vaginal application of povidone-iodine during delivery or topical use of disinfectant in newborns can lead to increased serum TSH concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/37-40\">",
"     37-40",
"    </a>",
"    ] and transient neonatal hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=see_link\">",
"     \"Clinical features and detection of congenital hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dietary iodine supplementation may increase the prevalence of hypothyroidism and Hashimoto's thyroiditis in the supplemented population [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Some patients take iodine supplements with the mistaken idea that more iodine is beneficial to thyroid function when, in fact, the opposite may be true.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6803675\">",
"    <span class=\"h3\">",
"     Diagnosis and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of iodine-induced hypothyroidism are similar to those seen in patients with other causes of hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=see_link\">",
"     \"Clinical manifestations of hypothyroidism\"",
"    </a>",
"    .) The history may uncover past treatment of hyperthyroidism with radioiodine or thyroidectomy or a past history of postpartum thyroiditis. A history of iodine ingestion or administration should be elicited. Physical examination may reveal thyroid enlargement. As with other causes of primary hypothyroidism, the diagnosis of iodine-induced hypothyroidism is primarily based upon laboratory testing (a high serum TSH concentration and a low serum free T4 concentration). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnosis of and screening for hypothyroidism\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Iodine-induced hypothyroidism typically resolves spontaneously and rapidly (within one to two weeks) after withdrawal of iodine [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/35,45,46\">",
"     35,45,46",
"    </a>",
"    ]. Most patients do not require thyroid hormone replacement. The time to recovery may be prolonged (eight weeks or longer) in patients exposed to iodide-containing substances that are not rapidly eliminated from the body. In such cases, or in cases where the source of iodine cannot be withdrawn (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ), thyroid function can be easily normalized by replacement with T4 while exposure to the iodine source continues. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link\">",
"     \"Treatment of hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25065?source=see_link&amp;anchor=H10#H10\">",
"     \"Amiodarone and thyroid dysfunction\", section on 'Hypothyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the underlying thyroid disease, patients who develop transient iodine-induced hypothyroidism are at risk for permanent hypothyroidism in the future [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20568/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2613714\">",
"    <span class=\"h2\">",
"     Amiodarone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both hypothyroidism and hyperthyroidism are complications of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    therapy. The clinical effects of amiodarone on thyroid function in a given individual are dependent upon the underlying status of that individual&rsquo;s thyroid gland. The diagnosis and treatment of amiodarone-induced thyroid dysfunction are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25065?source=see_link\">",
"     \"Amiodarone and thyroid dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4769049\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Iodine is essential for normal thyroid function and it can be obtained by consumption of foods that contain it or to which it is added. The recommended minimum daily intake of iodine is 150 mcg for nonpregnant adults, 220 mcg for pregnant women, 290 mcg for lactating women, and 90 to 120",
"      <span class=\"nowrap\">",
"       mcg/day",
"      </span>",
"      for children aged 1 to 13. (See",
"      <a class=\"local\" href=\"#H7754869\">",
"       'Sources of iodine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The key factor that protects organisms against wide variations in dietary intake of iodine is autoregulation by thyroid follicular cells. Sudden exposure to excess serum iodide inhibits organification of iodide, thereby diminishing hormone biosynthesis; this phenomenon is called the Wolff-Chaikoff effect. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Adaptation to iodide intake in normal subjects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The effects of iodine administration in patients with abnormal thyroid glands differ from those in normal subjects and depend upon the underlying disease process. Iodine administration may result in hyperthyroidism in patients with endemic goiter or in patients with nodular goiters containing autonomously functioning tissue. In contrast, iodine administration may induce or exacerbate hypothyroidism in patients with underlying autoimmune thyroiditis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Iodine-induced thyroid disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations and thyroid function test abnormalities (low serum TSH, elevated free T4",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      T3) in patients with iodine-induced hyperthyroidism are similar to those in patients with hyperthyroidism due to other causes. In most patients, the history of iodine exposure is apparent. (See",
"      <a class=\"local\" href=\"#H26089362\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although a 24-hour thyroid radioiodine uptake and scan are frequently performed to distinguish underlying Graves&rsquo; disease or thyroid autonomy (high uptake) from thyroiditis (low uptake), a radioactive iodine uptake test performed immediately after an iodine load must be interpreted with regard to the iodine load. An exogenous iodine load will dilute the administered radioiodine tracer, and the radioiodine uptake will be lowered depending upon the amount of the exogenous iodine load, whether the exposure is continuous (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      ), and the interval since the iodine exposure. (See",
"      <a class=\"local\" href=\"#H2880101\">",
"       'Evaluation for underlying thyroid disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=see_link&amp;anchor=H25975118#H25975118\">",
"       \"Diagnosis of hyperthyroidism\", section on 'Radioiodine uptake'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      If a 24-hour radioiodine uptake is obtained and is unexpectedly low in a patient with presumed Graves&rsquo; disease or autonomous thyroid nodular disease, and the history of iodine exposure is uncertain, a 24-hour urinary iodine level (or a spot urine iodine and creatinine to estimate the 24-hour urinary iodine concentration) can be obtained to assess the degree of iodine exposure. When urinary iodine levels are above 1000",
"      <span class=\"nowrap\">",
"       mcg/day,",
"      </span>",
"      iodine-induced thyroid dysfunction is likely, and the results of the radioiodine uptake should be interpreted accordingly. (See",
"      <a class=\"local\" href=\"#H2880101\">",
"       'Evaluation for underlying thyroid disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Iodine-induced hyperthyroidism is self-limiting (lasting 1 to 18 months) if the source of iodine is discontinued. The appropriate therapy for patients with iodine-induced hyperthyroidism is discontinuation of iodine, avoidance of further exposure, and the administration of a beta-adrenergic antagonist drug (assuming there are no contraindications to its use) to minimize the manifestations of hyperthyroidism. For patients with nodular thyroid disease who have severe or prolonged (&gt;1 month) hyperthyroid symptoms and in elderly patients with underlying heart disease, we suggest starting a thionamide (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"       methimazole",
"      </a>",
"      ) to achieve euthyroidism quickly (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). After resolution of the acute episode of iodine-induced hyperthyroidism, treatment of the underlying thyroid disease should be addressed. (See",
"      <a class=\"local\" href=\"#H26089418\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Iodine-induced hyperthyroidism is particularly important in elderly patients for several reasons: the prevalence of thyroid nodular disease is higher than in younger patients, the hyperthyroidism may be more difficult to detect clinically, and the elderly more often have underlying heart disease. For high-risk elderly patients (nodular goiter and borderline low or subnormal TSH concentrations), we suggest",
"      <strong>",
"       not",
"      </strong>",
"      administering routine preventive therapy with thionamides prior to radiographic contrast administration (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, in elderly patients at high risk for iodine-induced hyperthyroidism, we measure thyroid function tests (TSH, free T4, and T3) three to four weeks after exposure to radiographic contrast agents to assess for iodine-induced hyperthyroidism. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Prevention in the elderly'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of iodine-induced hypothyroidism are similar to those seen in patients with other causes of hypothyroidism. The diagnosis of iodine-induced hypothyroidism is primarily based upon laboratory testing (a high serum TSH concentration and a low serum free T4 concentration). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Iodide-induced hypothyroidism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Iodine-induced hypothyroidism typically resolves spontaneously and rapidly (within one to two weeks) after withdrawal of iodine. Most patients do not require thyroid hormone replacement. The time to recovery may be prolonged (eight weeks or longer) in patients exposed to iodides that are not rapidly eliminated from the body. In such cases, thyroid function can be easily normalized by replacement with T4 until the iodine is eliminated. (See",
"      <a class=\"local\" href=\"#H6803675\">",
"       'Diagnosis and management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/1\">",
"      B&uuml;rgi H. Iodine excess. Best Pract Res Clin Endocrinol Metab 2010; 24:107.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Nutrition Board Institute of Medicine. Dietary reference intake. Washington, DC: National Academy Press, 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/3\">",
"      Hollowell JG, Staehling NW, Hannon WH, et al. Iodine nutrition in the United States. Trends and public health implications: iodine excretion data from National Health and Nutrition Examination Surveys I and III (1971-1974 and 1988-1994). J Clin Endocrinol Metab 1998; 83:3401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/4\">",
"      WOLFF J, CHAIKOFF IL. Plasma inorganic iodide as a homeostatic regulator of thyroid function. J Biol Chem 1948; 174:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/5\">",
"      WOLFF J, CHAIKOFF IL. The temporary nature of the inhibitory action of excess iodine on organic iodine synthesis in the normal thyroid. Endocrinology 1949; 45:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/6\">",
"      BRAVERMAN LE, INGBAR SH. CHANGES IN THYROIDAL FUNCTION DURING ADAPTATION TO LARGE DOSES OF IODIDE. J Clin Invest 1963; 42:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/7\">",
"      GALTON VA, PITT-RIVERS R. The effect of excessive iodine on the thyroid of the rat. Endocrinology 1959; 64:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/8\">",
"      NAGATAKI S, INGBAR SH. RELATION BETWEEN QUALITATIVE AND QUANTITATIVE ALTERATIONS IN THYROID HORMONE SYNTHESIS INDUCED BY VARYING DOSES OF IODIDE. Endocrinology 1964; 74:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/9\">",
"      Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996; 379:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/10\">",
"      Eng PH, Cardona GR, Fang SL, et al. Escape from the acute Wolff-Chaikoff effect is associated with a decrease in thyroid sodium/iodide symporter messenger ribonucleic acid and protein. Endocrinology 1999; 140:3404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/11\">",
"      Saberi M, Utiger RD. Augmentation of thyrotropin responses to thyrotropin-releasing hormone following small decreases in serum thyroid hormone concentrations. J Clin Endocrinol Metab 1975; 40:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/12\">",
"      Markou KB, Paraskevopoulou P, Karaiskos KS, et al. Hyperthyrotropinemia during iodide administration in normal children and in children born with neonatal transient hypothyroidism. J Clin Endocrinol Metab 2003; 88:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/13\">",
"      Braverman LE. Iodine and the thyroid: 33 years of study. Thyroid 1994; 4:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/14\">",
"      Gartner W, Weissel M. Do iodine-containing contrast media induce clinically relevant changes in thyroid function parameters of euthyroid patients within the first week? Thyroid 2004; 14:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/15\">",
"      Ordene KW, Pan C, Barzel US, Surks MI. Variable thyrotropin response to thyrotropin-releasing hormone after small decreases in plasma thyroid hormone concentrations in patients of advanced age. Metabolism 1983; 32:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/16\">",
"      Martins MC, Lima N, Knobel M, Medeiros-Neto G. Natural course of iodine-induced thyrotoxicosis (Jodbasedow) in endemic goiter area: a 5 year follow-up. J Endocrinol Invest 1989; 12:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/17\">",
"      Roti E, Uberti ED. Iodine excess and hyperthyroidism. Thyroid 2001; 11:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/18\">",
"      Stanbury JB, Ermans AE, Bourdoux P, et al. Iodine-induced hyperthyroidism: occurrence and epidemiology. Thyroid 1998; 8:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/19\">",
"      Skare S, Frey HM. Iodine induced thyrotoxicosis in apparently normal thyroid glands. Acta Endocrinol (Copenh) 1980; 94:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/20\">",
"      Hintze G, Blombach O, Fink H, et al. Risk of iodine-induced thyrotoxicosis after coronary angiography: an investigation in 788 unselected subjects. Eur J Endocrinol 1999; 140:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/21\">",
"      Fradkin JE, Wolff J. Iodide-induced thyrotoxicosis. Medicine (Baltimore) 1983; 62:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/22\">",
"      Rhee CM, Bhan I, Alexander EK, Brunelli SM. Association between iodinated contrast media exposure and incident hyperthyroidism and hypothyroidism. Arch Intern Med 2012; 172:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/23\">",
"      Conn JJ, Sebastian MJ, Deam D, et al. A prospective study of the effect of nonionic contrast media on thyroid function. Thyroid 1996; 6:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/24\">",
"      Fricke E, Fricke H, Esdorn E, et al. Scintigraphy for risk stratification of iodine-induced thyrotoxicosis in patients receiving contrast agent for coronary angiography: a prospective study of patients with low thyrotropin. J Clin Endocrinol Metab 2004; 89:6092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/25\">",
"      Burman KD, Wartofsky L. Iodine effects on the thyroid gland: biochemical and clinical aspects. Rev Endocr Metab Disord 2000; 1:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/26\">",
"      Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011; 21:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/27\">",
"      Martin FI, Deam DR. Hyperthyroidism in elderly hospitalised patients. Clinical features and treatment outcomes. Med J Aust 1996; 164:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/28\">",
"      Muller R, Siggelkow H, Emrich D, et al. Prophylactic application of thyrostatic drugs during excessive iodine exposure in euthyroid patients with thyroid autonomy: a randomized study. Eur J Endocrinol 1996; 134:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/29\">",
"      Lawrence JE, Lamm SH, Braverman LE. The use of perchlorate for the prevention of thyrotoxicosis in patients given iodine rich contrast agents. J Endocrinol Invest 1999; 22:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/30\">",
"      Roti E, Minelli R, Gardini E, et al. Impaired intrathyroidal iodine organification and iodine-induced hypothyroidism in euthyroid women with a previous episode of postpartum thyroiditis. J Clin Endocrinol Metab 1991; 73:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/31\">",
"      K&auml;mpe O, Jansson R, Karlsson FA. Effects of L-thyroxine and iodide on the development of autoimmune postpartum thyroiditis. J Clin Endocrinol Metab 1990; 70:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/32\">",
"      Clark OH, Cavalieri RR, Moser C, Ingbar SH. Iodide-induced hypothyroidism in patients after thyroid resection. Eur J Clin Invest 1990; 20:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/33\">",
"      Costigan DC, Holland FJ, Daneman D, et al. Amiodarone therapy effects on childhood thyroid function. Pediatrics 1986; 77:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/34\">",
"      Alexandrides T, Georgopoulos N, Yarmenitis S, Vagenakis AG. Increased sensitivity to the inhibitory effect of excess iodide on thyroid function in patients with beta-thalassemia major and iron overload and the subsequent development of hypothyroidism. Eur J Endocrinol 2000; 143:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/35\">",
"      Markou K, Georgopoulos N, Kyriazopoulou V, Vagenakis AG. Iodine-Induced hypothyroidism. Thyroid 2001; 11:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/36\">",
"      Roti E, Gnudi A, Braverman LE. The placental transport, synthesis and metabolism of hormones and drugs which affect thyroid function. Endocr Rev 1983; 4:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/37\">",
"      Novaes J&uacute;nior M, Biancalana MM, Garcia SA, et al. Elevation of cord blood TSH concentration in newborn infants of mothers exposed to acute povidone iodine during delivery. J Endocrinol Invest 1994; 17:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/38\">",
"      Smerdely P, Lim A, Boyages SC, et al. Topical iodine-containing antiseptics and neonatal hypothyroidism in very-low-birthweight infants. Lancet 1989; 2:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/39\">",
"      AvRuskin TW, Greenfield E, Prasad V, et al. Decreased T3 and T4 levels following topical application of povidone-iodine in premature neonates. J Pediatr Endocrinol 1994; 7:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/40\">",
"      Koga Y, Sano H, Kikukawa Y, et al. Effect on neonatal thyroid function of povidone-iodine used on mothers during perinatal period. J Obstet Gynaecol (Tokyo 1995) 1995; 21:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/41\">",
"      l'Allemand D, Gr&uuml;ters A, Beyer P, Weber B. Iodine in contrast agents and skin disinfectants is the major cause for hypothyroidism in premature infants during intensive care. Horm Res 1987; 28:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/42\">",
"      Chanoine JP, Boulvain M, Bourdoux P, et al. Increased recall rate at screening for congenital hypothyroidism in breast fed infants born to iodine overloaded mothers. Arch Dis Child 1988; 63:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/43\">",
"      Teng W, Shan Z, Teng X, et al. Effect of iodine intake on thyroid diseases in China. N Engl J Med 2006; 354:2783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/44\">",
"      Pedersen IB, Laurberg P, Knudsen N, et al. An increased incidence of overt hypothyroidism after iodine fortification of salt in Denmark: a prospective population study. J Clin Endocrinol Metab 2007; 92:3122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/45\">",
"      Sato K, Okamura K, Hirata T, et al. Immunological and chemical types of reversible hypothyroidism; clinical characteristics and long-term prognosis. Clin Endocrinol (Oxf) 1996; 45:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20568/abstract/46\">",
"      Sato K, Ohmori T, Shiratori K, et al. Povidone iodine-induced overt hypothyroidism in a patient with prolonged habitual gargling: urinary excretion of iodine after gargling in normal subjects. Intern Med 2007; 46:391.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7844 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-E64CDCC3B7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_5_20568=[""].join("\n");
var outline_f20_5_20568=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4769049\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7754869\">",
"      SOURCES OF IODINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ADAPTATION TO IODIDE INTAKE IN NORMAL SUBJECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Follicular cell autoregulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Iodide effects on thyroid hormone secretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      IODINE-INDUCED THYROID DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Iodine-induced hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26089362\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2880101\">",
"      - Evaluation for underlying thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26089418\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Prevention in the elderly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Iodide-induced hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6803675\">",
"      - Diagnosis and management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2613714\">",
"      Amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4769049\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7844\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7844|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/26/18861\" title=\"table 1\">",
"      Sources of iodine",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25065?source=related_link\">",
"      Amiodarone and thyroid dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/17/275?source=related_link\">",
"      Beta blockers in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=related_link\">",
"      Clinical features and detection of congenital hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=related_link\">",
"      Diagnosis of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=related_link\">",
"      Diagnostic approach to and treatment of thyroid nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39864?source=related_link\">",
"      Iodine deficiency disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10852?source=related_link\">",
"      Iodine in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=related_link\">",
"      Overview of the clinical manifestations of hyperthyroidism in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41303?source=related_link\">",
"      Pharmacology and toxicity of thionamides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12410?source=related_link\">",
"      Radioiodine in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=related_link\">",
"      Subclinical hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12696?source=related_link\">",
"      Thionamides in the treatment of Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33320?source=related_link\">",
"      Thyroid hormone synthesis and physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21143?source=related_link\">",
"      Treatment of Graves' hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=related_link\">",
"      Treatment of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/30/41448?source=related_link\">",
"      Treatment of toxic adenoma and toxic multinodular goiter",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_5_20569="Clinical manifestations and diagnosis of acute pancreatitis";
var content_f20_5_20569=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of acute pancreatitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/5/20569/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/5/20569/contributors\">",
"     Santhi Swaroop Vege, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/5/20569/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/5/20569/contributors\">",
"     David C Whitcomb, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/5/20569/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/5/20569/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/5/20569/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute pancreatitis is an acute inflammatory process of the pancreas. It is usually associated with severe acute upper abdominal pain and elevated blood levels of pancreatic enzymes. Most cases are associated with alcoholism or gallstones, but the precise pathogenetic mechanisms are not fully understood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=see_link\">",
"     \"Etiology of acute pancreatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44774?source=see_link\">",
"     \"Pathogenesis of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute pancreatitis can be suspected clinically, but requires biochemical, radiologic, and sometimes histologic evidence to confirm the diagnosis. Clinical, biochemical, and radiologic features need to be considered together since none of them alone is diagnostic of acute pancreatitis (",
"    <a class=\"graphic graphic_table graphicRef68378 \" href=\"UTD.htm?10/60/11212\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This topic review will discuss the clinical features and diagnosis of acute pancreatitis. The grading of severity and subsequent management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44504?source=see_link\">",
"     \"Predicting the severity of acute pancreatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7738?source=see_link\">",
"     \"Treatment of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute pancreatitis is an important cause of acute upper abdominal pain. Because its clinical features are similar to a number of other acute illnesses, it is difficult to base a diagnosis only on symptoms and signs. The disease varies in severity and the diagnosis is often missed at the extreme ends of the spectrum [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Demographic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two most common causes of acute pancreatitis in adults are gallstones and alcoholism. Acute gallstone pancreatitis occurs more often in women, while alcoholic pancreatitis occurs more often in men. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=see_link\">",
"     \"Etiology of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of acute pancreatitis increases with age. Onset in the first decade suggests a hereditary cause (eg, hyperlipidemia or hereditary chronic pancreatitis), infection (eg, mumps), or trauma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all patients with acute pancreatitis have acute upper abdominal pain at the onset [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/2\">",
"     2",
"    </a>",
"    ]. The pain is steady and may be in the mid-epigastrium, right upper quadrant, diffuse, or, infrequently, confined to the left side. Biliary colic, which may herald or progress to acute pancreatitis, may occur postprandially. On the other hand, acute pancreatitis related to alcohol frequently occurs one to three days after a binge or cessation of drinking.",
"   </p>",
"   <p>",
"    Unlike biliary colic, which may last for six to eight hours, the pain of pancreatitis can last for days. Its onset is rapid, but not as abrupt as that with a perforated viscus, reaching maximum intensity in many cases within 10 to 20 minutes. One characteristic of the pain that is present in about one-half of patients, and that suggests a pancreatic origin, is band-like radiation to the back. Painless disease is uncommon (5 to 10 percent) and may be seen in the postoperative setting (especially renal transplantation), in patients receiving peritoneal dialysis, and those with Legionnaire's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/3\">",
"     3",
"    </a>",
"    ]. Acute pancreatitis may sometimes be diagnosed only on postmortem examination [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The abdominal pain is typically accompanied (in approximately 90 percent of patients) by nausea and vomiting, which may persist for many hours. Restlessness, agitation, and relief on bending forward are other notable symptoms. Patients with fulminant attacks may present in shock or coma.",
"   </p>",
"   <p>",
"    The pain of acute pancreatitis is usually severe enough to require a visit to the emergency department and admission to the hospital. Patients with recurrent episodes of pancreatitis or acute flares of chronic pancreatitis sometimes manage their flares at home by staying on clear liquids for a few days.",
"   </p>",
"   <p>",
"    Hemorrhagic complications are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/4\">",
"     4",
"    </a>",
"    ]. Ecchymotic discoloration of the flanks (Grey-Turner's sign) is due to retroperitoneal bleeding in patients with pancreatic necrosis. Bleeding may also occur into pseudocysts [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/5\">",
"     5",
"    </a>",
"    ] or rarely bleeding into the pancreatic duct is visible on endoscopy as blood coming from the ampulla (hemosuccus pancreaticus).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical findings vary depending upon the severity of an attack. Systemic features include fever, tachycardia, and, in severe cases, shock and coma. In mild disease, the epigastrium may be minimally tender. However, severe episodes are often associated with abdominal distention, especially in the epigastrium, and tenderness and guarding, which are less than expected from the intensity of the patient's discomfort. Respirations may be shallow due to diaphragmatic irritation from inflammatory exudate, and dyspnea may occur if there is an associated pleural effusion.",
"   </p>",
"   <p>",
"    Ecchymotic discoloration in the flank (Grey-Turner's sign) or the periumbilical region (Cullen's sign) occurs in 1 percent of cases but is not diagnostic. These signs reflect intraabdominal hemorrhage and are associated with a poor prognosis. Obstruction of the common bile duct, due to choledocholithiasis or edema of the head of the pancreas, can lead to jaundice.",
"   </p>",
"   <p>",
"    An epigastric mass due to pseudocyst formation may become palpable in the course of the disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17928?source=see_link\">",
"     \"Diagnosis and management of pseudocysts of the pancreas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Less common features include subcutaneous nodular fat necrosis (panniculitis), thrombophlebitis in the legs, and polyarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The lesions of fat necrosis, 0.5 to 2 cm tender red nodules, are usually located over the distal extremities but may occur elsewhere.",
"   </p>",
"   <p>",
"    There may also be findings indicative of underlying disorders such as hepatomegaly in alcoholic pancreatitis, xanthomas in hyperlipidemic pancreatitis, and parotid swelling associated with mumps.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LABORATORY TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of biochemical tests have been used in the diagnosis of acute pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/8\">",
"     8",
"    </a>",
"    ]. These can be broadly classified as serum or urinary levels of pancreatic digestive enzymes, serum or urinary levels of nonenzymatic pancreatic secretions, and",
"    <span class=\"nowrap\">",
"     immune/nonspecific",
"    </span>",
"    markers of inflammation (",
"    <a class=\"graphic graphic_table graphicRef68378 \" href=\"UTD.htm?10/60/11212\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pancreatic enzymes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early in the course of acute pancreatitis, there is a breakdown in the synthesis-secretion coupling of pancreatic digestive enzymes; synthesis continues while there is a blockade of secretion. As a result, digestive enzymes leak out of acinar cells through the basolateral membrane to the interstitial space and then the systemic circulation. This is postulated to be the mechanism for the early rise in serum concentrations of pancreatic digestive enzymes in acute pancreatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44774?source=see_link\">",
"     \"Pathogenesis of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, these findings are not specific for pancreatitis since other organs also produce digestive enzymes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Serum amylase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum amylase is the most frequently ordered test to diagnose acute pancreatitis. It rises within 6 to 12 hours of onset, and is cleared fairly rapidly from the blood (half-life approximately 10 hours). In uncomplicated attacks, serum amylase is usually elevated for three to five days.",
"   </p>",
"   <p>",
"    The sensitivity of serum amylase for detecting acute pancreatitis is difficult to assess because an elevated amylase concentration is often required to make the diagnosis. In mild attacks, other tests to detect pancreatic inflammation are either not sensitive enough (radiology, other biochemical markers) or not necessary (surgery). Substantial elevations in serum amylase (more than two times the upper limit of normal) may, for reasons that are not well understood, be less common in patients with hypertriglyceridemia-associated pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/9\">",
"     9",
"    </a>",
"    ]. In most cases, the presence of pancreatitis will be clarified by clinical and radiologic features; however, in some patients with hyperamylasemia, pancreatitis cannot be confidently excluded.",
"   </p>",
"   <p>",
"    An elevated serum amylase level is a nonspecific finding because it occurs in a number of conditions other than acute pancreatitis (",
"    <a class=\"graphic graphic_table graphicRef78538 \" href=\"UTD.htm?23/54/24428\">",
"     table 2",
"    </a>",
"    ). The serum amylase concentration in acute pancreatitis is usually more than three times the upper limit of normal. However, the serum amylase may be normal or minimally elevated (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10679?source=see_link\">",
"     \"Approach to the patient with elevated serum amylase or lipase\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A variety of mechanisms can account for hyperamylasemia in nonpancreatic disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disease can occur in other organs (eg, salivary glands and fallopian tubes) that produce amylase",
"     </li>",
"     <li>",
"      Transmural absorption in intestinal infarction and transperitoneal absorption with a perforated viscus and peritonitis probably explain the hyperamylasemia in these conditions",
"     </li>",
"     <li>",
"      There is decreased renal clearance of amylase in patients with renal failure",
"     </li>",
"     <li>",
"      Increased serum amylase in cholecystitis is probably due to subclinical or undiagnosed coexistent pancreatitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chronic elevations of serum amylase (without amylasuria) occur in macroamylasemia, a condition in which normal serum amylase is bound to an abnormal serum protein to form a macroamylase complex. Macroamylasemia can also be induced by the use of hydroxyethyl starch as a plasma substitute [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/10\">",
"     10",
"    </a>",
"    ]. Although an elevated serum amylase due to macroamylasemia causes confusion about the presence of pancreatic disease, macroamylasemia has no known clinical consequence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10679?source=see_link\">",
"     \"Approach to the patient with elevated serum amylase or lipase\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Simple analytical techniques can be used to separate pancreatic and salivary isoforms of the enzyme. Amylase of pancreatic origin (P-isoamylase) represents 35 to 50 percent of the normal serum amylase. Because pancreatic diseases lead to increased serum levels of pancreatic isoamylase, measurement of P-isoamylase improves diagnostic accuracy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10679?source=see_link\">",
"     \"Approach to the patient with elevated serum amylase or lipase\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Urine amylase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperamylasuria occurs in acute pancreatitis because the normal 3 percent amylase-to-creatinine clearance ratio (ACCR), which indicates that approximately 3 percent of filtered amylase is excreted, increases to approximately 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/11\">",
"     11",
"    </a>",
"    ]. Even moderate renal insufficiency interferes with accuracy and specificity of the ACCR, and urinary amylase excretion is not increased in macroamylasemia.",
"   </p>",
"   <p>",
"    However, other than to diagnose macroamylasemia, urinary amylase and the ACCR offer no advantage over routine serum amylase. In patients with elevated urinary amylase in the absence of elevated serum amylase, deliberate contamination of urine with saliva, as in Munchausen's syndrome, should be excluded by measuring salivary amylase in the urine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Serum lipase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because lipase measurements have been difficult to perform and lacked precision, they have been less frequently ordered than serum amylase [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/12\">",
"     12",
"    </a>",
"    ]. Inclusion of co-lipase in the assay of commercially available kits has improved diagnostic accuracy. In addition, a radioimmunoassay has been developed to measure serum lipase. In patients with acute pancreatitis, the magnitude of increase in serum lipase above upper normal reference limits can vary widely depending upon the method used [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sensitivity of serum lipase for the diagnosis of acute pancreatitis ranges from 85 to 100 percent in various reports [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/14\">",
"     14",
"    </a>",
"    ]. Lipase measurement is more specific than serum amylase and urinary total amylase in diagnostic accuracy both on day one and day three [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/15\">",
"     15",
"    </a>",
"    ]. However, nonspecific elevations of lipase have been reported in almost as many diseases as amylase [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/16\">",
"     16",
"    </a>",
"    ]. Serum lipase levels may be especially useful in patients with alcoholic pancreatitis presenting late to the physician [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10679?source=see_link\">",
"     \"Approach to the patient with elevated serum amylase or lipase\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Controversy exists about the clinical utility of combining amylase and lipase for improving diagnostic accuracy for acute pancreatitis, especially since some studies suggest that lipase elevations occur earlier and last longer than amylase elevations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/18\">",
"     18",
"    </a>",
"    ]. However, we and others have found that the combination of enzymes does not improve diagnostic accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Furthermore, daily measurement of enzymes has no value in assessing the clinical progress or prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/16\">",
"     16",
"    </a>",
"    ]. The level of pancreatic enzyme elevation does not correlate with severity of disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10679?source=see_link\">",
"     \"Approach to the patient with elevated serum amylase or lipase\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Other pancreatic enzymes",
"    </span>",
"    &nbsp;&mdash;&nbsp;During acute pancreatic inflammation, a number of pancreatic digestive enzymes other than amylase and lipase leak into the systemic circulation and are elevated in serum. These include phospholipase A, trypsin, carboxyl ester lipase, carboxypeptidase A, and co-lipase (",
"    <a class=\"graphic graphic_table graphicRef68378 \" href=\"UTD.htm?10/60/11212\">",
"     table 1",
"    </a>",
"    ). None of these, alone or in combination, has a significant clinical advantage over amylase and lipase. It has been suggested that measurement of urinary and serum trypsinogen-2 may be useful for early identification of pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], particularly after endoscopic retrograde cholangiopancreatography (ERCP) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. These preliminary studies await confirmation from other centers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28666?source=see_link&amp;anchor=H7#H7\">",
"     \"Post-ERCP pancreatitis\", section on 'Early diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Nonenzymatic pancreatic secretory products",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of nonenzymatic proteins are overexpressed in the acutely inflamed pancreas. Pancreatitis-associated protein (PAP) is a heat shock protein that is undetectable in the normal pancreas but its synthesis is markedly increased in acute pancreatitis. The sensitivity of PAP for the detection of acute pancreatitis appears to be no better than conventional tests [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another potential marker of acute pancreatitis is trypsinogen activation peptide (TAP), a five amino-acid peptide that is cleaved from trypsinogen to produce active trypsin. Since activation of trypsin is likely an early event in the pathogenesis of acute pancreatitis, TAP may be useful in detection of early acute pancreatitis. In one study, urinary TAP was a predictor of the severity of acute pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/28\">",
"     28",
"    </a>",
"    ]. Activation peptides TAP and carboxypeptidase activation peptide (CAPAP) show promise as markers of severity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Markers of immune activation/nonspecific markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum markers of immune activation may be useful in predicting a severe outcome of acute pancreatitis. These include IL-6, IL-8, IL-10, TNF, PMN elastase, and C-reactive protein. Levels of C-reactive protein above 150",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    at 48 hours discriminate severe from mild disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/25\">",
"     25",
"    </a>",
"    ]. A rapid dipstick method may be available in the near future for IL-8, while the methodology for the other markers is still cumbersome and expensive [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     RADIOLOGIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important radiologic features may be seen on a plain film of the abdomen, chest radiograph, and spiral (helical) CT scan. Abdominal ultrasound also can provide useful information but is often limited technically. Endoscopic ultrasound may become useful to document the presence of gallstones within the common bile duct. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43557?source=see_link\">",
"     \"Endoscopic ultrasound in patients with suspected choledocholithiasis\"",
"    </a>",
"    .) The role of MRI is being increasingly recognized in acute pancreatitis to detect pancreatic necrosis, differentiate fluid collections from areas of pancreatic necrosis, and to detect common bile duct stones using magnetic resonance cholangiopancreatography (MRCP) (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Magnetic resonance imaging'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Abdominal plain film",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of acute abdominal pain, an abdominal plain film helps to exclude other causes of abdominal pain such as obstruction and bowel perforation. The radiographic findings in acute pancreatitis range from unremarkable in mild disease to localized ileus of a segment of small intestine (\"sentinel loop\") or the \"colon cutoff sign\" in more severe disease. The latter reflects a paucity of air in the colon distal to the splenic flexure due to functional spasm of the descending colon secondary to spread of pancreatic inflammation to that area. Generalized ileus may occur in severe disease. A ground glass appearance may indicate ascites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Chest film",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-third of patients with acute pancreatitis have abnormalities visible on the chest roentgenogram such as elevation of a hemidiaphragm, pleural effusions, basal atelectasis, pulmonary infiltrates, or acute respiratory distress syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/29\">",
"     29",
"    </a>",
"    ]. Left-sided or bilateral pleural effusions suggest increased risk of complications [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Abdominal ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diffusely enlarged, hypoechoic pancreas is the classic ultrasonographic image of acute pancreatitis; it can also detect gallstones in the gallbladder (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58844 \" href=\"UTD.htm?23/43/24255\">",
"     image 1",
"    </a>",
"    ). A less frequent pattern is the presence of focal hypoechoic areas. However, 25 to 35 percent of patients have bowel gas that may obscure the pancreas. Because of the high frequency of incomplete examinations owing to overlying bowel gas due to ileus, ultrasound plays very little part in the diagnosis or staging of acute pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultrasound is ideal to image the gallbladder and biliary tree and can be used in mild, uncomplicated cases of acute pancreatitis. It cannot clearly delineate extrapancreatic spread of pancreatic inflammation or identify necrosis within the pancreas; these important findings are best seen by contrast enhanced CT scan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     CT scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT scan is the most important imaging test for the diagnosis of acute pancreatitis and its intraabdominal complications and also for assessment of severity. Patients with clinical and biochemical features of acute pancreatitis who do not improve with initial conservative therapy or who are suspected of having complications or other diagnoses should undergo CT scan of the abdomen.",
"   </p>",
"   <p>",
"    If possible, all patients should be scanned after oral contrast administration and then, renal function permitting, with intravenous contrast to identify any areas of pancreatic necrosis which are seen as unenhanced areas (less than 50 Hounsfield units after IV contrast) greater than 3 cm in size. If there is suspicion of infection, analysis of contents obtained by CT or US guided needle aspiration can differentiate between sterile and infected pancreatic necrosis or a pseudocyst (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73456 \" href=\"UTD.htm?18/22/18784\">",
"     image 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7738?source=see_link\">",
"     \"Treatment of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although iodinated contrast medium, when given at the onset of pancreatitis, increased necrosis in an experimental rat model of acute pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/31\">",
"     31",
"    </a>",
"    ], it did not do so in an opossum model [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/32\">",
"     32",
"    </a>",
"    ] and there is little evidence in humans to support that contrast media increase necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/33\">",
"     33",
"    </a>",
"    ]. Thus, contrast-enhanced CT continues to be used clinically when needed to assess extent of disease, usually no sooner than several days after onset of the attack. Experimental evidence in the rat suggests that gadolinium for MRI imaging does not increase necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The severity of acute pancreatitis has been classified into five grades based upon findings on unenhanced CT (",
"    <a class=\"graphic graphic_table graphicRef68191 \" href=\"UTD.htm?12/41/12956\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade A &ndash; Normal pancreas consistent with mild pancreatitis",
"     </li>",
"     <li>",
"      Grade B &ndash; Focal or diffuse enlargement of the gland, including contour irregularities and inhomogeneous attenuation but without peripancreatic inflammation",
"     </li>",
"     <li>",
"      Grade C &ndash; Abnormalities seen in grade B plus peripancreatic inflammation",
"     </li>",
"     <li>",
"      Grade D &ndash; Grade C plus associated single fluid collection",
"     </li>",
"     <li>",
"      Grade E &ndash; Grade C plus two or more peripancreatic fluid collections or gas in the pancreas or retroperitoneum",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a further modification of this grading system, the grades A to E based on unenhanced CT findings are given scores of 0 to 4, respectively, and combined with a score for the degree of pancreatic necrosis quantified by contrast-enhanced CT [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The sum of the two scores is the CT severity index for acute pancreatitis (",
"    <a class=\"graphic graphic_table graphicRef68191 \" href=\"UTD.htm?12/41/12956\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI and MRCP are being increasingly used in the diagnosis and management of acute pancreatitis. Magnetic resonance cholangiopancreatography, both enhanced and non-enhanced, has a strong correlation with contrast-enhanced CT in acute pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/38\">",
"     38",
"    </a>",
"    ]. The advantages of MRI over CT include: lower risk of nephrotoxicity from gadolinium in patients without underlying renal disease, ability of MRI to better categorize fluid collections as acute fluid collections, necrosis, abscess, hemorrhage, and pseudocyst [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/39\">",
"     39",
"    </a>",
"    ], and the greater sensitivity of MRI to detect mild acute pancreatitis compared with CT. In addition, unlike CT, MRCP delineates the pancreatic and bile ducts better, and MRCP is comparable to ERCP for the detection of choledocholithiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/40\">",
"     40",
"    </a>",
"    ]. In one report, MRI was reliable for staging the severity of AP, had prognostic value, was associated with fewer contraindications compared with CT, and was able to detect pancreatic duct disruptions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abdominal imaging using MRI is rapidly evolving both in terms of technology (hardware and software) as well as the protocols used for imaging (pulse sequences, contrast agents, use of breath holding, etc). This has made abdominal MRI operator-dependent with consequent variability in quality and technique. Its use in acute pancreatitis should currently be dictated by local expertise and availability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     ESTABLISHING THE CAUSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of acute pancreatitis has been established, the cause of the pancreatitis should be determined. Gallstones and alcohol abuse account for 60 to 75 percent and should be diligently looked for in all patients presenting with acute pancreatitis. The following table describes the clinical profile of patients in whom these and other causes of pancreatitis should be suspected as etiologies (",
"    <a class=\"graphic graphic_table graphicRef76483 \" href=\"UTD.htm?36/1/36892\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=see_link\">",
"     \"Etiology of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Alcoholic versus gallstone pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differentiation between alcoholic and gallstone pancreatitis has important therapeutic implications since elimination of the cause in either condition may prevent further attacks. Recurrent attacks of acute pancreatitis suggest an alcoholic etiology, but persons who have unrecognized gallstones may have recurrent biliary colic, pancreatitis, or cholecystitis. Among patients with acute biliary pancreatitis discharged from the hospital without a cholecystectomy, 30 to 50 percent develop recurrence of pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/42,43\">",
"     42,43",
"    </a>",
"    ], occurring an average of 108 days after discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/43\">",
"     43",
"    </a>",
"    ]. Thus, removing the gallbladder in biliary pancreatitis is imperative.",
"   </p>",
"   <p>",
"    For this reason, conventional transabdominal ultrasonography should be performed in every patient with a first attack of acute pancreatitis to search for gallstones in the gallbladder (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58844 \" href=\"UTD.htm?23/43/24255\">",
"     image 1",
"    </a>",
"    ). In the setting of acute pancreatitis, gallbladder visualization may be inadequate due to excessive bowel gas in 25 to 35 percent of patients. In such cases, a repeat ultrasound should be performed after resolution of acute pancreatitis. In our practice, the common bile duct is imaged in most patients with biliary pancreatitis by an operative cholangiogram during laparoscopic cholecystectomy performed during the same admission. EUS is the most accurate method to detect common duct stones [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/44\">",
"     44",
"    </a>",
"    ], and has been recommended for evaluating the common duct prior to cholecystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/31\">",
"     31",
"    </a>",
"    ]. However, we rarely perform EUS in this setting due to its invasive nature. MRCP may be an alternative to detect common duct stones in such patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43557?source=see_link\">",
"     \"Endoscopic ultrasound in patients with suspected choledocholithiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23351?source=see_link&amp;anchor=H5#H5\">",
"     \"Magnetic resonance cholangiopancreatography\", section on 'Bile duct obstruction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a common duct stone is found, it is either removed at operation or endoscopically after surgery. A randomized trial showed that laparoscopic exploration of the common bile duct was as safe and effective as postoperative ERCP in clearing the common duct of stones [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most stones pass during the acute attack. Our practice is to limit ERCP to patients with severe acute pancreatitis due to gallstones with persistent common bile duct obstruction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cholangitis and to those in whom the stone could not be removed during surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7738?source=see_link\">",
"     \"Treatment of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Others have looked at various laboratory studies to help distinguish between these two disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increase in serum alanine aminotransferase (ALT) is suggestive of gallstone pancreatitis. A meta-analysis has shown that the specificity of a serum ALT concentration above 150",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"      for gallstone pancreatitis was 96 percent; the sensitivity was only 48 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/46\">",
"       46",
"      </a>",
"      ]. Thus, a value greater than 150",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"      strongly suggests gallstone pancreatitis but a lower value does not exclude the diagnosis.",
"     </li>",
"     <li>",
"      The ratio of serum lipase to amylase also may be a distinguishing feature. In one study, a lipase-to-amylase ratio greater than 2.0 was 91 percent sensitive and 76 percent specific for detecting alcoholic pancreatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/47\">",
"       47",
"      </a>",
"      ]. Furthermore, the specificity for alcoholic pancreatitis may increase at higher ratios [",
"      <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/48\">",
"       48",
"      </a>",
"      ]. However, the utility of this test remains uncertain since other reports have not confirmed these observations [",
"      <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One study evaluated the use of a scoring system in 145 patients with pancreatitis due to either alcoholism or gallstone disease [",
"      <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/50\">",
"       50",
"      </a>",
"      ]. Seven variables (serum and urine amylase, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, lipase-to-amylase ratio, and erythrocyte mean corpuscular volume) were combined into a score which differentiated biliary pancreatitis and alcoholic pancreatitis with a sensitivity of 92 percent and a specificity of 94 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, to distinguish between alcohol and gallstones as the cause of acute pancreatitis, we rely first upon the history. With the first attack of pancreatitis, establishing the etiology as alcohol is not very difficult if a reliable history regarding alcohol use is available. If alcohol abuse is not present, we rely upon serum ALT values and gallbladder ultrasonography.",
"   </p>",
"   <p>",
"    The more difficult problem is the patient who has no clues to the etiology. We do not do further testing if such a patient has an uncomplicated first attack. However, a second attack would prompt a laparoscopic cholecystectomy to exclude gallstones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of relatively less common causes of pancreatitis should be sought in patients with acute pancreatitis not due to gallstones or alcohol use. These include drug-induced pancreatitis and hypertriglyceridemia-induced pancreatitis (",
"    <a class=\"graphic graphic_table graphicRef76483 \" href=\"UTD.htm?36/1/36892\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=see_link\">",
"     \"Etiology of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No obvious etiology is identifiable in approximately 30 percent of patients with acute pancreatitis. The majority of patients have no further attacks. In a retrospective study, for example, only 1 of 31 patients with a first episode of idiopathic acute pancreatitis suffered another attack during a median follow-up of 36 months [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/51\">",
"     51",
"    </a>",
"    ]. This finding suggests that extensive investigation for unusual causes of pancreatitis is not required after the first episode of idiopathic pancreatitis.",
"   </p>",
"   <p>",
"    The approach to the patient with recurrent pancreatitis without obvious cause is more controversial. In a discussion of this topic, a wide range of responses was elicited from a panel of pancreatologists [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Believers in the more nebulous causes of pancreatitis, such as sphincter of Oddi dysfunction and pancreas divisum, tended to favor ERCP and sphincter of Oddi manometry as the first step towards etiologic diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12874?source=see_link\">",
"       \"Clinical manifestations and diagnosis of sphincter of Oddi dysfunction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3431?source=see_link\">",
"       \"Anatomy and clinical significance of pancreas divisum\"",
"      </a>",
"      .) It was also suggested that, at the time of ERCP, duodenal juice should be sampled for microcrystals (cholesterol and calcium bilirubinate). However, this test is not standardized and its value has never been proven in a controlled study.",
"     </li>",
"     <li>",
"      Others suggest laparoscopic cholecystectomy as the first step.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mutations in the genes for serine protease 1 (PRSS1, which encodes cationic trypsinogen), pancreatic secretory trypsin inhibitor (PSTI or SPINK1), and cystic fibrosis transmembrane conductance regulator (CFTR) gene have been identified in some patients with recurrent idiopathic pancreatitis. The clinical significance and therapeutic implications of these mutations remain uncertain. We do not routinely look for an inherited cause of pancreatitis unless patients have a strong family history of pancreatitis or disease onset at a young age (&lt;35 years) in the absence of an apparent cause. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44774?source=see_link\">",
"     \"Pathogenesis of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach to diagnosis of recurrent idiopathic pancreatitis should be individualized and the strategy clearly discussed with the patient. Some of the procedures (eg, sphincter of Oddi manometry) have significant risks and intervention may or may not prevent further attacks of pancreatitis. Endoscopic ultrasonography may provide useful information but has only been studied in a small number of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/5/20569/abstract/53\">",
"     53",
"    </a>",
"    ]. Our policy is to advise laparoscopic cholecystectomy after two attacks of presumed idiopathic acute pancreatitis to exclude a biliary cause. We do not perform biliary microscopy because the results of this test will not change the recommendation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/26/42401?source=see_link\">",
"       \"Patient information: Pancreatitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/36/41537?source=see_link\">",
"       \"Patient information: Acute pancreatitis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute pancreatitis can be suspected clinically, but requires, biochemical, radiologic, and sometimes histologic evidence to confirm the diagnosis. Clinical, biochemical, and radiologic features need to be considered together since none of them alone is diagnostic of acute pancreatitis (",
"    <a class=\"graphic graphic_table graphicRef68378 \" href=\"UTD.htm?10/60/11212\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend amylase or lipase for the diagnosis of acute pancreatitis. Lipase, while more expensive,&nbsp;is preferred to amylase due to its longer period of elevated levels and increased specificity.",
"     </li>",
"     <li>",
"      Serum amylase is the most frequently ordered test to diagnose acute pancreatitis. It rises within 6 to 12 hours of onset, and is cleared fairly rapidly from the blood (half-life 10 hours). In uncomplicated attacks, serum amylase is usually elevated for three to five days. However, an elevated serum amylase level is a nonspecific finding because it occurs in a number of conditions other than acute pancreatitis (",
"      <a class=\"graphic graphic_table graphicRef78538 \" href=\"UTD.htm?23/54/24428\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The sensitivity of serum lipase for the diagnosis of acute pancreatitis ranges from 85 to 100 percent in various reports. Lipase measurement is more specific than serum amylase and urinary total amylase in diagnostic accuracy both on day one and day three. However, nonspecific elevations of lipase have been reported in almost as many diseases as amylase. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10679?source=see_link\">",
"       \"Approach to the patient with elevated serum amylase or lipase\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although measurement of amylase and lipase are useful for diagnosis of pancreatitis, serial measurements in patients with acute pancreatitis are not useful to predict prognosis or for altering management.",
"     </li>",
"     <li>",
"      Important radiologic features may be seen on a plain film of the abdomen, chest radiograph, and spiral (helical) CT scan. CT scan is the most important imaging test for the diagnosis of acute pancreatitis and its intraabdominal complications and also for assessment of severity. Patients with clinical and biochemical features of acute pancreatitis who do not improve with initial conservative therapy or who are suspected of having complications should undergo CT scan of the abdomen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and UpToDate would like to thank Dr. Suresh T. Chari, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Go, VL. Etiology of pancreatitis in the United States. In: Acute pancreatitis: Diagnosis and therapy, Bradley, EL (Eds), Raven, New York 1994. p.235.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/2\">",
"      Swaroop VS, Chari ST, Clain JE. Severe acute pancreatitis. JAMA 2004; 291:2865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/3\">",
"      Toouli J, Brooke-Smith M, Bassi C, et al. Guidelines for the management of acute pancreatitis. J Gastroenterol Hepatol 2002; 17 Suppl:S15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/4\">",
"      Andersson E, Ansari D, Andersson R. Major haemorrhagic complications of acute pancreatitis. Br J Surg 2010; 97:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/5\">",
"      Balthazar EJ, Fisher LA. Hemorrhagic complications of pancreatitis: radiologic evaluation with emphasis on CT imaging. Pancreatology 2001; 1:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/6\">",
"      Dahl PR, Su WP, Cullimore KC, Dicken CH. Pancreatic panniculitis. J Am Acad Dermatol 1995; 33:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/7\">",
"      Bennett RG, Petrozzi JW. Nodular subcutaneous fat necrosis. A manifestation of silent pancreatitis. Arch Dermatol 1975; 111:896.",
"     </a>",
"    </li>",
"    <li>",
"     Kazmierczak SC. Biochemical indicators of acute pancreatitis. In: Clinical pathology of pancreatic disorders, Lott JA (Ed), Humana Press, Totowa, NJ 1997. p.75.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/9\">",
"      Fortson MR, Freedman SN, Webster PD 3rd. Clinical assessment of hyperlipidemic pancreatitis. Am J Gastroenterol 1995; 90:2134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/10\">",
"      Mishler JM, D&uuml;rr GH. Macroamylasemia induced by hydroxyethyl starch--confirmation by gel filtration analysis of serum and urine. Am J Clin Pathol 1980; 74:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/11\">",
"      Johnson SG, Ellis CJ, Levitt MD. Mechanism of increased renal clearnace of amylase/creatinine in acute pancreatitis. N Engl J Med 1976; 295:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/12\">",
"      Tietz NW, Shuey DF. Lipase in serum--the elusive enzyme: an overview. Clin Chem 1993; 39:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/13\">",
"      Lessinger JM, F&eacute;rard G. Plasma pancreatic lipase activity: from analytical specificity to clinical efficiency for the diagnosis of acute pancreatitis. Eur J Clin Chem Clin Biochem 1994; 32:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/14\">",
"      Agarwal N, Pitchumoni CS, Sivaprasad AV. Evaluating tests for acute pancreatitis. Am J Gastroenterol 1990; 85:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/15\">",
"      Treacy J, Williams A, Bais R, et al. Evaluation of amylase and lipase in the diagnosis of acute pancreatitis. ANZ J Surg 2001; 71:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/16\">",
"      Yadav D, Agarwal N, Pitchumoni CS. A critical evaluation of laboratory tests in acute pancreatitis. Am J Gastroenterol 2002; 97:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/17\">",
"      Smotkin J, Tenner S. Laboratory diagnostic tests in acute pancreatitis. J Clin Gastroenterol 2002; 34:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/18\">",
"      Gwozdz GP, Steinberg WM, Werner M, et al. Comparative evaluation of the diagnosis of acute pancreatitis based on serum and urine enzyme assays. Clin Chim Acta 1990; 187:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/19\">",
"      Werner M, Steinberg WM, Pauley C. Strategic use of individual and combined enzyme indicators for acute pancreatitis analyzed by receiver-operator characteristics. Clin Chem 1989; 35:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/20\">",
"      Keim V, Teich N, Fiedler F, et al. A comparison of lipase and amylase in the diagnosis of acute pancreatitis in patients with abdominal pain. Pancreas 1998; 16:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/21\">",
"      Kyl&auml;np&auml;&auml;-B&auml;ck M, Kemppainen E, Puolakkainen P, et al. Reliable screening for acute pancreatitis with rapid urine trypsinogen-2 test strip. Br J Surg 2000; 87:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/22\">",
"      Mayumi T, Inui K, Maetani I, et al. Validity of the urinary trypsinogen-2 test in the diagnosis of acute pancreatitis. Pancreas 2012; 41:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/23\">",
"      Kemppainen E, Hedstr&ouml;m J, Puolakkainen P, et al. Increased serum trypsinogen 2 and trypsin 2-alpha 1 antitrypsin complex values identify endoscopic retrograde cholangiopancreatography induced pancreatitis with high accuracy. Gut 1997; 41:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/24\">",
"      Kemppainen E, Hedstr&ouml;m J, Puolakkainen P, et al. Urinary trypsinogen-2 test strip in detecting ERCP-induced pancreatitis. Endoscopy 1997; 29:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/25\">",
"      Dervenis C, Johnson CD, Bassi C, et al. Diagnosis, objective assessment of severity, and management of acute pancreatitis. Santorini consensus conference. Int J Pancreatol 1999; 25:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/26\">",
"      Iovanna JL, Keim V, Nordback I, et al. Serum levels of pancreatitis-associated protein as indicators of the course of acute pancreatitis. Multicentric Study Group on Acute Pancreatitis. Gastroenterology 1994; 106:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/27\">",
"      Pezzilli R, Billi P, Migliori M, Gullo L. Clinical value of pancreatitis-associated protein in acute pancreatitis. Am J Gastroenterol 1997; 92:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/28\">",
"      Tenner S, Fernandez-del Castillo C, Warshaw A, et al. Urinary trypsinogen activation peptide (TAP) predicts severity in patients with acute pancreatitis. Int J Pancreatol 1997; 21:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/29\">",
"      Ranson JH, Turner JW, Roses DF, et al. Respiratory complications in acute pancreatitis. Ann Surg 1974; 179:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/30\">",
"      Talamani G, Uomo G, Pezzilli R, et al. Renal function and chest x-rays in the assessment of 539 acute pancreatitis patients. Gut 1997; 41:A136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/31\">",
"      Schmidt J, Hotz HG, Foitzik T, et al. Intravenous contrast medium aggravates the impairment of pancreatic microcirculation in necrotizing pancreatitis in the rat. Ann Surg 1995; 221:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/32\">",
"      Kaiser AM, Grady T, Gerdes D, et al. Intravenous contrast medium does not increase the severity of acute necrotizing pancreatitis in the opossum. Dig Dis Sci 1995; 40:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/33\">",
"      Balthazar EJ, Freeny PC. Contrast-enhanced computed tomography in acute pancreatitis: is it beneficial or harmful? Gastroenterology 1994; 106:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/34\">",
"      Werner J, Schmidt J, Warshaw AL, et al. The relative safety of MRI contrast agent in acute necrotizing pancreatitis. Ann Surg 1998; 227:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/35\">",
"      Balthazar EJ, Robinson DL, Megibow AJ, Ranson JH. Acute pancreatitis: value of CT in establishing prognosis. Radiology 1990; 174:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/36\">",
"      Balthazar EJ, Freeny PC, vanSonnenberg E. Imaging and intervention in acute pancreatitis. Radiology 1994; 193:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/37\">",
"      Balthazar EJ, Ranson JH, Naidich DP, et al. Acute pancreatitis: prognostic value of CT. Radiology 1985; 156:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/38\">",
"      Lecesne R, Taourel P, Bret PM, et al. Acute pancreatitis: interobserver agreement and correlation of CT and MR cholangiopancreatography with outcome. Radiology 1999; 211:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/39\">",
"      Morgan DE, Baron TH, Smith JK, et al. Pancreatic fluid collections prior to intervention: evaluation with MR imaging compared with CT and US. Radiology 1997; 203:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/40\">",
"      Taylor AC, Little AF, Hennessy OF, et al. Prospective assessment of magnetic resonance cholangiopancreatography for noninvasive imaging of the biliary tree. Gastrointest Endosc 2002; 55:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/41\">",
"      Arvanitakis M, Delhaye M, De Maertelaere V, et al. Computed tomography and magnetic resonance imaging in the assessment of acute pancreatitis. Gastroenterology 2004; 126:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/42\">",
"      Ranson JH. The timing of biliary surgery in acute pancreatitis. Ann Surg 1979; 189:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/43\">",
"      Paloyan D, Simonowitz D, Skinner DB. The timing of biliary tract operations in patients with pancreatitis associated with gallstones. Surg Gynecol Obstet 1975; 141:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/44\">",
"      Aubertin JM, Levoir D, Bouillot JL, et al. Endoscopic ultrasonography immediately prior to laparoscopic cholecystectomy: a prospective evaluation. Endoscopy 1996; 28:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/45\">",
"      Rhodes M, Sussman L, Cohen L, Lewis MP. Randomised trial of laparoscopic exploration of common bile duct versus postoperative endoscopic retrograde cholangiography for common bile duct stones. Lancet 1998; 351:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/46\">",
"      Tenner S, Dubner H, Steinberg W. Predicting gallstone pancreatitis with laboratory parameters: a meta-analysis. Am J Gastroenterol 1994; 89:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/47\">",
"      Gumaste VV, Dave PB, Weissman D, Messer J. Lipase/amylase ratio. A new index that distinguishes acute episodes of alcoholic from nonalcoholic acute pancreatitis. Gastroenterology 1991; 101:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/48\">",
"      Tenner SM, Steinberg W. The admission serum lipase:amylase ratio differentiates alcoholic from nonalcoholic acute pancreatitis. Am J Gastroenterol 1992; 87:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/49\">",
"      Jaakkola M, Sillanaukee P, L&ouml;f K, et al. Blood tests for detection of alcoholic cause of acute pancreatitis. Lancet 1994; 343:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/50\">",
"      Stimac D, Lenac T, Marusi�� Z. A scoring system for early differentiation of the etiology of acute pancreatitis. Scand J Gastroenterol 1998; 33:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/51\">",
"      Ballinger AB, Barnes E, Alstead EM, Fairclough PD. Is intervention necessary after a first episode of acute idiopathic pancreatitis? Gut 1996; 38:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/52\">",
"      Steinberg WM, Geenen JE, Bradley EL 3rd, Barkin JS. Controversies in clinical pancreatology. Recurrent \"idiopathic\" acute pancreatitis: should a laparoscopic cholecystectomy be the first procedure of choice? Pancreas 1996; 13:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/5/20569/abstract/53\">",
"      Tandon M, Topazian M. Endoscopic ultrasound in idiopathic acute pancreatitis. Am J Gastroenterol 2001; 96:705.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5652 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-5450C57513-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_5_20569=[""].join("\n");
var outline_f20_5_20569=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Demographic features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LABORATORY TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pancreatic enzymes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Serum amylase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Urine amylase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Serum lipase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Other pancreatic enzymes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Nonenzymatic pancreatic secretory products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Markers of immune activation/nonspecific markers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      RADIOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Abdominal plain film",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Chest film",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Abdominal ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CT scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ESTABLISHING THE CAUSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Alcoholic versus gallstone pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/5652\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5652|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/43/24255\" title=\"diagnostic image 1\">",
"      Gallstone in gallbladder US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/22/18784\" title=\"diagnostic image 2\">",
"      Pancreatic abscess CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5652|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/60/11212\" title=\"table 1\">",
"      Features of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/54/24428\" title=\"table 2\">",
"      Differential dx hyperamylasemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/41/12956\" title=\"table 3\">",
"      CT grading acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/1/36892\" title=\"table 4\">",
"      Approach to establishing the cause of acute pancreatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3431?source=related_link\">",
"      Anatomy and clinical significance of pancreas divisum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10679?source=related_link\">",
"      Approach to the patient with elevated serum amylase or lipase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12874?source=related_link\">",
"      Clinical manifestations and diagnosis of sphincter of Oddi dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17928?source=related_link\">",
"      Diagnosis and management of pseudocysts of the pancreas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43557?source=related_link\">",
"      Endoscopic ultrasound in patients with suspected choledocholithiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=related_link\">",
"      Etiology of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23351?source=related_link\">",
"      Magnetic resonance cholangiopancreatography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44774?source=related_link\">",
"      Pathogenesis of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/36/41537?source=related_link\">",
"      Patient information: Acute pancreatitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/26/42401?source=related_link\">",
"      Patient information: Pancreatitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28666?source=related_link\">",
"      Post-ERCP pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44504?source=related_link\">",
"      Predicting the severity of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7738?source=related_link\">",
"      Treatment of acute pancreatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_5_20570="Ciprofloxacin (systemic): Drug information";
var content_f20_5_20570=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ciprofloxacin (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/11/17590?source=see_link\">",
"    see \"Ciprofloxacin (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/11/44216?source=see_link\">",
"    see \"Ciprofloxacin (systemic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9611220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9611233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cipro&reg;;",
"     </li>",
"     <li>",
"      Cipro&reg; I.V.",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9611234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Ciproflox&reg;;",
"     </li>",
"     <li>",
"      Auro-Ciprofloxacin;",
"     </li>",
"     <li>",
"      Ciprofloxacin Injection;",
"     </li>",
"     <li>",
"      Ciprofloxacin Intravenous Infusion;",
"     </li>",
"     <li>",
"      Cipro&reg;;",
"     </li>",
"     <li>",
"      Cipro&reg; XL;",
"     </li>",
"     <li>",
"      CO Ciprofloxacin;",
"     </li>",
"     <li>",
"      Dom-Ciprofloxacin;",
"     </li>",
"     <li>",
"      JAMP-Ciprofloxacin;",
"     </li>",
"     <li>",
"      Mar-Ciprofloxacin;",
"     </li>",
"     <li>",
"      Mint-Ciprofloxacin;",
"     </li>",
"     <li>",
"      Mylan-Ciprofloxacin;",
"     </li>",
"     <li>",
"      Novo-Ciprofloxacin;",
"     </li>",
"     <li>",
"      PHL-Ciprofloxacin;",
"     </li>",
"     <li>",
"      PMS-Ciprofloxacin;",
"     </li>",
"     <li>",
"      PRO-Ciprofloxacin;",
"     </li>",
"     <li>",
"      RAN&trade;-Ciproflox;",
"     </li>",
"     <li>",
"      ratio-Ciprofloxacin;",
"     </li>",
"     <li>",
"      Riva-Ciprofloxacin;",
"     </li>",
"     <li>",
"      Sandoz-Ciprofloxacin;",
"     </li>",
"     <li>",
"      Taro-Ciprofloxacin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9660646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Quinolone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9611424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Extended release tablets and immediate release formulations are not interchangeable. Unless otherwise specified, oral dosing reflects the use of immediate release formulations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Anthrax:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Inhalational (postexposure prophylaxis):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 500 mg every 12 hours for 60 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 400 mg every 12 hours for 60 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Cutaneous (treatment, CDC guidelines):",
"     </i>",
"     Oral: Immediate release formulation: 500 mg every 12 hours for 60 days.",
"     <b>",
"      Note:",
"     </b>",
"     In the presence of systemic involvement, extensive edema, lesions on head/neck, refer to I.V. dosing for treatment of inhalational/gastrointestinal/oropharyngeal anthrax.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Inhalational/gastrointestinal/oropharyngeal (treatment, CDC guidelines):",
"     </i>",
"     I.V.:  400 mg every 12 hours.",
"     <b>",
"      Note:",
"     </b>",
"     Initial treatment should include two or more agents predicted to be effective (per CDC recommendations). Continue combined therapy for 60 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bone/joint infections:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 500-750 mg twice daily for 4-6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Mild/moderate:",
"     </i>",
"     400 mg every 12 hours for 4-6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Severe/complicated:",
"     </i>",
"     400 mg every 8 hours for 4-6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chancroid (unlabeled use):",
"     </b>",
"     Oral: 500 mg twice daily for 3 days (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Endocarditis due to HACEK organisms (AHA guidelines, unlabeled use):",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Not first-line option; use only if intolerant of beta-lactam therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: 500 mg every 12 hours for 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: 400 mg every 12 hours for 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Epididymitis, chlamydial (unlabeled use):",
"     </b>",
"     Oral: 500 mg single dose (Canadian STI Guidelines, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Febrile neutropenia:",
"     </b>",
"     I.V.: 400 mg every 8 hours for 7-14 days (combination therapy generally recommended)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gonococcal infections:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Urethral/cervical gonococcal infections:",
"     </i>",
"     Oral: 250-500 mg as a single dose (CDC recommends concomitant doxycycline or azithromycin due to possible coinfection with",
"     <i>",
"      Chlamydia",
"     </i>",
"     );",
"     <b>",
"      Note:",
"     </b>",
"     As of April 2007, the CDC no longer recommends the use of fluoroquinolones for the treatment of uncomplicated gonococcal disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Disseminated gonococcal infection (CDC guidelines):",
"     </i>",
"     Oral: 500 mg twice daily to complete 7 days of therapy (initial treatment with ceftriaxone 1 g I.M./I.V. daily for 24-48 hours after improvement begins);",
"     <b>",
"      Note:",
"     </b>",
"     As of April 2007, the CDC no longer recommends the use of fluoroquinolones for the treatment of more serious gonococcal disease, unless no other options exist and susceptibility can be confirmed via culture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Granuloma inguinale (donovanosis) (unlabeled use):",
"     </b>",
"     Oral: 750 mg twice daily for at least 3 weeks (and until lesions have healed) (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Infectious diarrhea:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Salmonella:",
"     </i>",
"     500 mg twice daily for 5-7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Shigella:",
"     </i>",
"     500 mg twice daily for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Traveler's diarrhea:",
"     </i>",
"     Mild: 750 mg for one dose; Severe: 500 mg twice daily for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Vibrio cholerae:",
"     </i>",
"     1 g for one dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Intra-abdominal, complicated, community-acquired (in combination with metronidazole): Note:",
"     </b>",
"     Avoid using in settings where",
"     <i>",
"      E. coli",
"     </i>",
"     susceptibility to fluoroquinolones is &lt;90%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: 500 mg every 12 hours for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: 400 mg every 12 hours for 7-14 days;",
"     <b>",
"      Note:",
"     </b>",
"     2010 IDSA guidelines recommend treatment duration of 4-7 days (provided source controlled)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lower respiratory tract, skin/skin structure infections:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 500-750 mg twice daily for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Mild/moderate:",
"     </i>",
"     400 mg every 12 hours for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Severe/complicated:",
"     </i>",
"     400 mg every 8 hours for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Meningococcal meningitis prophylaxis (unlabeled use):",
"     </b>",
"     Oral:  500 mg as a single dose (CDC, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nosocomial pneumonia:",
"     </b>",
"     I.V.: 400 mg every 8 hours for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Periodontitis (unlabeled use):",
"     </b>",
"     Oral: 500 mg every 12 hours for 8-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prostatitis (chronic, bacterial):",
"     </b>",
"     Oral: 500 mg every 12 hours for 28 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sinusitis (acute):",
"     </b>",
"     Oral: 500 mg every 12 hours for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Typhoid fever:",
"     </b>",
"     Oral: 500 mg every 12 hours for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Urinary tract infection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Acute uncomplicated, cystitis:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Immediate release formulation: 250 mg every 12 hours for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Extended release formulation (Cipro&reg; XR): 500 mg every 24 hours for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.: 200 mg every 12 hours for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Complicated (including pyelonephritis):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Immediate release formulation: 500 mg every 12 hours for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Extended release formulation (Cipro&reg; XR): 1000 mg every 24 hours for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 400 mg every 12 hours for 7-14 days",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9611423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/11/44216?source=see_link\">",
"      see \"Ciprofloxacin (systemic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See Warnings/Precautions.",
"     <b>",
"      Note:",
"     </b>",
"     Extended release tablets and immediate release formulations are not interchangeable. Unless otherwise specified, oral dosing reflects the use of immediate release formulations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anthrax:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Inhalational (postexposure prophylaxis):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     15 mg/kg/dose every 12 hours for 60 days; maximum: 500 mg dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     10 mg/kg/dose every 12 hours for 60 days; do",
"     <b>",
"      not",
"     </b>",
"     exceed 400 mg dose (800 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Cutaneous (treatment, CDC guidelines):",
"     </i>",
"     Oral: 10-15 mg/kg every 12 hours for 60 days (maximum: 1 g/day); amoxicillin 80 mg/kg/day divided every 8 hours is an option for completion of treatment after clinical improvement.",
"     <b>",
"      Note:",
"     </b>",
"     In the presence of systemic involvement, extensive edema, lesions on head/neck, refer to I.V. dosing for treatment of inhalational/gastrointestinal/oropharyngeal anthrax.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Inhalational/gastrointestinal/oropharyngeal (treatment, CDC guidelines):",
"     </i>",
"     I.V.: Initial: 10-15 mg/kg every 12 hours for 60 days (maximum: 500 mg dose); switch to oral therapy when clinically appropriate; refer to adult dosing for notes on combined therapy and duration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Community-acquired pneumonia (CAP) (IDSA/PIDS, 2011):",
"     </b>",
"     <i>",
"      H. influenzae,",
"     </i>",
"     moderate-to-severe infection (alternative to ampicillin, ceftriaxone, or cefotaxime): Infants &gt;3 months and Children: I.V.: 30 mg/kg/day divided every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cystic fibrosis (unlabeled use):",
"     </b>",
"     Children 5-17 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     40 mg/kg/day divided every 12 hours administered following 1 week of I.V. therapy has been reported in a clinical trial; total duration of therapy: 10-21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     30 mg/kg/day divided every 8 hours for 1 week, followed by oral therapy, has been reported in a clinical trial",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shigella dysentery type 1 (unlabeled use):",
"     </b>",
"     Oral: 30 mg/kg/day in 2 divided doses for 3 days (WHO, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Urinary tract infection (complicated) or pyelonephritis:",
"     </b>",
"     Children 1-17 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     20-40 mg/kg/day in 2 divided doses (every 12 hours) for 10-21 days; maximum: 1500 mg daily.",
"     <b>",
"      Note:",
"     </b>",
"     30-40 mg/kg/day reserved for severe infections (Red Book, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     6-10 mg/kg every 8 hours for 10-21 days (maximum: 400 mg/dose)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9611425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Adjust dose carefully based on renal function.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F9611426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Manufacturer's recommendations:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral, immediate release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute: 250-500 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     5-29 mL/minute: 250-500 mg every 18 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     ESRD on intermittent hemodialysis (IHD)/peritoneal dialysis (PD) (administer after dialysis on dialysis days): 250-500 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral, extended release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: 500 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     ESRD on intermittent hemodialysis (IHD)/peritoneal dialysis (PD) (administer after dialysis on dialysis days): 500 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     5-29 mL/minute: 200-400 mg every 18-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Alternate recommendations:",
"     </i>",
"     Oral (immediate release), I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No dosage adjustment necessary (Aronoff, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 50% to 75% of usual dose every 12 hours (Aronoff, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 50% of usual dose every 12 hours (Aronoff, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Minimally dialyzable (&lt;10%): Oral: 250-500 mg every 24 hours",
"     <b>",
"      or",
"     </b>",
"     I.V.: 200-400 mg every 24 hours (Heintz, 2009).",
"     <b>",
"      Note:",
"     </b>",
"     Dosing dependent on the assumption of 3 times weekly, complete IHD sessions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     CVVH/CVVHD/CVVHDF: I.V.: 200-400 mg every 12-24 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9611523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W: 200 mg (100 mL); 400 mg (200 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cipro&reg; I.V.: 200 mg (100 mL [DSC]); 400 mg (200 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W [preservative free]: 200 mg (100 mL); 400 mg (200 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 10 mg/mL (20 mL, 40 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 10 mg/mL (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Microcapsules for suspension, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cipro&reg;: 250 mg/5 mL (100 mL) [contains sucrose 1.4 g/5 mL; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cipro&reg;: 500 mg/5 mL (100 mL) [contains sucrose 1.3 g/5 mL; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride [strength expressed as base]: 100 mg, 250 mg, 500 mg, 750 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cipro&reg;: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as base and hydrochloride [strength expressed as base]: 500 mg, 1000 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9611236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes suspension",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F9611231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cipro&reg;:",
"     <a href=\"file://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019537s701984744198575120780282147325L.pdf\" target=\"_blank\">",
"      file://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019537s701984744198575120780282147325L.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9611451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May administer with food to minimize GI upset; avoid antacid use; maintain proper hydration and urine output. Administer immediate release ciprofloxacin and Cipro&reg; XR at least 2 hours before or 6 hours after antacids or other products containing calcium, iron, or zinc (including dairy products or calcium-fortified juices). Separate oral administration from drugs which may impair absorption (see Drug Interactions).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral suspension: Should not be administered through feeding tubes (suspension is oil-based and adheres to the feeding tube). Patients should avoid chewing on the microcapsules.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nasogastric/orogastric tube: Crush immediate-release tablet and mix with water. Flush feeding tube before and after administration. Hold tube feedings at least 1 hour before and 2 hours after administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet, extended release: Do not crush, split, or chew. May be administered with meals containing dairy products (calcium content &lt;800 mg), but not with dairy products alone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Administer by slow I.V. infusion over 60 minutes into a large vein (reduces risk of venous irritation).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F9611369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, NS, SWFI;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in peritoneal dialysis solution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amifostine, amiodarone, anidulafungin, aztreonam, bivalirudin, calcium gluconate, ceftazidime, cisatracurium, cyclosporine, dexmedetomidine, digoxin, diltiazem, diphenhydramine, dobutamine, docetaxel, dopamine, doripenem, doxorubicin liposome, etoposide phosphate, fenoldopam, gallium nitrate, gemcitabine, gentamicin, granisetron, hetastarch in lactate electrolyte injection (Hextend&reg;), hydroxyzine, lidocaine, linezolid, lorazepam, metoclopramide, metronidazole, midazolam, milrinone, piperacillin, potassium acetate, potassium chloride, promethazine, quinupristin and dalfopristin, ranitidine, remifentanil, tacrolimus, telavancin, teniposide, thiotepa, tigecycline, tobramycin, vasopressin, verapamil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Aminophylline, amphotericin B cholesteryl sulfate complex, ampicillin, ampicillin/sulbactam, azithromycin, cefepime, dexamethasone sodium phosphate, drotrecogin alfa, furosemide, hydrocortisone sodium succinate, methylprednisolone sodium succinate, pantoprazole, pemetrexed, phenytoin, potassium phosphate, propofol, vancomycin, warfarin. Variable (consult detailed reference): Caspofungin, heparin, magnesium sulfate, sodium bicarbonate, sodium phosphates.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9611256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Complicated urinary tract infections and pyelonephritis due to",
"     <i>",
"      E. coli",
"     </i>",
"     .",
"     <b>",
"      Note:",
"     </b>",
"     Although effective, ciprofloxacin is not the drug of first choice in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adults: To reduce incidence or progression of disease following exposure to aerolized",
"     <i>",
"      Bacillus anthracis",
"     </i>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Treatment of the following infections when caused by susceptible bacteria: Urinary tract infections; acute uncomplicated cystitis in females; chronic bacterial prostatitis; lower respiratory tract infections (including acute exacerbations of chronic bronchitis); acute sinusitis; skin and skin structure infections; bone and joint infections; complicated intra-abdominal infections (in combination with metronidazole); infectious diarrhea; typhoid fever due to",
"     <i>",
"      Salmonella typhi",
"     </i>",
"     (eradication of chronic typhoid carrier state has not been proven); uncomplicated cervical and urethra gonorrhea (due to",
"     <i>",
"      N. gonorrhoeae",
"     </i>",
"     ); nosocomial pneumonia; empirical therapy for febrile neutropenic patients (in combination with piperacillin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     As of April 2007, the CDC no longer recommends the use of fluoroquinolones for the treatment of gonococcal disease.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F9611258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute pulmonary exacerbations in cystic fibrosis (children); cutaneous/gastrointestinal/oropharyngeal anthrax (treatment, children and adults); disseminated gonococcal infection (adults); chancroid (adults); epididymitis (adults); prophylaxis to",
"     <i>",
"      Neisseria meningitidis",
"     </i>",
"     following close contact with an infected person; empirical therapy (oral) for febrile neutropenia in low-risk cancer patients; HACEK group endocarditis; infectious diarrhea (children); periodontitis; chronic oral antimicrobial suppression of prosthetic joint infection",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3198418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ciprofloxacin may be confused with cephalexin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cipro&reg; may be confused with Ceftin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9611305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Neurologic events (children 2%, includes dizziness, insomnia, nervousness, somnolence); fever (children 2%); headache (I.V. administration); restlessness (I.V. administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (children 2%, adults 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (3%); diarrhea (children 5%, adults 2%); vomiting (children 5%, adults 1%); abdominal pain (children 3%, adults &lt;1%); dyspepsia (children 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased, AST increased (adults 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reactions (I.V. administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis (children 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal gait, acute generalized exanthemous pustulosis (AGEP), acute renal failure, agitation, agranulocytosis, albuminuria, alkaline phosphatase increase, allergic reactions, anaphylactic shock, anemia, angina pectoris, angioedema, anorexia,anxiety, arthralgia, ataxia, atrial flutter, bilirubin (serum) increase, bone marrow depression (life-threatening), bronchospasm, BUN increased, candidiasis, cardiopulmonary arrest, chills, cholestatic jaundice, chromatopsia,",
"     <i>",
"      Clostridium difficile",
"     </i>",
"     -associated diarrhea (CDAD), confusion, constipation, CPK increase, crystalluria (particularly in alkaline urine), cylindruria, delirium, depression (including self-injurious behavior), dizziness, drowsiness, dyspepsia (adults), dyspnea, edema, eosinophilia, erythema multiforme/nodosum, exfoliative dermatitis, fever (adults), fixed eruption, gastrointestinal bleeding, gout flare, hallucinations, headache (oral), hematocrit decreased, hematuria, hemoglobin decreased, hemolytic anemia, hepatic failure (some fatal), hepatic necrosis, hyper-/hypoglycemia, hyper-/hypotension, hyperesthesia, hyperpigmentation, hypertonia, insomnia, interstitial nephritis, intestinal perforation, intracranial pressure increased, irritability, joint pain, laryngeal edema, LDH increased, lightheadedness, lipase increased, lymphadenopathy, malaise, manic reaction, methemoglobinemia, MI, migraine, myalgia, myasthenia gravis exacerbation, myoclonus, nephritis, nightmares, nystagmus, palpitation, pancreatitis, pancytopenia (life-threatening or fatal), paranoia, peripheral neuropathy, petechiae, photosensitivity/toxicity, pneumonitis, polyneuropathy, prolongation of PT/INR (in patients treated with vitamin K antagonists), pseudotumor cerebri, psychosis (toxic), PT decrease, pulmonary edema, renal calculi, seizure (including grand mal), serum cholesterol increased, serum creatinine increased, serum sickness-like reactions, serum triglycerides increased, status epilepticus, Stevens-Johnson syndrome, suicidal thoughts/ideation/attempts and completions, syncope, tachycardia, taste loss, tendon rupture, tendonitis, thrombocytopenia, thrombocytosis, thrombophlebitis, tinnitus, torsade de pointes, toxic epidermal necrolysis, tremor, twitching, unresponsiveness, urethral bleeding, uric acid increased, vaginitis, vasculitis, ventricular arrhythmia, visual disturbance, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9611301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ciprofloxacin, any component of the formulation, or other quinolones; concurrent administration of tizanidine",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9611302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: Fluoroquinolones may prolong QT",
"     <sub>",
"      c",
"     </sub>",
"     interval; avoid use in patients with a history of or at risk for QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, torsade de pointes, uncorrected hypokalemia, hypomagnesemia, cardiac disease (heart failure, myocardial infarction, bradycardia) or concurrent administration of other medications known to prolong the QT interval (including Class Ia and Class III antiarrhythmics, cisapride, erythromycin, antipsychotics, and tricyclic antidepressants).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Tremor, restlessness, confusion, and very rarely hallucinations, increased intracranial pressure (including pseudotumor cerebri) or seizures may occur; use with caution in patients with known or suspected CNS disorder. Reactions may occur following the first dose. Discontinue in patients who experience significant CNS adverse effects (eg, dizziness, hallucinations, psychotic reactions, suicidal ideations/thoughts or attempts, or self-injurious behavior).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Crystalluria: Rarely, crystalluria has occurred; urine alkalinity may increase the risk. Ensure adequate hydration during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glucose regulation: Fluoroquinolones have been associated with the development of serious, and sometimes fatal, hypoglycemia. These events have occurred most often in elderly patients with diabetes, but have also been reported in patients without a prior history of diabetes. Prompt identification and treatment of hypoglycemia is essential. Individual quinolones may differ in their potential to cause this effect. It was most evident with gatifloxacin (no longer marketed as a systemic formulation). Hyperglycemia has also been associated with the use of fluoroquinolones. Patients should be monitored closely for signs/symptoms of disordered glucose regulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity:  Hepatocellular, cholestatic, or mixed liver injury has been reported, including hepatic necrosis, life-threatening hepatic events, and fatalities. Acute liver injury can be rapid onset (range: 1-39 days), often associated with hypersensitivity. Most fatalities occurred in patients &gt;55 years of age. Discontinue immediately if signs/symptoms of hepatitis (abdominal tenderness, dark urine, jaundice, pruritus) occur. Additionally, temporary increases in transaminases or alkaline phosphatase, or cholestatic jaundice may occur (highest risk in patients with previous liver damage).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Severe hypersensitivity reactions, including anaphylaxis, have occurred with quinolone therapy. The spectrum of these reactions can vary widely; reactions may present as typical allergic symptoms (eg, itching, urticaria, rash, edema) after a single dose, or may manifest as severe idiosyncratic dermatologic (eg, Stevens-Johnson, toxic epidermal necrolysis), vascular (eg, vasculitis), pulmonary (eg, pneumonitis), renal (eg, nephritis), hepatic (eg, hepatitis, jaundice, hepatic failure or necrosis), and/or hematologic (eg, anemia, cytopenias) events, usually after multiple doses. Prompt discontinuation of drug should occur if skin rash or other symptoms arise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral neuropathy: The use of quinolones has been linked to peripheral neuropathy (rare); discontinue if symptoms of sensory or sensorimotor neuropathy occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity/phototoxicity: Avoid excessive sunlight and take precautions to limit exposure (eg, loose fitting clothing, sunscreen); may cause moderate-to-severe phototoxicity reactions which may appear as exaggerated sunburn reactions. Discontinue use if phototoxicity occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tendon inflammation/rupture:",
"     <b>",
"      [U.S. Boxed Warning]: There have been reports of tendon inflammation and/or rupture with quinolone antibiotics in all ages; risk may be increased with concurrent corticosteroids, solid organ transplant recipients, and in patients &gt;60 years of age.",
"     </b>",
"     Rupture of the Achilles tendon sometimes requiring surgical repair has been reported most frequently; but other tendon sites (eg, rotator cuff, biceps) have also been reported. Inflammation and rupture may occur bilaterally. Cases have been reported within the first 48 hours, during, and up to several months after discontinuation of therapy. Strenuous physical activity may be an independent risk factor for tendonitis. Discontinue at first sign of tendon inflammation or pain. Use with caution in patients with a history of tendon disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis:",
"     <b>",
"      [U.S. Boxed Warning]: May exacerbate muscle weakness related to myasthenia gravis.",
"     </b>",
"     Cases of severe exacerbations, including the need for ventilatory support and deaths have been reported; avoid use in patients with myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required. May increase risk of tendon rupture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rheumatoid arthritis: Use with caution in patients with rheumatoid arthritis; may increase risk of tendon rupture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in individuals at risk of seizures (CNS disorders or concurrent therapy with medications which may lower seizure threshold; status epilepticus has occurred) or if clinically appropriate, consider alternative antimicrobial therapy. Discontinue if seizures occur. Potential for seizures, although very rare, may be increased with concomitant NSAID therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Syphilis: Since ciprofloxacin is ineffective in the treatment of syphilis and may mask symptoms, all patients should be tested for syphilis at the time of gonorrheal diagnosis and 3 months later.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Theophylline: Serious and fatal reactions including seizures, status epilepticus, cardiac arrest, and respiratory failure have been reported with concomitant administration of theophylline. If concurrent use is unavoidable, monitor serum theophylline levels and adjust theophylline dose as warranted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Adverse effects (eg, tendon rupture, QT changes) may be increased in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glucose-6-phosphate dehydrogenase (G6PD) deficiency: Hemolytic reactions may (rarely) occur with quinolone use in patients with latent or actual G6PD deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics:  Adverse effects, including those related to joints and/or surrounding tissues, are increased in pediatric patients and therefore, ciprofloxacin should not be considered as drug of choice in children (exception is anthrax treatment).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9611328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of P-glycoprotein;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (strong), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9611329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of quinolones.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Sodium Bicarbonate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bendamustine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Bendamustine. Concentrations of the active metabolites of bendamustine may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caffeine: Quinolone Antibiotics may decrease the metabolism of Caffeine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Calcium Chloride.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Ciprofloxacin (Systemic) may increase the serum concentration of CloZAPine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Quinolone Antibiotics may enhance the adverse/toxic effect of Corticosteroids (Systemic). Risk of tendon-related side effects, including tendonitis and rupture, may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Strong) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: May decrease the serum concentration of Quinolone Antibiotics. Quinolone Antibiotics may decrease the serum concentration of Didanosine. Management: Administer oral quinolones at least 2 hours before or 6 hours after didanosine. Monitor for decreased therapeutic effects of quinolones, particularly if doses cannot be separated as recommended. This does not apply to unbuffered enteric coated didanosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Ciprofloxacin (Systemic) may increase the serum concentration of Erlotinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Ciprofloxacin (Systemic) may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: May enhance the hyperglycemic effect of Quinolone Antibiotics. Insulin may enhance the hypoglycemic effect of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of Quinolone Antibiotics. Management: Administer oral quinolone antibiotics at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Ciprofloxacin (Systemic) may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Quinolone Antibiotics. Specifically, polyvalent cations in multivitamin products may decrease the absorption of orally administered quinolone antibiotics. Management: Interactions can be minimized by administering the oral quinolone at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (i.e., calcium, iron, magnesium, selenium, zinc).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Quinolone Antibiotics may decrease the serum concentration of Mycophenolate. Specifically, quinolones may decrease concentrations of the active metabolite of mycophenolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: Ciprofloxacin (Systemic) may enhance the adverse/toxic effect of Pentoxifylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Ciprofloxacin (Systemic) may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pirfenidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinapril: May decrease the serum concentration of Quinolone Antibiotics. Management: Separate doses of quinapril and oral quinolones by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the quinolone if these products are used concomitantly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: Ciprofloxacin (Systemic) may increase the serum concentration of Roflumilast.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: Ciprofloxacin (Systemic) may decrease the metabolism of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ropivacaine: Ciprofloxacin (Systemic) may decrease the metabolism of Ropivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sevelamer: May decrease the absorption of Quinolone Antibiotics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: May decrease the serum concentration of Quinolone Antibiotics. Management: In order to minimize any potential impact of strontium ranelate on quinolone antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during quinolone therapy.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the serum concentration of Quinolone Antibiotics. Management: Administer oral quinolones at least 2 hours before or 6 hours after the sucralfate dose.  Greater separation of doses may further lessen the risk for a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Quinolone Antibiotics may enhance the hypoglycemic effect of Sulfonylureas. This appears to be particularly concerning early in the course of combination therapy. Quinolone Antibiotics may diminish the hypoglycemic effect of Sulfonylureas. With longer-term combination, there is a greater risk of hyperglycemia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Quinolone Antibiotics may decrease the metabolism of Theophylline Derivatives. Ciprofloxacin and enoxacin are of greatest concern.  Theophylline/quinolone therapy might augment the seizure-producing potential of each of the individual agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: Ciprofloxacin (Systemic) may decrease the metabolism of TiZANidine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varenicline: Quinolone Antibiotics may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concurrent use of levofloxacin or other quinolone antibiotics, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Quinolone Antibiotics may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zinc Salts: May decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Zinc Chloride.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F9611333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food decreases rate, but not extent, of absorption. Ciprofloxacin serum levels may be decreased if taken with divalent or trivalent cations. Ciprofloxacin may increase serum caffeine levels if taken concurrently. Rarely, crystalluria may occur. Enteral feedings may decrease plasma concentrations of ciprofloxacin probably by &gt;30% inhibition of absorption. Management: May administer with food to minimize GI upset. Avoid or take ciprofloxacin 2 hours before or 6 hours after antacids, dairy products, or calcium-fortified juices alone or in a meal containing &gt;800 mg calcium, oral multivitamins, or mineral supplements containing divalent and/or trivalent cations. Restrict caffeine intake if excessive cardiac or CNS stimulation occurs. Ensure adequate hydration during therapy. Ciprofloxacin should not be administered with enteral feedings. The feeding would need to be discontinued for 1-2 hours prior to and after ciprofloxacin administration. Nasogastric administration produces a greater loss of ciprofloxacin bioavailability than does nasoduodenal administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Dong quai and St John's wort may also cause photosensitization. Management: Avoid dong quai and St John's wort.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9611259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9611260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal reproduction studies. Ciprofloxacin crosses the placenta and produces measurable concentrations in the amniotic fluid and cord serum (Ludlam, 1997). An increased risk of teratogenic effects has not been observed in animals or humans following ciprofloxacin use during pregnancy; however, because of concerns of cartilage damage in immature animals, ciprofloxacin should only be used during pregnancy if a safer option is not available. Ciprofloxacin is recommended for prophylaxis and treatment of pregnant women exposed to anthrax (CDC, 2001a; CDC, 2001b). Serum concentrations of ciprofloxacin may be lower during pregnancy than in nonpregnant patients (Giamarellou, 1989).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9611263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates \"compatible\"; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9611300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ciprofloxacin is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother. However, due to the low concentrations in human milk, minimal toxicity would be expected in the nursing infant and infant serum levels were undetectable in one report (Gardner, 1992). Nondose-related effects could include modification of bowel flora. There has been a single case report of perforated pseudomembranous colitis in a breast-feeding infant whose mother was taking ciprofloxacin (Harmon, 1992).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9611450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Food: Drug may cause GI upset; take without regard to meals (manufacturer prefers that immediate release tablet is taken 2 hours after meals). Extended release tablet may be taken with meals that contain dairy products (calcium content &lt;800 mg), but not with dairy products alone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dairy products, calcium-fortified juices, oral multivitamins, and mineral supplements: Absorption of ciprofloxacin is decreased by divalent and trivalent cations. The manufacturer states that the usual dietary intake of calcium (including meals which include dairy products) has not been shown to interfere with ciprofloxacin absorption. Immediate release ciprofloxacin and Cipro&reg; XR may be taken 2 hours before or 6 hours after any of these products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caffeine: Patients consuming regular large quantities of caffeinated beverages may need to restrict caffeine intake if excessive cardiac or CNS stimulation occurs.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F9611525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Cipro in D5W Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg/100 mL (100 mL): $15.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg/200 mL (200 mL): $30.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Cipro Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg/20 mL (20 mL): $14.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ciprofloxacin in D5W Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg/100 mL (100 mL): $2.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg/200 mL (200 mL): $3.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ciprofloxacin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg/20 mL (20 mL): $2.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg/40 mL (40 mL): $3.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Cipro Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 MG/5ML (5%) (100 mL): $123.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 MG/5ML (10%) (100 mL): $144.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Cipro XR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (50): $523.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mg (50): $595.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Ciprofloxacin-Ciproflox HCl ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (50): $489.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mg (50): $555.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cipro Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $527.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $626.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ciprofloxacin HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (6): $20.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $458.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $536.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     750 mg (50): $278.41",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9611455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, renal and hepatic function during prolonged therapy",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F9611372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic: 2.6-3 mcg/mL; Toxic: &gt;5 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Antox (CR, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Bacquinor (ID);",
"     </li>",
"     <li>",
"      Bactiflox (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SG, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Baflox (CO);",
"     </li>",
"     <li>",
"      Baquinor (ID);",
"     </li>",
"     <li>",
"      Baycip (CN);",
"     </li>",
"     <li>",
"      Bernoflox (ID);",
"     </li>",
"     <li>",
"      C-Flox (AU, UY);",
"     </li>",
"     <li>",
"      Cefaxin (KP);",
"     </li>",
"     <li>",
"      Cetraxal (CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Ciclodin (PH);",
"     </li>",
"     <li>",
"      Cifloc (ZA);",
"     </li>",
"     <li>",
"      Ciflodal (PH);",
"     </li>",
"     <li>",
"      Ciflox (FR, VE);",
"     </li>",
"     <li>",
"      Cifloxin (HK, MY, PH);",
"     </li>",
"     <li>",
"      Cifran (AU, BF, BJ, CI, CL, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Cimoxin (PE);",
"     </li>",
"     <li>",
"      Cinaflox (PE);",
"     </li>",
"     <li>",
"      Cipflox (NZ);",
"     </li>",
"     <li>",
"      Ciploc (PK);",
"     </li>",
"     <li>",
"      Ciplox (BF, BJ, CI, ET, GH, GM, GN, HK, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Ciplus (KP);",
"     </li>",
"     <li>",
"      Cipocin (TW);",
"     </li>",
"     <li>",
"      Ciprecu (EC);",
"     </li>",
"     <li>",
"      Ciprinol (BG, EE);",
"     </li>",
"     <li>",
"      Cipro (AR, BR, CO, PY);",
"     </li>",
"     <li>",
"      Ciprobay (AE, BG, BH, CL, CY, CZ, EG, IQ, IR, JO, KP, KW, LB, LY, MY, OM, PH, PL, QA, SA, SY, TH, YE, ZA);",
"     </li>",
"     <li>",
"      Ciprobay Uro (DE);",
"     </li>",
"     <li>",
"      Ciprobeta (DE);",
"     </li>",
"     <li>",
"      Ciprobid (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TH, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Ciprobiotic (GT, HN, ID, NI);",
"     </li>",
"     <li>",
"      Ciprocan (KP);",
"     </li>",
"     <li>",
"      Ciprocep (TH);",
"     </li>",
"     <li>",
"      Ciprocin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Ciprodar (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Ciprodex (IL);",
"     </li>",
"     <li>",
"      Ciproflox (PE);",
"     </li>",
"     <li>",
"      Ciprogis (IL);",
"     </li>",
"     <li>",
"      Ciprohexal (SG);",
"     </li>",
"     <li>",
"      Ciprol (AU);",
"     </li>",
"     <li>",
"      Ciprolet (SG);",
"     </li>",
"     <li>",
"      Ciprolin (PE);",
"     </li>",
"     <li>",
"      Ciprolon (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Cipromed (PE);",
"     </li>",
"     <li>",
"      Cipromycin (GR);",
"     </li>",
"     <li>",
"      Cipropharm (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Ciprouro SR (KP);",
"     </li>",
"     <li>",
"      Ciproval (CN);",
"     </li>",
"     <li>",
"      Ciprox (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, MY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Ciproxan (JP);",
"     </li>",
"     <li>",
"      Ciproxin (AT, AU, CH, DK, FI, GB, GR, HK, ID, IE, IT, KP, NO, NZ, SE, TW);",
"     </li>",
"     <li>",
"      Ciproxina (BB, BM, BS, BZ, CR, DO, EC, GT, HN, JM, NI, NL, PA, PR, PT, SR, SV, TT);",
"     </li>",
"     <li>",
"      Ciproxine (BE);",
"     </li>",
"     <li>",
"      Ciproxyl (HK, TH);",
"     </li>",
"     <li>",
"      Ciriax (PE);",
"     </li>",
"     <li>",
"      Cirok (PH, SG);",
"     </li>",
"     <li>",
"      Citopcin (KP);",
"     </li>",
"     <li>",
"      Citro (KP);",
"     </li>",
"     <li>",
"      Cixa (TW);",
"     </li>",
"     <li>",
"      Cobay (TH);",
"     </li>",
"     <li>",
"      Cobay-500 (PH);",
"     </li>",
"     <li>",
"      Corsacin (ID);",
"     </li>",
"     <li>",
"      Cosflox (IN);",
"     </li>",
"     <li>",
"      Cycin (KP, SG);",
"     </li>",
"     <li>",
"      Cypral (VE);",
"     </li>",
"     <li>",
"      Cypro (KP);",
"     </li>",
"     <li>",
"      Eni (CR, DO, GT, HN, NI);",
"     </li>",
"     <li>",
"      Enoxin (SG, TH);",
"     </li>",
"     <li>",
"      Eprocin (KP);",
"     </li>",
"     <li>",
"      Floroxin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Floxsid (ID);",
"     </li>",
"     <li>",
"      Glojaya (ID);",
"     </li>",
"     <li>",
"      Hexiquin (ID);",
"     </li>",
"     <li>",
"      Iprobac (PH);",
"     </li>",
"     <li>",
"      Iprolan (PH);",
"     </li>",
"     <li>",
"      Isotic (ID);",
"     </li>",
"     <li>",
"      Jayacin (ID);",
"     </li>",
"     <li>",
"      Kinoves (PH);",
"     </li>",
"     <li>",
"      Lofucin (KP);",
"     </li>",
"     <li>",
"      Loxan (CO);",
"     </li>",
"     <li>",
"      Maxpro (PH);",
"     </li>",
"     <li>",
"      Novidat (AR);",
"     </li>",
"     <li>",
"      Orpic (PH);",
"     </li>",
"     <li>",
"      Procip (NZ);",
"     </li>",
"     <li>",
"      Proflox (EC, TH);",
"     </li>",
"     <li>",
"      Profloxin (AU);",
"     </li>",
"     <li>",
"      Proquin (AU);",
"     </li>",
"     <li>",
"      Proseloc (PH);",
"     </li>",
"     <li>",
"      Proxacin (BR);",
"     </li>",
"     <li>",
"      Qinosyn (PH);",
"     </li>",
"     <li>",
"      Quilox (PH);",
"     </li>",
"     <li>",
"      Quinobiotic (ID, PE);",
"     </li>",
"     <li>",
"      Qupron (KP);",
"     </li>",
"     <li>",
"      Serviflox (MY, SG);",
"     </li>",
"     <li>",
"      Sifloks (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Siflox (ID);",
"     </li>",
"     <li>",
"      Superocin (TW);",
"     </li>",
"     <li>",
"      Supraflox (TH);",
"     </li>",
"     <li>",
"      Topistin (SG);",
"     </li>",
"     <li>",
"      Uniflox (FR, PH);",
"     </li>",
"     <li>",
"      Uroxin (HK, SG);",
"     </li>",
"     <li>",
"      Vilox (ID);",
"     </li>",
"     <li>",
"      Xenoflox (PH);",
"     </li>",
"     <li>",
"      Zumaflox (ID);",
"     </li>",
"     <li>",
"      Zyflox (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9611370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits DNA-gyrase in susceptible organisms; inhibits relaxation of supercoiled DNA and promotes breakage of double-stranded DNA",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9611373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Immediate release tablet: Rapid (~50% to 85%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 2.1-2.7 L/kg; tissue concentrations often exceed serum concentrations especially in kidneys, gallbladder, liver, lungs, gynecological tissue, and prostatic tissue; CSF concentrations: 10% of serum concentrations (noninflamed meninges), 14% to 37% (inflamed meninges)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 20% to 40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Partially hepatic; forms 4 metabolites (limited activity)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Children: 2.5 hours; Adults: Normal renal function: 3-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Immediate release tablet: 0.5-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Extended release tablet: Cipro&reg; XR: 1-2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (30% to 50% as unchanged drug); feces (15% to 43%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abramowicz M, &ldquo;Antimicrobial Prophylaxis in Surgery,&rdquo;",
"      <i>",
"       Medical Letter on Drugs and Therapeutics, Handbook of Antimicrobial Therapy",
"      </i>",
"      , 16th ed, New York, NY: Medical Letter, 2002.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics. \"Antibacterial Drugs,\" In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds.",
"      <i>",
"       Red Book&reg;: 2012 Report of the Committee on Infectious Diseases.",
"      </i>",
"      29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, &ldquo;Transfer of Drugs and Other Chemicals into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Thoracic Society and Infectious Diseases Society of America, &ldquo;Guidelines for the Management of Adults With Hospital-Acquired, Ventilator-Associated, and Healthcare-Associated Pneumonia,&rdquo;",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2005, 171(4):388-416.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/15699079/pubmed\" id=\"15699079\" target=\"_blank\">",
"        15699079",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 97.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baddour LM, Wilson WR, Bayer AS, et al, &ldquo;Infective Endocarditis. Diagnosis, Antimicrobial Therapy, and Management of Complications. A Statement for Healthcare Professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2005, 111(23):e394-434.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/15956145/pubmed\" id=\"15956145\" target=\"_blank\">",
"        15956145",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bayer A, Gajewska A, Stephens M, et al, &ldquo;Pharmacokinetics of Ciprofloxacin in the Elderly,&rdquo;",
"      <i>",
"       Respiration",
"      </i>",
"      , 1987, 51(4):292-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/3659579/pubmed\" id=\"3659579\" target=\"_blank\">",
"        3659579",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al.  &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2013, 70(3):195-283.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/23327981/pubmed\" id=\"23327981\" target=\"_blank\">",
"        23327981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canadian Guidelines on Sexually Transmitted Infections, \"Epididymitis,\" 2008; Ottawa, ON: Public Health Agency of Canada. Available at file://www.phac-aspc.gc.ca/std-mts/sti-its/guide-lignesdir-eng.php",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;CDC Health Information for International Travel 2012,&rdquo; Atlanta: U.S. Department of Health and Human Services, Public Health Service, 2012. Available at",
"      <a href=\"file://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-2-the-pre-travel-consultation/travelers-diarrhea.htm\" target=\"_blank\">",
"       file://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-2-the-pre-travel-consultation/travelers-diarrhea.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC),&ldquo;Prevention and Control of Meningococcal Disease Recommendations of the Advisory Committee on Immunization Practices (ACIP),&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2005, 54(RR-7):1-28. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/pdf/rr/rr5407.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/pdf/rr/rr5407.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Recommentations for the Use of Antibiotics for the Treatment of Cholera,&rdquo; 2011. Available at",
"      <a href=\"file://www.cdc.gov/cholera/treatment/antibiotic-treatment.html\" target=\"_blank\">",
"       file://www.cdc.gov/cholera/treatment/antibiotic-treatment.html",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Updated Recommendations for Antimicrobial Prophylaxis Among Asymptomatic Pregnant Women After Exposure to",
"      <i>",
"       Bacillus anthracis",
"      </i>",
"      ,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2001a, 50(43):960.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/11708594/pubmed\" id=\"11708594\" target=\"_blank\">",
"        11708594",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Update: Investigation of Bioterrorism-Related Anthrax and Interim Guidelines for Exposure Management and Antimicrobial Therapy, October 2001,&rdquo;",
"      <i>",
"       MMWR",
"      </i>",
"      , October 26, 2001, 50(42):909-19. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5042a1.htm\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5042a1.htm",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/11699843/pubmed\" id=\"11699843\" target=\"_blank\">",
"        11699843",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2006: Fluoroquinolones No Longer Recommended for Treatment of Gonococcal Infections,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2007, 56(14):332-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/17431378/pubmed\" id=\"17431378\" target=\"_blank\">",
"        17431378",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chung AM, Reed MD, and Blumer JL, &ldquo;Antibiotics and Breast-Feeding: A Critical Review of the Literature,&rdquo;",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2002, 4(12):817-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/12431134/pubmed\" id=\"12431134\" target=\"_blank\">",
"        12431134",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Committee on Infectious Diseases, &ldquo;The Use of Systemic Fluoroquinolones,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 118(3):1287-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/16951028/pubmed\" id=\"16951028\" target=\"_blank\">",
"        16951028",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davies SP, Azadian BS, Kox WJ, et al, &ldquo;Pharmacokinetics of Ciprofloxacin and Vancomycin in Patients With Acute Renal Failure Treated by Continuous Haemodialysis,&rdquo;",
"      <i>",
"       Nephrol Dial Transplant",
"      </i>",
"      , 1992, 7(8):848-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/1325620/pubmed\" id=\"1325620\" target=\"_blank\">",
"        1325620",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de la Cabada Bauche J and DuPont HL. &ldquo;New Developments in Traveler&rsquo;s Diarrhea,&rdquo;",
"      <i>",
"       Gastroenterol Hepatol",
"      </i>",
"      , 2011, 7(2):88-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/21475415/pubmed\" id=\"21475415\" target=\"_blank\">",
"        21475415",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Food and Drug Administration (FDA), &ldquo;CIPRO (Ciprofloxacin) Use by Pregnant and Lactating Women.&rdquo; Available at",
"      <a href=\"file://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm130712.htm\" target=\"_blank\">",
"       file://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm130712.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Friedrich LV and Dougherty R, &ldquo;Fatal Hypoglycemia Associated With Levofloxacin,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2004, 24(12):1807-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/15585448/pubmed\" id=\"15585448\" target=\"_blank\">",
"        15585448",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gamboa F, Rivera JM, Gomez Mateos JM, et al, &ldquo;Ciprofloxacin-Induced Henoch-Sch&ouml;nlein Purpura,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1995, 29(1):84.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gardner DK, Gabbe SG, and Harter C, \"Simultaneous Concentrations of Ciprofloxacin in Breast Milk and in Serum in Mother and Breast-Fed Infant,\"",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1992, 11(4):352-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/1563233/pubmed\" id=\"1563233\" target=\"_blank\">",
"        1563233",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Giamarellou H, Kolokythas E, Petrikkos G, et al, &ldquo;Pharmacokinetics of Three Newer Quinolones in Pregnant and Lactating Women,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1989, 87(Suppl 5A):49-51.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gould FK, Denning DW, Elliott TS, et al, &ldquo;Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults:  A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2012, 67(2):269-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/22086858/pubmed\" id=\"22086858\" target=\"_blank\">",
"        22086858",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guay DRP, Awni WM, Peterson PK, et al, &ldquo;Single and Multiple Dose Pharmacokinetics of Oral Ciprofloxacin in Elderly Patients,&rdquo;",
"      <i>",
"       Int J Clin Pharmacol Ther Toxicol",
"      </i>",
"      , 1988, 26(6):279-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/3410603/pubmed\" id=\"3410603\" target=\"_blank\">",
"        3410603",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guerrant RL, Van Gilder T, Steiner TS, et al, &ldquo;Practice Guidelines for the Management of Infectious Diarrhea,&rdquo;",
"      <i>",
"       Clin Inf Dis",
"      </i>",
"      , 2001, 32(3):331-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/11170940/pubmed\" id=\"11170940\" target=\"_blank\">",
"        11170940",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harmon T, Burkhart G, and Applebaum H, \"Perforated Pseudomembranous Colitis in the Breast-Fed Infant,\"",
"      <i>",
"       J Pediatr Surg",
"      </i>",
"      , 1992, 27(6):744-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/1501036/pubmed\" id=\"1501036\" target=\"_blank\">",
"        1501036",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hughes WT, Armstrong D, Bodey GP, et al, &ldquo;2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients With Cancer,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2002, 15;34(6):730-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/11850858/pubmed\" id=\"11850858\" target=\"_blank\">",
"        11850858",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kapila K, Chysky V, Hullman R, et al, &ldquo;Worldwide Clinical Experience on Safety of Ciprofloxacin in Children on Compassionate Use Basis,&rdquo;",
"      <i>",
"       Proceedings of Third International Symposium on New Quinolones",
"      </i>",
"      , Vancouver, Canada, 1990, 9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khaliq Y and Zhanel GG, &ldquo;Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2003, 36(11):1404-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/12766835/pubmed\" id=\"12766835\" target=\"_blank\">",
"        12766835",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipsky BA, Berendt AR, Cornia PB, et al, \"2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 54(12):e132-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/22619242/pubmed\" id=\"22619242\" target=\"_blank\">",
"        22619242",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Loebstein R, Addis A, Ho E, et al, &ldquo;Pregnancy Outcome Following Gestational Exposure to Fluoroquinolones: A Multicenter, Prospective Controlled Study,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1998, 42(6):1336-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/9624471/pubmed\" id=\"9624471\" target=\"_blank\">",
"        9624471",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lomaestro BM and Bailie GR, &ldquo;Quinolone-Cation Interactions: A Review,&rdquo;",
"      <i>",
"       DICP",
"      </i>",
"      , 1991, 25(11):1249-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/1763542/pubmed\" id=\"1763542\" target=\"_blank\">",
"        1763542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ludlam H, Wreghitt TG, Thornton S, et al, \"Q Fever in Pregnancy,\"",
"      <i>",
"       J Infect",
"      </i>",
"      , 34(1):75-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/9120330/pubmed\" id=\"9120330\" target=\"_blank\">",
"        9120330",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mackay AD and Mehta A, &ldquo;Autoimmune Haemolytic Anemia Associated With Ciprofloxacin,&rdquo;",
"      <i>",
"       Clin Lab Haematol",
"      </i>",
"      , 1995, 17(1):97-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/7621639/pubmed\" id=\"7621639\" target=\"_blank\">",
"        7621639",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Malone RS, Fish DN, Abraham E, et al, &ldquo;Pharmacokinetics of Levofloxacin and Ciprofloxacin During Continuous Renal Replacement Therapy in Critically Ill Patients,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2001, 45(10):2949-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/11557500/pubmed\" id=\"11557500\" target=\"_blank\">",
"        11557500",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mohr JF, McKinnon PS, Peymann PJ, et al, &ldquo;A Retrospective, Comparative Evaluation of Dysglycemias in Hospitalized Patients Receiving Gatifloxacin, Levofloxacin, Ciprofloxacin, or Ceftriaxone,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2005, 25(10):1303-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/16185173/pubmed\" id=\"16185173\" target=\"_blank\">",
"        16185173",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mullen CA, &ldquo;Ciprofloxacin in Treatment of Fever and Neutropenia in Pediatric Cancer Patients,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2003, 22(12):1138-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/14688588/pubmed\" id=\"14688588\" target=\"_blank\">",
"        14688588",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nilsson-Ehle I and Ljungberg B, &ldquo;Quinolone Disposition in the Elderly: Practical Implications,&rdquo;",
"      <i>",
"       Drugs Aging",
"      </i>",
"      , 1991, 1(4):279-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/1794020/pubmed\" id=\"1794020\" target=\"_blank\">",
"        1794020",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2013, 56(1):e1-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/23223583/pubmed\" id=\"23223583\" target=\"_blank\">",
"        23223583",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Paul J and Brown NM, &ldquo;Tinnitus and Ciprofloxacin,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 1995, 311(6999):232.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rams TE and Slots J, &ldquo;Antibiotics in Periodontal Therapy: An Update,&rdquo;",
"      <i>",
"       Compendium",
"      </i>",
"      , 1992, 13(12):1130, 1132, 1134.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/1298559/pubmed\" id=\"1298559\" target=\"_blank\">",
"        1298559",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rfidah EI, Findlay CA, and Beattie TJ, &ldquo;Reversible Encephalopathy After Intravenous Ciprofloxacin Therapy,&rdquo;",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 1995, 9(2):250-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/7794728/pubmed\" id=\"7794728\" target=\"_blank\">",
"        7794728",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubio TT, Miles MV, Lettieri JT, et al, &ldquo;Pharmacokinetic Disposition of Sequential Intravenous/Oral Ciprofloxacin in Pediatric Cystic Fibrosis Patients With Acute Pulmonary Exacerbation,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1997, 16:112-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/9002120/pubmed\" id=\"9002120\" target=\"_blank\">",
"        9002120",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schaad UB, abdus Salam M, Aujard Y, et al, &ldquo;Use of Fluoroquinolones in Pediatrics: Consensus Report of an International Society of Chemotherapy Commission,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1995, 14(1):1-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/7715981/pubmed\" id=\"7715981\" target=\"_blank\">",
"        7715981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      ,  2010, 50(2):133-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/20034345/pubmed\" id=\"20034345\" target=\"_blank\">",
"        20034345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Szarfman A, Chen M, and Blum MD, &ldquo;More on Fluoroquinolone Antibiotics and Tendon Rupture,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 332(3):193.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, &ldquo;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(8):1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Workowski KA and Berman SM, \"Centers for Disease Control and Prevention: Sexually Transmitted Diseases Treatment Guidelines,\"",
"      <i>",
"       MMWR",
"      </i>",
"      , 2006, 55(RR-11):1-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/16888612/pubmed\" id=\"16888612\" target=\"_blank\">",
"        16888612",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      World Health Organization (WHO), &ldquo;Guidelines for the Control of Shigellosis, Including Epidemics Due to",
"      <i>",
"       Shigella dysenteriae",
"      </i>",
"      type 1&rdquo;, 2005.  Available at file://whqlibdoc.who.int/publications/2005/9241592330.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zacher JL and Givone DM, &ldquo;False-Positive Urine Opiate Screening Associated With Fluoroquinolone Use,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2004, 38:1525-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/15252190/pubmed\" id=\"15252190\" target=\"_blank\">",
"        15252190",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zimbabwe, Bangladesh, South Africa (Zimbasa) Dysentery Study Group, &ldquo;Multicenter, Randomized, Double Blind Clinical Trial of Short Course Versus Standard Course Oral Ciprofloxacin for",
"      <i>",
"       Shigella dysenteriae",
"      </i>",
"      Type 1 Dysentery in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2002, 21(12):1136-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/5/20570/abstract-text/12488664/pubmed\" id=\"12488664\" target=\"_blank\">",
"        12488664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9053 Version 54.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.96.59.103-18C17D12B8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_5_20570=[""].join("\n");
var outline_f20_5_20570=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611220\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611233\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611234\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9660646\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611424\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611423\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611425\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611426\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611523\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611236\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611231\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611451\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611369\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611256\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611258\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3198418\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611305\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611301\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611302\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611328\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611329\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611333\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611259\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611260\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611263\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611300\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611450\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611525\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611455\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611372\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961927\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611370\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611373\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9053\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9053|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/7/26740?source=related_link\">",
"      Ciprofloxacin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/39/36468?source=related_link\">",
"      Ciprofloxacin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/50/6947?source=related_link\">",
"      Ciprofloxacin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/20/27971?source=related_link\">",
"      Ciprofloxacin (otic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/21/15700?source=related_link\">",
"      Ciprofloxacin (otic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/48/38658?source=related_link\">",
"      Ciprofloxacin (otic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/11/17590?source=related_link\">",
"      Ciprofloxacin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/11/44216?source=related_link\">",
"      Ciprofloxacin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_5_20571="Fluid requirements newborns";
var content_f20_5_20571=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Fluid requirements (mL/kg per day) in newborns",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Birth weight (g)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Days 1-2",
"       </td>",
"       <td class=\"subtitle1\">",
"        Day 3",
"       </td>",
"       <td class=\"subtitle1\">",
"        &gt; Day 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;1000",
"       </td>",
"       <td>",
"        90-120",
"       </td>",
"       <td>",
"        140",
"       </td>",
"       <td>",
"        150",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1001-1250",
"       </td>",
"       <td>",
"        80-100",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        150",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1251-1500",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        150",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1501-2000",
"       </td>",
"       <td>",
"        65-80",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        150",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;2000",
"       </td>",
"       <td>",
"        65-80",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        150",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     These are intended as guidelines and should be adjusted according to the infant's clinical status.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter M Haney, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_5_20571=[""].join("\n");
var outline_f20_5_20571=null;
var title_f20_5_20572="CSHCN transition adulthood";
var content_f20_5_20572=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Components of transition for adolescents with special health care needs within the medical home model*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Maintain the adolescent in the home or community whenever possible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Identify the individual who will be responsible for assessing health status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Establish a plan for communication with the health care provider",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Organize critical information and make it accessible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assess the adolescent's ability to provide an accurate medical history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shift the responsibility for information management from the parent to the adolescent or other responsible adult",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Identify the collaborating team",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reassess the need for specialty and subspecialty care",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assess the family/adolescent's readiness to make the transition to adult specialist(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Develop a plan for the transition of care to new physicians",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Develop a formal process to say \"goodbye\" to valued, established health care providers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Coordinate care with family, home, and community providers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reassess the developmental appropriateness of current community services",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Determine whether there are unmet needs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assess the need for formal evaluation that will help to identify areas of strength and areas where support will be required",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Coordinate subspecialty service of value to the family",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assess capacity of adolescent to assume responsibility for coordination of care",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Begin to transfer responsibility to the adolescent and allow time for him or her to \"practice\" this responsibility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reassign responsibility for areas of needed support",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The needs are on a continuum based upon the skills and abilities of the adolescent.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Kelly AM, Kratz B, Bielski M, Rinehart PM. Implementing transitions for youth with complex chronic conditions using the medical home model. Pediatrics 2002; 110:1322.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_5_20572=[""].join("\n");
var outline_f20_5_20572=null;
var title_f20_5_20573="Phenotypes of vancomycin-resistant enterococci";
var content_f20_5_20573=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F83403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F83403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Phenotypes of vancomycin-resistant enterococci (VRE)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Phenotype",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ligase gene",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ending of peptidoglycan*",
"       </td>",
"       <td class=\"subtitle1\">",
"        MIC vancomycin",
"        <br/>",
"        (micrograms/mL)",
"       </td>",
"       <td class=\"subtitle1\">",
"        MIC teicoplanin",
"        <br/>",
"        (micrograms/mL)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Transferability between strains",
"       </td>",
"       <td class=\"subtitle1\">",
"        Species",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        VanA",
"       </td>",
"       <td class=\"centered\">",
"        <em>",
"         vanA",
"        </em>",
"       </td>",
"       <td class=\"centered\">",
"        D-Ala-D-Lac",
"       </td>",
"       <td class=\"centered\">",
"        64-1000",
"       </td>",
"       <td class=\"centered\">",
"        16-512",
"       </td>",
"       <td class=\"centered\">",
"        YES",
"       </td>",
"       <td>",
"        E. faecium, E. faecalis, E. durans, E. hirae, E. gallinarum, E. casseliflavus, E. raffinosus, E. avium, E. mundtii",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        VanB",
"       </td>",
"       <td class=\"centered\">",
"        <em>",
"         vanB",
"        </em>",
"       </td>",
"       <td class=\"centered\">",
"        D-Ala-D-Lac",
"       </td>",
"       <td class=\"centered\">",
"        4-32",
"       </td>",
"       <td class=\"centered\">",
"        0.5-1",
"       </td>",
"       <td class=\"centered\">",
"        YES",
"       </td>",
"       <td>",
"        E. faecium, E. faecalis, E. durans, E. gallinarum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        VanC",
"       </td>",
"       <td class=\"centered\">",
"        <em>",
"         vanC",
"        </em>",
"       </td>",
"       <td class=\"centered\">",
"        D-Ala-D-Ser",
"       </td>",
"       <td class=\"centered\">",
"        8-32",
"       </td>",
"       <td class=\"centered\">",
"        0.5-1",
"       </td>",
"       <td class=\"centered\">",
"        NO",
"       </td>",
"       <td>",
"        E. gallinarum, E. casseliflavus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        VanD",
"       </td>",
"       <td class=\"centered\">",
"        <em>",
"         vanD",
"        </em>",
"       </td>",
"       <td class=\"centered\">",
"        D-Ala-D-Lac",
"       </td>",
"       <td class=\"centered\">",
"        64-128",
"       </td>",
"       <td class=\"centered\">",
"        4-64",
"       </td>",
"       <td class=\"centered\">",
"        NO",
"       </td>",
"       <td>",
"        E. faecium, E. faecalis, E. raffinosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        VanE",
"       </td>",
"       <td class=\"centered\">",
"        <em>",
"         vanE",
"        </em>",
"       </td>",
"       <td class=\"centered\">",
"        D-Ala-D-Ser",
"       </td>",
"       <td class=\"centered\">",
"        8-32",
"       </td>",
"       <td class=\"centered\">",
"        0.5-1",
"       </td>",
"       <td class=\"centered\">",
"        NO",
"       </td>",
"       <td>",
"        E. faecalis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        VanG",
"       </td>",
"       <td class=\"centered\">",
"        <em>",
"         vanG",
"        </em>",
"       </td>",
"       <td class=\"centered\">",
"        D-Ala-D-Ser",
"       </td>",
"       <td class=\"centered\">",
"        8-16",
"       </td>",
"       <td class=\"centered\">",
"        0.5-1",
"       </td>",
"       <td class=\"centered\">",
"        YES",
"       </td>",
"       <td>",
"        E. faecalis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        VanL",
"       </td>",
"       <td class=\"centered\">",
"        <em>",
"         vanL",
"        </em>",
"       </td>",
"       <td class=\"centered\">",
"        D-Ala-D-Ser",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        8",
"       </td>",
"       <td class=\"centered\">",
"        0.5",
"       </td>",
"       <td class=\"centered\">",
"        NO",
"       </td>",
"       <td>",
"        E. faecalis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        VanM",
"       </td>",
"       <td class=\"centered\">",
"        <em>",
"         vanM",
"        </em>",
"       </td>",
"       <td class=\"centered\">",
"        D-Ala-D-Lac",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        &gt;256",
"       </td>",
"       <td class=\"centered\">",
"        64 - &gt;256",
"       </td>",
"       <td class=\"centered\">",
"        YES",
"       </td>",
"       <td>",
"        E. faecium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        VanN",
"       </td>",
"       <td class=\"centered\">",
"        <em>",
"         vanN",
"        </em>",
"       </td>",
"       <td class=\"centered\">",
"        D-Ala-D-Ser",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        8",
"       </td>",
"       <td class=\"centered\">",
"        0.5",
"       </td>",
"       <td class=\"centered\">",
"        YES",
"       </td>",
"       <td>",
"        E. faecium",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     &nbsp;",
"    </p>",
"    <div class=\"footnotes\">",
"     D-Ala-D-Lac: D-alanine-D-lactate; D-Ala-D-Ser: D-alanine-D-serine; MIC: minimal inhibitory concentration.",
"     <br/>",
"     * Refers to the last two amino acids of peptidoglycan precursors which are normally D-Ala-D-Ala; in some phenotypes the ending is deduced from the amino acid sequence of the corresponding ligase.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Predicted but not actually confirmed.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cesar Arias, MD and Barbara Murray, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_5_20573=[""].join("\n");
var outline_f20_5_20573=null;
var title_f20_5_20574="Persistent low hCG";
var content_f20_5_20574=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Persistent low hCG",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\">",
"        Diagnosis false positive hCG test, 94 cases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        A. History",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Discovered by incidental pregnancy test",
"       </td>",
"       <td>",
"        76 of 94",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Discovered after treatment of hydatidiform mole",
"       </td>",
"       <td>",
"        6 of 94",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Discovered after treatment of choriocarcinoma/GTN",
"       </td>",
"       <td>",
"        4 of 94",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cases receiving unnecessary chemotherapy",
"       </td>",
"       <td>",
"        54 of 94",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cases receiving unnecessary hysterectomy",
"       </td>",
"       <td>",
"        9 of 94",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Duration of persistent hCG results before referral",
"       </td>",
"       <td>",
"        3 months-2 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Age (mean &plusmn; standard deviation)",
"       </td>",
"       <td>",
"        34 &plusmn; 6.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        B. hCG and related test results at time of diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum total hCG, mean &plusmn; standard deviation",
"       </td>",
"       <td>",
"        101 &plusmn; 152 mIU/ml",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum total hCG, range",
"       </td>",
"       <td>",
"        6.1-900 mIU/ml",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urine total hCG, mean &plusmn; standard deviation",
"       </td>",
"       <td>",
"        &lt;1 mIU/ml",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urine total hCG, range",
"       </td>",
"       <td>",
"        &lt;1-&lt;1 mIU/ml",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\">",
"        Diagnosis pituitary hCG, peri-menopause, 30 cases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        A. History",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Age range, patient has documented oligomenorrhea",
"       </td>",
"       <td>",
"        33 to 53",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Discovered by incidental pregnancy test",
"       </td>",
"       <td>",
"        22 of 30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Discovered post-evacuation of hydatidiform mole",
"       </td>",
"       <td>",
"        3 of 30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Discovered after treatment of choriocarcinoma/GTN",
"       </td>",
"       <td>",
"        3 of 30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Critical surgery postponed due to positive hCG test",
"       </td>",
"       <td>",
"        6 of 30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cases receiving unnecessary chemotherapy",
"       </td>",
"       <td>",
"        2 of 30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cases receiving unnecessary hysterectomy",
"       </td>",
"       <td>",
"        0 of 30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pituitary hCG suppressed with high estrogen contraceptive pill",
"       </td>",
"       <td>",
"        20 of 30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        B. hCG and related test results at presentation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum total hCG, mean &plusmn; standard deviation",
"       </td>",
"       <td>",
"        7.7 &plusmn; 5.0 mIU/ml",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum total hCG, range",
"       </td>",
"       <td>",
"        2.0-25 mIU/ml",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urine total hCG, mean &plusmn; standard deviation",
"       </td>",
"       <td>",
"        4.5 &plusmn; 1.9 mIU/ml",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urine total hCG, range",
"       </td>",
"       <td>",
"        &lt;1-12 mIU/ml",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\">",
"        Diagnosis pituitary hCG, bilateral salphingo-oophorectomy, 14 cases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        A. History",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Age range",
"       </td>",
"       <td>",
"        33 to 52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Discovered by incidental pregnancy test",
"       </td>",
"       <td>",
"        10 of 14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Discovered post-evacuation of hydatidiform mole",
"       </td>",
"       <td>",
"        0 of 14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Discovered after treatment of choriocarcinoma/GTN",
"       </td>",
"       <td>",
"        3 of 14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Critical surgery postponed due to positive hCG test",
"       </td>",
"       <td>",
"        3 of 14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cases receiving unnecessary chemotherapy",
"       </td>",
"       <td>",
"        1 of 14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cases receiving unnecessary hysterectomy",
"       </td>",
"       <td>",
"        0 of 14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pituitary hCG suppressed with high estrogen contraceptive pill",
"       </td>",
"       <td>",
"        7 of 14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        B. hCG and related test results at presentation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum total hCG, mean &plusmn; standard deviation",
"       </td>",
"       <td>",
"        9.1 &plusmn; 5.5 mIU/ml",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum total hCG, range",
"       </td>",
"       <td>",
"        2.0-25 mIU/ml",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urine total hCG, mean &plusmn; standard deviation",
"       </td>",
"       <td>",
"        5.7 &plusmn; 2.1 mIU/ml",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urine total hCG, range",
"       </td>",
"       <td>",
"        2.2-30 mIU/ml",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\">",
"        Diagnosis pituitary hCG, post-menopause, 40 cases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        A. History",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Age range, patient has document amenorrhea",
"       </td>",
"       <td>",
"        42 to 69",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Discovered by incidental pregnancy test",
"       </td>",
"       <td>",
"        31 of 40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Discovered post-evacuation of hydatidiform mole",
"       </td>",
"       <td>",
"        1 of 40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Discovered after treatment of choriocarcinoma/GTN",
"       </td>",
"       <td>",
"        1 of 40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Critical surgery postponed due to positive hCG test",
"       </td>",
"       <td>",
"        9 of 40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cases receiving unnecessary chemotherapy",
"       </td>",
"       <td>",
"        3 of 40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cases receiving unnecessary hysterectomy",
"       </td>",
"       <td>",
"        1 of 40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pituitary hCG suppressed with high estrogen contraceptive pill",
"       </td>",
"       <td>",
"        23 of 40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        B. hCG and related test results at presentation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum total hCG, mean &plusmn; standard deviation",
"       </td>",
"       <td>",
"        11 &plusmn; 8.9 mIU/ml",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum total hCG, range",
"       </td>",
"       <td>",
"        3.5-32 mIU/ml",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urine total hCG, mean &plusmn; standard deviation",
"       </td>",
"       <td>",
"        6.6 &plusmn; 1.8 mIU/ml",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urine total hCG, range",
"       </td>",
"       <td>",
"        2.0-24 mIU/ml",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The USA hCG Reference Service experience with 178 cases with persistent low levels of hCG persisting for 3 months or longer, with no evidence of pregnancy or imaging evidence of tumor. The 94 cases diagnosed as having false positive hCG were based on multiple observations by the USA hCG Reference Service. These are: 1. the presence of hCG immunoreactivity in serum but not urine; 2. negative results in 2 or more hCG tests; 3. the suppression of result by a heterophilic antibody blocking agent. The 84 pituitary hCG cases were defined as peri-or post-menopausal women or women with history of bilateral salphingo-oophorectomy with low levels of hCG having excluded false positive hCG, non trophoblastic malignancy and choriocarcinoma/gestational trophoblastic neoplasm (GTN) or placental site trophoblastic malignancy. All serum and urine hCG values are those determined at the USA hCG Reference Service.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_5_20574=[""].join("\n");
var outline_f20_5_20574=null;
var title_f20_5_20575="Tapetoretinal degeneration";
var content_f20_5_20575=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62898&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62898&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tapetoretinal degeneration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 273px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAERAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAoopaAEpfairmm2Mt9cCOFc+p9BSbSV2VGLbshljaS3k6xQqST1PYV0a+FV8sF7gj14rZsbBbGyMVsB5h5LEck0+WYrAwb7+MEVyTrtv3T0KeHio+9uc+fDUfJW6yB3xVW20Izudsh2bsZxWnpcT3ErK+4KpyRW/bwxxLiNcZPNKVWUOoQw8amtrHOHwouwkXBLDoMVPD4QieEMbhw3ptroJIiJlaPJzwR/WrTSOsG3j2rGWIn3OmnhabdrHLL4PjfG25YnvxTT4PjxgXLZHXiustI5OW7YziozHh3deO+PWksTO9rlvBwtpE5dfCEZIBuWB+lSjwXGRxdt+VdEMEjdnP8quW8RcEjsPzoeImupKwcH0OSXwXGSR9qbjvimP4MVFyLliPpXZQqAX38L2pHTc21D83pU/Wql9y/qdNbo44eDo8A/aW59qWbwZGkW/7S2fTbXVDhmBONvYVZdQ6Bd/J7U3iancf1Ok1scWng2MqP8ASW/KopvCCKCVuSfqK7EgxkqOfpVS6LSRsijBHWqjiJt7mU8LTS2OQvvC32WJXa5HzdiKpW2htO5AlG0ck4rvpLBLyCPeWYADFMt9KSCNoz8zuCAK0WJ01epyvCvm0WhxV14fVVX7PcCZz2UVd0/wfLcJ88m1sZxiuv07R0hY5J46mrrSCC4Cpxxis54uXwxZ10MDF6zRxn/CEsS4885XuRUZ8GMOsxH4V2c07LJjPyZ708yRtj5snrUfWapr9Tot2SOLj8FMw/4+OPpUcvg1kfAuQfwrtvtIziMEDpzVediRkdapYiqzKWEpp6LQ41/CLJjNyM/Sm/8ACJPgn7QM/SuwW3ZlLdfeklXyk4+9VfWJ9yfqtJ7I47/hE5OP3459qY3hWQHicflXXplzlqY7EMcjgVXt5g8JT7HKf8InNgnz1/Kon8L3AUlZFY+mK7BZcqeaF56nApqvMzlhaZ5jPDJbytHKpVlOCDUdeg6xpUWoQYUbZV6NXCXdtLaTNFMpVh+tdVOqqiOCtRdN+RDSUtJWpgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUALQKKdGjSOFUZJOABQNE1laS3k4ihGWP6V6BpOnxWFt5cOPMx8zepqpommLp9rl+ZnA3e3tWixMbDFcNarze6tj1MNQjFXe4ktwYVGEJOccVYaPchcKC2M0Bdygnn3pWxEo3Hg96579jqcObYzdEVmE7OMOXNa7REEY5FR2AVYmbHJOR71b3/MDjg9qmpNtmtOiklFkcdu+8H7oI70si/IufWrMkoIwBge9Rqc5HYVlds6Y03G9y1bbUixjnFQyAOTgAY9apfanWV0CnKj86ngYy/M4ILc5pcrWrIhJPQkgtxNyCufSr0UflIAce1QQxbZDIvXGKeCWYMynA7VEncqz6DZMuTjgD9aasexw2MHvk1YDJ83GCTxTZEwhLnr2oUhyWiK/lFsuyjaTRJEPtSleI8c+tW1iIUE9MdPWq0ylnGMhR0pqV2Lkuhs6gsAvT0qPahUgDBPU1ZjiGRzzU0aIqsCv3v0o57FxpLdmVYyeUkkTk/IeD7VeiQBd/Vj0NZUqR/b5d7kL6DvV4XWUCxwsQO5qpLqgcLvYtBWjPfnmq0qFrk7sZxTgbi4xsVUI9TUUFnJM0gmuMHOML3qVZasbizOv4/Ok2xTFcHlu1SJIkcYDSqSO9F1bxwSAIu7tz1qxDsSBkeBDI3QkdK35lY5VC0xnmwhOZFDHvmqk7oyFBOfqtX3tYtgIjUt346VN5EBVdqqD9KlSS1NakFJcpk29yY12ZdlHfHWpJrpWVVEbn8K0ZQkaMEXk+gqmr7TluvvVpp6oyUOXRFRrnHBQrT1/frkFQAORT7W333DSEkk9j0pLm3UOGHyn1FVdXsFna7WoeWoOe1MYbW46VDK8kY3H5lFEd5E2CDz71VnuYNq9mWEbC5NZmu6ampQZACzIPlb+laPmLt46UinPJHFEW4u6InDnVnseay2s8TsrxsCvXioSMcHrXqIKHOUXHfiub8W6fEIBdxKqEEBgB1rsp1+Z2aPNqYflV0zkqSlxSV0HKFFFFABRRRQAUUUUAFFFFABS0lLQACuu8JaT8v2yVSH/AIAf51g6JYte3yLj5FO5j7V6JZssQ2IAFAxXNiKjS5UdeGpXfMxp+9g9aFlVpPLJG/GcVTuTcy3h2ALF/eq4iRgl9uXA61xvRanoQd5XQqKVLYBIoMW9GyM45p8JyD15NSE/u345wazb1O9QT95BboRDH9KvQqpQkjkVn26sI1GeMCr8Hy4PX1qKhcU3ElSMOQwHA6ikdVViqk0gKrNtDEZ6Cp9gGT3NZt2BPm+RAir5g43ZFWVQAFWGAOntSxBBJjHNSttJy456cGs5Sdy7Jp2IRGwzhs5qS2j9etJHtV+hP41KgIfd2NKTCOu4xlyc8Yob5sfLmnzNn+HFUp7qG2J3SdR060RTkNNMuDIAJYcetVpNrHC446ms+XUJJTi2hdj6ngVGIb9/vSrHnsBzWkabW42jReZY8AsAMc9qqXmogL5dud7njI7VHb2SOW+0u7sD0zxVn7NHtKIoUdqdoxepd0RWNntG6Q5ZuSfer0fySKjjg1Xt5SCY5OGHf1qweRnnIqZybdgt1H3cyIjeVw3QVFbKF+bJ3Y5qvI2+4Veo6mp0PlseOaVrImwbQzZbr9Kr30LyxBVO35hjHWrhyMfLkHv6UbGA8x+nQU1JoTimtR1tF5Vtzyx45qpcutuhc881fhcNIEbpiq195YVlxk5oi7vUzloR7laPcRgYrKG6SVhztz1q/MgYq27KY6U0lV+4vHetou2xnJN7kIURqcE8jGaZgeWoPIFPfLttB+Q9M1E4YAL2q0ZXb0IpIxICHBFCQp5RBGT7jpUsZJBz1oMm0EECqTdtDF2TKRiAb5SRTXeVDwAy1bOH9qr3NxFbj96eTwB61adyZystSBLraQJFKisrxXcM9gERGKlhk46VqRBpH3yjHoPSn3EKXUTxSj5W4rSLUZJs5JXnFo84pKtajaPZXTxSDoeD6iqtegnfU85qzswooooEFFFFABRRRQAUUUUAKKACTxRWv4bsRd3wLj93HyaUnyq7KjHmdkdBoVoLOyRsYkfljWxHIAfmFNhUI3lN9QacBl8nGM4rzpy5nqepGEqasi2sYaPdTFXapxT9527QuQKeFBGTwfSsLm8dLISJAw2gc5rSltFW1LMOoxVGDEcgJGam1C+3RCNARkiok+iO6mm7diusWFIU9Klib5RnrSxjHQ/nT0jZQcdKlvubL3ZWQMimSOV/4TkVdaSNo93PJ5qFPnXaRT5VCqFwOazbuD0d0Gw7hg84p4YF1XuOppdvyfLndTVKQ5JIwO5qB2T0RMQEBx96oprmKCPfK2Mdu5rPm1B7iUxWiFz/AHj0FTWlgqEyXDebL79BVcttZAoqOgzN3qTZiPkwep6mnLp8ULjK72HVm5q7A4RT/IUwyEkkilzvZbD5ewkm0BQowB6UwcHr1pXPB5ppHyZJFCK5SFWxckY+8KlcY5FQPxPGRyOalbJwcVTKURrxh1/2hyDSwykP5cvB7HsalVcjPc1FdbRHsxliMCle+jHboOiCmWR/TgU4uCx749qrwu8TCLAYAZBNTiVehG00NEskkdvKBXHP6VICxT52BAqANkdQeaUPgY45pGck2IznzcgfSomy8mD681I7YYcdqaRnk8d6tMFDuRywO4cRYyBWXaTyq8yT5ODgVs+YBGypyT3pjRqyLtAyOpq4T01Ma1Lmadyn56OQpwG606UggbegomRA+8IM9M090/dbWOD2q7roRJOOhSmyI3OcZHBHas63tbmcxyPMSinOMYzUt2Ghu4wxYxHO41oJOjW48ogqfStruK0ORxU35mfc3P2c9Rk+tRxIt95dy6/Kv3Qec03WIhPa8qcg8Y71etYwkConAAxVXSV0Q6Tc+V7DCueM01Bg4604ofM+9SsuOc0rlSgomH4psftNv5sY/eR/qK4uvT1UOCrdK4HXbP7FqDxj7h+Za68PO/us83E07e8Z1FLSV0nIFFFFABRRRQAUUUUAKK77w5YraaaN3EkuHNcfo1r9r1CKPgrnLZ9K9APyAAdBXLiZacqO7B0uZ8zFlQud4+8OlSRRqyZB5PamiY8ADIpIpNknIwpPFcbv0PTUW0XIQ3QjBHellyD61IOVDBgSOv0p4hLHPrWTkbwpxehDB6npROgd4wBj5utTeWU6rxTJe2Ox61PNrc3jTsiVmAUKD+NSxNlCueahCAvk81OibQGGKh2G42dx0IIcAjpUskYLbmJwOgp0bBULMBnrWZLdz3cjR2gzg8segrNXb0NlG6LEl2lsD5jDJ7Dqfaq4gnv5N8wMcA6L3NSxaYEUyTEyTdQTVyK4DKNxAA61XMl8IcltUNiiSJQkagKPSpX2qMVFJKqn5Dn3puTISc7azd3qwjEUMB07GkzluemO1GMDjgdzUW88j9apIu1hXwSSKQtz85phYkZxzSck1VgQ2ZgGRgMAHmplcEY6ioJNoUhiMVDDI0vyAbQOp7mqtcdrl17hY/lT5m9BUCpIzb5CC3QegpUi24A/+vTuQM9BStbYYyRgssZYEE8VaVRtDDkntVSP94+49F4FTgEN8rUNEMQxfMSrbaVGKnEnT1pwI3YPBp2QVOFqbktDonUyYK5GKZMhMgUcVF80bhug/lUwZi3PWi1gHMEjj+UcjrVbeegGDSsWcnnH0qSMBVJZRmqWm5DQ3YPJ3jFNyJ8FeWFRxxnLjJ2k5x6U4fu87DVehmqXNuU723Eu4SDioNNiBhIUYUErWj5Zdt7d+MVXkCRDYhxk5rVTdrGUqMU+ZEN4VQqirkGh32KdnXGKeRkZ446VBIBv564q12M1NJ3GR5Y89uaU9Tk9KAwDYUcmhhtNUY1PeeomcHisLxXaGezFwo+eLr9K2zyKjuEWSB42AwwIOaunLllcxrx5otHm1FTXcJguZIj/AAnFRV6R4rVhKKKKACiiigAoopR1oA6XwagEk8pGTjArqtuayvDtqLexifb8zruJrYjxwTXnVpXk2exhouMAWFtvHSpAgKhWAxQzFBkUok3Dp+dYNs9CC0GxubdwGOY27+lX42+cfMfbFRIgmQhwMGoUU2s6AkmI9Ce1Q7S9S4Js0WUk4zUMysqgkHAIrTiiV0VuuelNukwijHO7Fc6nrY15tLFUKOh5NOUEHBzirUVv85JPFN1Z0gtxs5kfhR6mjmu7IUZX0KNw5upfssP3f4mH8q1LW0S2iUKB0qtploLSDdL99+WJp894DkKdxHGBU1Lv3Y7G0ZdCeTnOD0qlNgHqOlSRqxw0p4PapGRSOgqF7ujNIorKygAZ4qORlPIbFSzKnYVTaNTnitY2epdrD2nwME8UwyoOSwH40xoUIBwKfFEhx8q/lV2SATzgT8gL/TpSkSOOuwe1JtMRO0fL6VLv+UY/SgVyJYgDnGT6mlACOD68Uv8AWgqGBUmjUnmJsqfrTGO4Y6CoYyQSh5x0qVDzStYOYjhOEKj1qRSRjPWmS8PuHHqKbk9qe4ifrwetHmlFwenrTQflznmnLhk5qbEtkgIZMkgimRSENtcc+tMKrnofwqI585cEimlcQ922vt71NLJ+7AU5NVZEO7OeaaFfscmqsIngdtpDGomYM5z+lLh+OeahO4FiTx04qkr6mbm4rQne4X5UXqKrTQmRiRgd+akMO+FvL4JHBFKluba1UPJvcjkmqTS2Odybd2UjvQ4ZsfSkMZJySTU8lukrI5Yq/setOkzG2F6AVpzGcptOzRXKmMhsce9MkbcamZt68jjNRyJtAx37U79zLm6shyce9QzZBHWrG0jORUR+bn0q0Z1NTkPEsJS7EuMBxWNXYeJoA+nmQAZQg5rj676UrxPJrR5ZBRRRWhkFFFFABUkEbSzJGgyzEACmdq0/DMH2jWrZN2MHdn6DNKTsmyoLmkkd5AFit40CldqgYpwIGMGrEkY6NzUO2Pd8wP4V5PNc96EVsLkMM55qWNAVz600W5BLRPx6NyKkjkCNiZDj+8vSs3LsdypK2jJIN2avi2E8BDjJPQ1HAUwShBB6CtW3x5O5QBj1rCpNrYFeJS06cxk28pIZeg9a0Xi82JSo5DDPFQSae1yhmj4kTkEV6Fouhw/2HHdThWYpuwPauOvXjHVbmihfVnOx6RLNEPLhY8Zrn5bCW41Qu8f7i34/GvV9Wvza6an2G3BmlUKgUdDjrUfh3w4Y41l1KLc3URnpz1J9TXIsZKN2bQpRjHmeh5xdWkt0AoBjj6Z6ZqnJZpaLtxz717ZqGh2l5EAqJGw6YFcN4m8PTR5EEfmD+/jgVpTxiejMkk3ocPIR5Yyc+1V1lI+UkgdqtS6dPGxBY5HbFZ8iuT8xxt7V3Q5ZLQ6IaCyv/tcVFuXkEil2Djjn1pojUgjGDWySRTDcOgNKr46YFMZQo4pMr2AqiWyRnU49aj45KHBpGYAc1CZMHiqUbmE6lifzMjkDNIWJ6HmqruffNIJM/e4NWoHO6xZXLEt6VOCcA+1U45cJjPNPSXOADz71LizSNRMssPlIP51EEKnaB9DT1ORk09Tls+gqNjVSuR/Oo+ano+DtI4ocZANMIxjPNK9wHSOAc9ulNI3nJ49Ka2CQO+eakJ3N7UMCM5Y4HWpVwM57CkIx0HSkkOcgd6NzObdhynLADr70y4j8s5zn2zTWIUZJ5FNaQSjIq0mc7WmokL+WG+b8KJGZvXBoVepI4pAw3H0qvMxdTsNXkgEYxUjxlgSCMVCyEnhsGkkcrtUnGTTsZTlz6kc6FUYjpjihMtCjn0qG5Wa4BRHCxHjd71OVEUKR7t20YzVsi/NvsN3dcDNRbByOKdnCketMEm1uapDk0tirqUAmspo8AsykD6156wKkg9QcV6XKxKtggZGM151fR+VeTRg52uRmuzDPRo87FLVMgopaSuk5AooooAWt7wbD5mreYDgxqW/pWBXTeBwftsxH9zH6is6ztBm+HjzVEjsSTyTScHGakZ1xgj5qi27j0wa8q57sINssowwAuTUh+UDPfrVeM+U3tUySjkNWTXY7IxtuSRxDfuiyrfpWivnuEjyowcE1nq47GrunSg3AMh7isql1Fsu+tjvfDWlT/ZmLosiMCCc46inXF9qGgWr28tv59vID5RU9K6bw7tn0uIx8DOeKd4nsfOWzcjEYcqx9MgivClUvLU6KM1zcsloa/wALdO+36Wmo337x5P8AVqeiL7V38thE642j8q4TwDdyaJaCwvgAqH5HB4Ir0Czvre8B8mQMR2Brkrxk5Nx2PGzB1VWcunQ56901YmJVcj6VQniDxNGU49xXaTwhwa5+9hCSnjFZ0pX0YUMS5qzPHfE+nmOWSMMoPPQc1wl7abS2WP1r1jxpZtFciZBwRXmuvK0c7HopGa9fDTd0j1qMrxMBwV4VgfrUbSMuMjJp0jjJIPNMJ5r1kjRsGYkfdqu8yYxnn09akdiQVXoetVJyARgAEVtBGM5DS+/pke1KM1GPUHmnBvpW1jzqs2x+fWjjr2qIHJpwbH0p2MeYkAB7CmMuGDLxQr07qOKm3cuM2TxyEp6Cnxkgnn3qsGKn2/lU8ZywyOazkjqhULCMCf8AGkkHy5zSoOSM0yXp3IrLqbojjG6QHoBUoxxjmo0OBj0pycnOcUModjr3pRtx04pCePekJ4IoREtNiCYfN1ohXZyelOKjBJ60oO8YzjFaJmDS36i3DDYNoNQtgjJqaUBUIJwaryc4HWnFGc4xew12Lcjr7UKQxHmY+ppqjBwc4Pp2ondITl2HArSxg2kSttC4WqlyjsjCPg01LrzJgm0jIzzVyMgY3DIp6xMvi2KxVggBzkDFVnVt2QOKvygFjVeTKrlvwqkyJKxXKu3qK4rXUCapMAMdP5V3SuWGMVxviePZqJbH3xmunDvU48QvduY9FL2pK6zjCiiigBTXW+CFHl3D984rkq6zwLIubiM9fvVjiP4bOnCP96jqCM9MfjUYkdTkEdae5wTnimKOeAcV5vTU+ipO3qWU+cZJPNSCNeuTn3NJCPk5FPJIrJs6lZ6CKvzEAH86kQskikfjSRMNwJHFWo3RWAI3E9BUS2sRL3T1rwDdEabiQjaPU1p+J9Vt/wCyzbJKpeV1TA6jJriPB03l3Keccg8bO2K6DxQLaRUgsoYzcSDJZeqj1rwq1K0zanyuabIwy3ni200iynlMUK7pn3nJPpXs2i2tvYp+7HXqa8Btbj/hHPEWm3E6kIQUklH8YOOTXslpqsU0avBIGRumDxWWITsuXYzzGnOolGOx1U12iCsO8l82TK/nVV7oyNjPFRPKI0aR2AA561ywhZ3PNp4f2fqcv43nVSFLDIryLxDPvlbnPb610vjTV2lu5SHBUE457V55d3Rkc5PBNevg6DbUj1qMVGJC5+Y/WnOQAMc1EXUcFhTDOvRfmbFevylMfu3MSKrTE5NSqxXggDPeoJsg9MGtYrU5ar0GgUx2+Y4pd31pjDJzWqR503ccGwPagvk8VGRgdajViprTlMUyfdjvzU0bgiqYJbrU8QqJIpSZYJzn1qSAnIyagJxg1JGeR3zWclodEJWLgYZzT9wxVYHkDHA9KmOCh557Vg0dlOTYhwGJApEIxyOc0xmGPmODTonBUYGaLFykDEk5GCKNx4JpzkjpxSDHQnmmjGTFDZFM5DcYpx4NI3yqMDJNMzabd7jJPmBzyc0jJzgVZZEKZYgewqs6sp4qosiom9bkaphs571Dc2vnzgvwi8/WrG7sRQzHHsKpM55xutSEWy+eZd3bAAFShTkj0FVo3/eGXcQo6Col1LzHdYkJwceuatxbMU1HRMfNvMnBII9O9JIzFfm7VPHucZlAX2FPljBXk89qLobTaM8HByM1y3i05vYv9yuuZMMBiuS8XDF7Fx/BXRQ+I5q6tAwaKKK7TgCiiigBe1dJ4HOL+b/rn/UVzdb3gyUprCxjpIpB/LP9KzrL3Gb4eVqiZ26IGfk8Gp5SoCqoGKrNJH5piz8w5qWJQuC5ryWurPo6c+ZWiWYYztLnoKAQ/TGakSdDCVH41VZGdiFOFrPd6nVBJLQUZD4B49a0rFflOO/f1qkAsaDPT37UsDTXJ/0clYxxu/wpS1QnFyN2K/kgkEcA3S+3QV0Wiao9uwacB5XPzE1z+lQJbIAwO88knvWlDFG0m7rn9K4ayixK62N6RrTVbiVbwgKoJQDtnFUbCaXQdWjt470raT/dJ52mqOlsqXrq7cbRg/jS+IQtzEFif94nKt71zey15ejOiNa3uvY9Dl1Oa1hBN5E4xnIXmuS8ReJ7qVWjNx+76fKMZrjbXXJogba8JVxwM9DTLmRp1bnIrSGDs/e2Mpb6FDVGM0hIdiD79aofZl6sTn61dkjYtk8GmMNpAPNenD3VZFq6K6woD90UuwbuB0p7MT0FJVagxCgYEY4NVpIepJJ9KuL1A9aRgASKalZmVSF0Z460jLxVl4wOc1EUIHPStlK5wTptFcrkUm0elWAtLsFXzGPIVlTpxVhQF/Cj0OMCkPWk3cpUxzEEc1LAudvbioQCV9e1WoVZVA/ixUSdkbRpkj4QfL1oIwu7vTiMDPVqhkkPI9ax3OnSIx2/vcinRfeXb6VCp+YA/eqSPiVsVdtDOW5PIeMLUWTuHc+lLkYPao1JGW5waSWhlK7JcsT6UFznOOOtNLc/yoI3Aqfu9DTSMm3aw9ZVZNyNnBxSSSgnkc9qjtYVgjMafd6808gZ560WVyIyaWoYDA54NMbaEOTgd6CdpwTWfqEEtxLGodkh53Ad6uMddTOc3bQS7h85AkMnyHhsU+1iS1TauB/M0yUx2NofLBwDVDTphc6i5+ZlUZHPArZJ2uczsmu7NUknnoKJJ2O0dcU9j97jiq0jBATxUWRrdoVpfWuP8UzeZqO3sigV0zMxb2Ncfrrh9TmI7ED9K6aC945sRO8bFE0lFFdZxC4pKcMY5pXbdjjGKppANrS8OTNDrVqyjJZtn58Vm96fC5jlR1OCpyCKiSumiouzTPU5Y8vnbg+tOESgDeeaS2k8+2ikTkMgIqRVZN3mEe1eNJu9j6jDpNXHKm7heg6mp41KxljjA7mnIFij5bAPJFUppzcOY48iMfeas/iOm/M0okbb752C5EQPJ9a17FRBsXIGTTLZF8rC4CgUkTKJDnv0FTN8ysaxjy6myZP9rk1JHcPFglqpTpuiQoetQncEwT+NcqipCcXcmlu2W+Rw2Q2Rj0q29xvI2ZB96xryMiHeDyDmr1m4l2MeOPWrnFKKYKN2RXcazsFlUFenvms8CawkIB8yA+vUVp3WN+A3fioLkAgjdweKunK6s9iuTlYrSxyxjpk96gkhYjc3aqNvujnaJztkH3c9DV7z3RSJkIHqKtx5dhsgaP2xUTgA5zUrtJIMgYFQeXk/OMmrXmJoUTAH5QWPtSkuxyE/OlAx0GKkB+XnpTIlqQMDkBk+tNkC4qdW/WnMQeODTUjNpFUpknA/WonQ7lGferRiwx2krxTEicy5LA4GOlWpGbppkKrgc807yi3oKnMb5+8B+FNkDIjZYE/SlzXGqSEt1x8xxgVKvc45qvEJVVfmDDriniUM5DfKw9aTuy1C2xI7E96hbL47UMDyB0p6r7mhaGU0OVFPB60yIDY/+9Tmz2H40y2IVpFY9GzQUtUDsD8oHBoVl5FTCIb+vzGmzxleAOaEzCceXUjzjB4pGbB5xn0p+0bee3SkKYIYH8KpGLY0kjGOpqG4ExdTERx97NS3NzHbxmSRgFFUU1OIo8qtlQcDHerim9TlqTS0ZeO7jcOaQYdv6VSh1iOYsqxkOOu44qVJSy7l4quV9SIyV9Au0V0eNgCCMVUt44bZSkKhSOvvUxYnHfFEgzyFqtlYGru5FJcHIIHBNDsH5IoPTDKKikc7sAfrTsSrrcV1zGW6EVwl4/mXczjozE12V7M8VnM4IXavFcQTkknvXVQW7OXEPVISiiitzmHUUUVQCUUGikwPR/C1352jxAHLoNpzWq+Qu+RuOpNcb4IuBvngduCAwz0rq1DTtgnEQ/WvIrw5ajPo8FNzpJt6D5ne5Q+VnYByfWp9MRDHtHy49e9NWVeIol46GrUcIRfQ1zt2VjtjLnl7oSv8oAHtxRHzJz1ppcBwGOD6VJGQXBI79ajodPMktyyWIiGO3eq7se2TmnSzAMRn5frVc3TFjHbqXI9qmMWi3UUtCd8rbsr8s3QVZ09WTbE3UnioNNikZmkuCCxHHoKuxnJA79iKzqSWsQirbE81vkENgEdKptDhDuHH860FmEoIYYI61DKMrxlvQelc8KjWjHyXMTUbXzUDISJByDTLKYzxtFLxIvBFaJG/H6jFZmoxNFJ9phGCvUeorujLm90cY9WToCGKcZHQ0MoD9OaSBvtUQZDhjUUkjGTYBiSqSZjPRiTcZVetJtLYBNSqmByee9PO0DpTuHQg2kYxxik3c/SpCeT3prAc8UEjN+R1yPWo0Y7m+vSpD0PpUMK5LH3qkLlJ0PyjPNMYZU8U/Bz0wKdGmSfSlsIhgOVHr0qTavO4ZppAhfj7p/nTxjnNF76jsQmI5GxiPY1MCyg7kzjuKUjpjpTyflJApXFJdyJXUjnpVdF3TSYPy561JM4CkYyTwB70fZwkO0ZD98GrWhDtYcGIPT8ac8hIAJFReVJgbXODTfJkDkFifwp2Rg9XqSCQMwUcGnMuxsBqhSJvMHz4PuKkddpPmOcgc+9OxhNWKWr28UkIVl3E8Dmm2umwRwLkDcoqdAZ08wZ29sinrHjnJOK05mla5zOnGT5mU5LSASs4hDuRkk1ZiWNohwFIHQVDcyEkIh2lh1oSI7UwTlevvVPVakxWrSFkC5CoefSo1I3balWNGk3d6glfZKSOlCJd47i3GGx7VUYAZOadNJuNQu47VaRnJmb4hnC6f5YIy7DiuWrV8QTb7oIDwg6e9ZVdtONonDVlzSCiilqzMWiiirAQ0UGgVLBF3SLr7HqEUp+6Dhh7V6exQIpRc5GeK8kr0fwhei+0pYzjzYMIfp2rhxkNOY9LAT1dNs3YQuwFQAaWGQmXkHb3pjIIwcEk1PAoAU9RXltnvQUUlZ7DDai4lLldv9ahmzHKqrlieAo71c1GUwKGUbieAKZaxrCRI5BlfqfSpjJ21NuTR22M22Rpb3E6sBnJQ9K3oRDGSAFBPHFQLh5CeufQU9oAowxJzyKmpPmdmXTpqEdS1GvyHaBgDGTSQqRIAp6d6hhuGBZXH6VdidWiZlAxjnPauabcdDTle5CzKJSepHBPrTreWME4yR9arupwx7GmQyCJ2wRntV8l1oCvcnkAWUt09qryqsn+7U0ZMsjMep4NH8RVVyBzTi2jSTs7IxLmOXTZvNiP7pz09KvxwrNCrNycZzVq5hWeJlb7tZ1i7W0ptZshc5Rj3FdEZ80dNzKUbu4uyWNm5DDrg0xphjayFSa0ZYi2WXPHGarug4zjNNSvuZO1yuApGe9NxuJyeadLF5b7wfl9KCoVN2eMVVwSGSgJGT3pkUZCjPU9cUi/Mctx6CplOSc9aewN2EJ2/jSqRsyDSuCwyOKbwOOKRKYydfMTHtTInyoB6rwasZyQO1V42BuJOKpFXHb8cU+Mg53GkIU9B15qvISZPLQe5NCVyb3LNvAHcykblXoP61aMIfawNR28gAAbj2FXBHsXIO5T1FRKVjNRdyvGoJKgDPaop5UyFJG+peLduDkse9VLqFGk3MMOOlVHfUwqXWqI5yA6/Nmq17O837qDlwM7j0q26xyQKigFh1NMTbEFAUBe9bRaOWonLVlG1urgOIbhAAehHSr1uwV8npWQ12Zb9jjZGowAepqa5ujEuADgrnOK1lFtmEZJRbuRa6ERRKCQVPBXrUen326Mb1ZT0we9VdJL3ReViWUHhDzWvIy4Xcg4qpJJcrMqc3zc3QpRXUn9otCUKptypNTTMMk4pwkSQFhjjjJ7VBPMu3AOT7Ujbo7saVDZNV58Rxu7dFBNSK6t0JrH8Q3QjgEKH5n5P0rSCbdjnm1GNznp5DLM8h6sajooruPNCiiigB1FFFWAhpKU0lSwFrb8KagbDUl3NiOTCtWJSgkEEHkVE4qcbM0pzdOSkuh7EMEAnkHnNWYSCDjGBXM+F9SbUNPCM2ZozhvcVvsBGoKN9RXh1KfLLlZ9JSrpxUokksyNcRIcbQM4I70xoWeZXLZAPAA61SbEs7SNu444rV0990ZBzx3NZy91XNqFXm92RZhGFLleR0FMaXzmJAxz0pyyFbZ2AyfU1DFgKpYkE1zxV3zHdzXQ+JzEzGTGPenJO8gbYAcioQFaZlfLKPekhmMBY+WxjPAOeapxTBTcSRWcuAQFXvmoCP37njHrUnnDqQSajhX5TuPOauKsPUmt229GJPWrSuPLYnAOOKoBjG/Hc1ac5wnC/WpnG7uDbsS2SsSQQCPeqWpWouU4OHTO1qsruSNiWOfaoI5CwAOTSjpLmQ4P3dSDTbwmJoJztlXt/eqbILZwMd6rX1osymSMkSqMg1XtdSEaKJ0bjqcVukn70TKcb7GhdbEi5wc9BVK3Ry5jlPygblFPgmiuH3uwK54FTTx7lzGcFec57U17uhlqkNMQ2npmojheBzVopH94PnNRXCLwV49aaJc9CIc8ZpQMNyOlEfQdAPWrEqBIjuIBx1zQ9ATbIGAIJHAqC2UkyMCPvYpkl2ASkKlz+lRRQ3Qyd4QMc8VaRdrbkk+9AQmSx6VZsIk8pt33sZJqt9mmB3rPuYeop6XLJGwlhO7puU0S1QWtoTXDRx4ZjjtThcBML5nB5GDSQeTeKQ/zJj6Gh0gVNsa4x6iputmiXGbehK4DbS/ODVe9wQqoTk8Z9qQyEcE8AZqla3JuLlu6J8vPrVQi9znqtbPqXLK2VYzhi3fnrTZTvyq8MO5pGk2OAMj3rPtJ5zd3EUrblzleOlXFN6nLUbi1FkY0s+c0jyZXrn3qww3oARuTpn2okLDepc7W7elR3TtawIIV3HpgnrWt2zNU+S+hFYQizunVBiJuQfQ+lWpSrOSeajLZUFuD3GarTTbW+XLGjd3J5eVW6DSwMpB+76Co3XaTtHymn7lxyCppHyy/Kc1RLjpdELFEUk8YFcfqVybq6ZyeBwPpW3r935MIhU/vH6+wrma7KMbK55+Ind8qFpKKK2OYKKKKAHUUUVYCGkooqWAtA6UUCkM0dA1F9N1COZSdmcOPUV6YbhZYlkgIYSDIxXkVdb4N1UJKtncsAnOwk9/SuPFUeZc63R34GraXJLqdpHEyRqo6mtTTId0pD8DHNZrDDAjpVmOd0Bxjp0rx6l5KyPehFR941G8s20gCbySQBWYxEezPPt6VNaXLNlegx196jnUZ3Nj8KwhHkk0zqg1KFxtk67nJOGp84MiALz3qOKNVRm5H1qSZz5aDIC4rVvW6G0Mjwk438bRUcwAY7T34qxbgeYzkgjpzVWfaXbAHXIprexpFBGzu7AgBV71bIwA4JJNVYo8BucgZzV632ugyeQMUpuxTT3ZaWMSw7unHSqSgx5bqtXi3lxDqO9VJ5RuKjADc/SsKbd2g3K0rF9yx9xxTdIgL2zJOozkgetWoMAA8ZBzUVpIhu5wjk8546Vvz6NIzcL2ZXvtMgwGAKE91qjFaTq37q4bB7Gte4kL5Xsvc1DGdsYKj7p5NaQnLl1B2SM57W683y2mCg8ggUn2SQjElw5x2rSum82AMT82flPrVcrKiA4BrRTdrnO2mimlm2FPnuB6VZWyViS7u4HYmgy7cblx9auptdDggcdKc5MmMknZlcJHH9wfTFHzAFnG1SeBSIqKHAO1s9RTbi5VECYLH2pK9x6yFjIYt25pJsRRFzkj/AGeap+cwIJGAfWrkUgWMkkEYzVOLREp3QjRJKgcK0T47cE00Q3akbHV1/wBrrUVjffaxIYsYVsc9603YJEGUde1TJuLtYulVU1cyp5ZIyRNAemMqc1WsIYt5MbnrnGatm6jkuDGzjd6VDc2yNKTHlT1yK1i7aMxquMndll2QOA2CBwaz92L1niXdkbahnlkjgYsSQOOBzUmmuDao2eSMmrUbK5zykublexI8UzbjhQKgxISFZ8EdKvSS5HTkjFVGALbhwRRFstuOweWoG48k0x1BHAp7N0o4xx0pmT1KzHB56VDdyJBA0rnaAM8GrbhQCTxiuQ1+/wDOmMERzEp5x3NbUoc7OOrU9krmZdTtcXDyOSSTUNLSV3nlN3d2FFFFAgooooAdRSZpaoBtFFFJgFKKSlFIBacpKkFTgimUvakWmejeEtaF9biC4IM0YwCe4rbkLF89K8ktLmW1mWWFirL3Br0nQtVTU7cMpxMvDqf515eJw/I+eOx7+BxiqR5J7o1rZthYsetSJ8xO449BTETIznH9afszjby1efJnpKy0ROMuDGxCgHOaZJCpUEHPrzTZ2MaDJAPehHV1bB6VCTWprzK5T35hdVYqxOQapzXRKHIIYYBNXmCIuTjk4qqYhO5RRgE5JrphbqTdvVFy2mBgTbn5hyDViNCGRlJ9TzVNUEQTPO08VZ819wSIDPoazmrm3M0a+d8IIY5HY1UvtqrHIo5xzT0OxVMg574qJgrxOWY4U5ANckI8si781hkbl1yOh4qrJItteptwFcYP1qeIjYSB2rPvgShyQcfMvtXXBK7MmnsSXkrxnMYy7HAqxC7FSnU4BaqE9whgjkB5xS2Lu8xdiQGAGK15fdOapdT3LNzIWCL0VT0p5uUjQGUZUjGR2qvqMRU5z1PGKSBC9u+70oSVrmc72si4yROVDcxkcA+lRwgIx5GwHgGoLZi7LG75xx71PfbW2sB0HTHejVPlOezvzFe4kXzzgHHvUM8igAhSM1IA2RJ1Hf2qWWdZFVcLu6dKvQ2hVkr3MyVlmQq2cflU0SI9t5aPgnjrVwpHjBAz34qq0YU8DA9RVKWhEpKbu0Q2VodO3hW3ZJbNTPO8sR2HD+9RzqyoNshPsag+eMhgciqtzasFDljyxJIII433Sf6wnOasSSgcZyBVZGc8nBBoZWIJ9KLdzNPl0Dgk9sjNMhhWJCB0znFIpwQGqQ4x71RElrcHYHjGCKYcEYqNy1DHGOaDN6MVcEe9MZiDgdKbkknjms3WNTWzi2pzMw49veqjFydkTVmoq7K3iLUxGht4W+cj5j6CuX96dI7SOWclmPUmm16MIKCsjx6tR1HdhSUtJVGYUUUUAFFFFACiikop3AKKKKQBRRRQAUtJRQA6rFheSWVyk0LEMD+dVhS8Umk1Zlxk4u6PWfD+r2+q2alWCzrw0eefrWpH97HO6vGrG7msrlZoHKup6iung8a3KkF4oy2Ooryq2Bd7w2Paw+ZRtapud7LAzNk4NNMaodysMgdK4lfHEwIxAuc80knjaRhj7OoPrWKwdZdDreYUbbnZ7BtDZ5NMjUo2eoNcaPGcm3HkChfGTAHMAP41X1Sr2KjmNBdTrpSd/TNWrF90iqRwW6muJ/4TMkYNuB9DSr4z2sD9nHHvRLCVWrWNVmWH7nfzqw3sGyvp6VWI3IVxzjrXHHxyxYnyBk+9Rf8ACaHcCbfn61nHBVUrWB5nQ7nXl2Xaeh6Ypl2v8ajJxyK5Cbxj5hBaD8jTf+Ev2rgQH862WFqLWxMsxofzHRWtsku4yDoelWY4WhcGLL+x7VycXi4RuzC34Y5xmp28ajyyotQCe+at0KvYyljsPLqdZIWmjZpE5HYVCA3lEISK5hfGgUf8e2fxpknjBXJK223PUZpLDVOxDxtB6cx2FvFHHIpI5NXGUMpiChh2I6iuEHjL5QDbE49TU8Xjoo6sbUHHvUSwtV62EsXh0tzrLiMqAqArnrmoBColDAZxz0rm7jx15zZ+yhec8Gof+E06/wCj9femsNVtqivrtC+501y+48dO1JGCeQOTXKP4sV+tv+tL/wAJcu0YtyMe9X9Xqdi5YzDNbnSzxkgn9KiLqFAI5rn38XKwGbc/nUUniiNz/wAe5/OrjQqdjB4uh/MdG7AElelJ/Du7VzX/AAksXeBvzoHidACPIbB96fsJ9iXiMP8AzHQyHkY7Ug+bkcGuf/4SZM5EDfnSHxMv/Pufzp+xn2IeJobXOgPoetDDK1z7+J1YcW/P1qGXxI7RFY4grHoSelNUJ9jKWJpW0ZoavqS2SbVIaU9Fz0965GaV5pC8hLMTnmklkaWRnc5Y8k03NdkKagjzatZ1HrsFJRRVmIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAO7CkFFFIoWloooGho606iigSCiiigYUUUUAFFFFACHrQaKKBB3ooooAPSiiigAFFFFAAaO1FFABRRRQAdqKKKAEpKKKYgpTRRQIBQaKKAEooooAKKKKACiiigApRRRQAGkoooA//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fundoscopic appearance of a patient with Senior-Loken syndrome demonstrating tapetoretinal degeneration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_5_20575=[""].join("\n");
var outline_f20_5_20575=null;
